

(19) **DANMARK**

(10) **DK/EP 3086637 T3**



Patent- og
Varemærkestyrelsen

(12) **Oversættelse af
europæisk patentskrift**

-
- (51) Int.Cl.: **A 01 K 67/027 (2006.01)** **C 07 K 14/705 (2006.01)** **C 07 K 16/28 (2006.01)**
C 12 N 15/85 (2006.01) **G 01 N 33/50 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2019-04-08**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2019-01-02**
- (86) Europæisk ansøgning nr.: **15813960.0**
- (86) Europæisk indleveringsdag: **2015-11-25**
- (87) Den europæiske ansøgnings publiceringsdag: **2016-11-02**
- (86) International ansøgning nr.: **US2015062614**
- (87) Internationalt publikationsnr.: **WO2016089692**
- (30) Prioritet: **2014-12-05 US 201462087992 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, USA**
- (72) Opfinder: **GURER, Cagan, c/o Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, USA**
IOFFE, Ella, c/o Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, USA
MUJICA, Alexander, c/o Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, USA
THURSTON, Gavin, c/o Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, USA
- (74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**
- (54) Benævnelse: **NON-HUMANE DYR MED ET HUMANISERET CLUSTER AF DIFFERENTIERINGS-47-GEN**
- (56) Fremdragne publikationer:
WO-A1-2013/063556
WO-A1-2013/144165
WO-A2-2007/033221
WO-A2-2014/071397
WO-A2-2014/093678
DATABASE EMBL [Online] 19 November 2010 (2010-11-19), "Mus musculus strain C57L integrin-associated protein (CD47) mRNA, complete cds.", XP002753825, retrieved from EBI accession no. EM_STD:HQ585874 Database accession no. HQ585874
DATABASE UniProt [Online] November 1995 (1995-11), "RecName: Full=Leukocyte surface antigen CD47; AltName: Full=Antigenic surface determinant protein OA3; AltName: Full=Integrin-associated protein; Short=IAP; AltName: Full=Protein MER6; AltName: CD_antigen=CD47; Flags: Precursor;", XP002753826, retrieved from EBI accession no. UNIPROT:Q08722 Database accession no. Q08722

Fortsættes ...

DATABASE UniProt [Online] 8 February 2011 (2011-02-08), "SubName: Full=Integrin-associated protein {ECO:0000313|EMBL:ADQ12919.1}";", XP002753827, retrieved from EBI accession no. UNIPROT:E5Q371 Database accession no. E5Q371

ANNY DEVOY ET AL: "Genomically humanized mice: technologies and promises", NATURE REVIEWS GENETICS, vol. 13, 2012, pages 14-20, XP55126260,

SCHICKEL JÖRG ET AL: "Gene for integrin-associated protein (IAP, CD47): physical mapping, genomic structure, and expression studies in skeletal muscle.", BIOCHEMISTRY AND CELL BIOLOGY = BIOCHIMIE ET BIOLOGIE CELLULAIRE 2002, vol. 80, no. 2, 2002, pages 169-176, XP009188360, ISSN: 0829-8211

E SICK ET AL: "CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest", BRITISH JOURNAL OF PHARMACOLOGY, vol. 167, no. 7, 6 November 2012 (2012-11-06), pages 1415-1430, XP055247122, BASINGSTOKE, HANTS; GB ISSN: 0007-1188, DOI: 10.1111/j.1476-5381.2012.02099.x

LEONARD D. SHULTZ ET AL: "Humanized mice for immune system investigation: progress, promise and challenges", NATURE REVIEWS IMMUNOLOGY, vol. 12, no. 11, November 2012 (2012-11), pages 786-798, XP055064740, ISSN: 1474-1733, DOI: 10.1038/nri3311

D. TSENG ET AL: "Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 27, 20 May 2013 (2013-05-20), pages 11103-11108, XP055245737, US ISSN: 0027-8424, DOI: 10.1073/pnas.1305569110

DESCRIPTION

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 62/087,992, filed December 5, 2014.

SEQUENCE LISTING

[0002] A Sequence Listing in the ASCII text file, named 32584_10108WO01_SequenceListing.txt of 96.0 KB and created on November 23, 2015, was submitted to the United States Patent and Trademark Office via EFS-Web.

BACKGROUND

[0003] Cancer therapy can be separated into four main categories: chemo/radio therapy, hormone therapy, targeted therapy, and immunotherapy. An intense focus of medical research and development has focused on targeted therapy and significant improvements have been made, yet cancer remains a major challenge to patients and to the healthcare industry worldwide. This major challenge is due, in part, to the ability of cancer cells to evade the monitoring mechanisms of the innate and adaptive immune systems, which is partly the result of inhibition of phagocytic clearance. Currently, no *in vivo* system exists to optimally determine the therapeutic potential of new cancer therapies that are designed to activate phagocytic clearance of cancer cells and determine the molecular aspects of how cancer cells provide inhibitory signals to macrophages and phagocytic cells. Such a system provides a source for assays in phagocytosis and macrophage functions *in vivo*, and identification of new cancer therapies that are targeted at providing an anti-tumor environment by promoting pro-phagocytic signals to the immune system.

[0004] WO2007/033221 relates to methods and compositions for inhibition of immune responses. WO2013/063556 relates to a humanized IL-6 and IL-6 receptor.

SUMMARY

[0005] The present invention is based on the recognition that it is desirable to engineer non-human animals to permit improved systems for identifying and developing new cancer therapeutics. The present invention is also based on the recognition that it is desirable to engineer non-human animals to permit improved engraftment of human hematopoietic stem cells. Further, the present invention is also based on the recognition that non-human animals having a humanized CD47 gene and/or otherwise expressing, containing, or producing a human or humanized CD47 polypeptide are desirable, for example for use in identifying and developing cancer therapeutics that overcome systemic toxicity associated with blockade of CD47 and overcome CD47-mediated inhibition of phagocytosis of tumor cells, and provide a more efficient *in vivo* system for engraftment of human hematopoietic stem cells that provides an increase in homeostasis of a broader number of human cell types.

[0006] The invention provides a rodent whose genome comprises a humanized CD47 gene, wherein the humanized CD47 gene comprises exon 1 of an endogenous rodent CD47 gene, exons 2-7 of a human CD47

gene, and the exons downstream of exon 7 of the endogenous rodent CD47 gene, wherein the humanized CD47 gene is operably linked to an endogenous rodent CD47 promoter.

[0007] The invention also provides an isolated rodent cell or tissue whose genome comprises a humanized CD47 gene, wherein the humanized CD47 gene comprises exon 1 of an endogenous rodent CD47 gene, exons 2-7 of a human CD47 gene, and the exons downstream of exon 7 of the endogenous rodent CD47 gene, wherein the humanized CD47 gene is operably linked to an endogenous rodent CD47 promoter, and optionally the rodent cell or tissue is mouse cell or mouse tissue, or a rat cell or rat tissue.

[0008] The invention further provides a rodent embryo generated from the embryonic stem cell of the invention.

[0009] The invention additionally provides a method of providing a rodent whose genome comprises a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide, the method comprising modifying the genome of a rodent so that it comprises a humanized CD47 gene, wherein the humanized CD47 gene comprises exon 1 of an endogenous rodent CD47 gene, exons 2-7 of a human CD47 gene, and the exons downstream of exon 7 of the endogenous rodent CD47 gene, wherein the humanized CD47 gene is operably linked to an endogenous rodent CD47 promoter, thereby providing said rodent.

[0010] The invention also provides a method for assessing engraftment of human cells, wherein said method comprises assessing engraftment of human cells in a rodent of the invention, wherein optionally the human cells are hematopoietic stem cells.

[0011] The invention further provides a method of assessing the therapeutic efficacy of a drug targeting human cells, the method comprising: administering a drug candidate to a rodent of the invention into which one or more human cells have been transplanted; and monitoring the human cells in the rodent to determine the therapeutic efficacy of the drug candidate.

[0012] Described herein is a non-human animal having a genome comprising a CD47 gene that includes genetic material from two different species (e.g., a human and a non-human). The CD47 gene of the non-human animals as described herein may encode a CD47 polypeptide that contains human and non-human portions, wherein the human and non-human portions are linked together and form a functional CD47 polypeptide.

[0013] A non-human animal described herein may comprise a CD47 gene that comprises an endogenous portion and a human portion, wherein the endogenous and human portions are operably linked to an endogenous promoter.

[0014] An endogenous portion may comprise exon 1 and the exons downstream of exon 7 of an endogenous CD47 gene. Exon 1 and the exons downstream of exon 7 of an endogenous CD47 gene may be at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to the corresponding exon 1 and the exons downstream of exon 7 of a mouse CD47 gene that appears in Table 3. Exon 1 and the exons downstream of exon 7 of an endogenous CD47 gene may be identical to the corresponding exon 1 and the exons downstream of exon 7 of a mouse CD47 gene that appears in Table 3.

[0015] A human portion may encode amino acids 16-292 of a human CD47 polypeptide. A human portion may encode amino acids 19-292 of a human CD47 polypeptide. A human portion may encode amino acids 19-141 of a human CD47 polypeptide. A human portion may encode amino acids 19-127 of a human CD47 polypeptide. A human portion may comprise exons 2-7 of a human CD47 gene.

[0016] Exons 2-7 of a human CD47 gene may be at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to the corresponding exons 2-7 of a human CD47 gene that appears in Table 3. Exons 2-7 of a human CD47 gene may be identical to the corresponding exons 2-7 of a human CD47 gene that appears in Table 3.

[0017] A non-human animal described herein may express a CD47 polypeptide comprising an extracellular portion of a human CD47 polypeptide and an intracellular portion of an endogenous CD47 polypeptide. A CD47 polypeptide may comprise a transmembrane portion of a human CD47 polypeptide. A CD47 polypeptide may comprise a transmembrane portion of a non-human CD47 polypeptide. A CD47 polypeptide may be translated in a cell of a non-human animal with a non-human signal peptide. A non-human signal peptide may be a rodent (e.g., a mouse or a rat) signal peptide.

[0018] A CD47 polypeptide described herein may be expressed from an endogenous non-human CD47 gene.

[0019] An intracellular portion of an endogenous CD47 polypeptide may comprise an intracytoplasmic tail that has an amino acid sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to an intracytoplasmic tail of a mouse CD47 polypeptide that appears in Table 3. An intracellular portion of the endogenous CD47 polypeptide may comprise an intracytoplasmic tail that has an amino acid sequence that is identical to an intracytoplasmic tail of a mouse CD47 polypeptide that appears in Table 3.

[0020] An extracellular portion of a human CD47 polypeptide may comprise amino acids corresponding to residues 19-141 of a human CD47 polypeptide. An extracellular portion of a human CD47 polypeptide may comprise amino acids corresponding to residues 19-127 of a human CD47 polypeptide. The extracellular portion of a human CD47 polypeptide may comprise an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to a corresponding amino acid sequence of an extracellular portion of a human CD47 polypeptide that appears in Table 3. An extracellular portion of a human CD47 polypeptide may comprise an amino acid sequence that is identical to a corresponding amino acid sequence of an extracellular portion of a human CD47 polypeptide that appears in Table 3.

[0021] Also described herein is a CD47 polypeptide encoded by the CD47 gene of a non-human animal as described herein. An encoded CD47 polypeptide may comprise an amino acid sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 or SEQ ID NO: 20. An encoded CD47 polypeptide may comprise an amino acid sequence that is identical to SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 or SEQ ID NO: 20.

[0022] A humanized CD47 gene comprising one or more exons of a non-human CD47 gene operably linked to one or more exons of a human CD47 gene. A humanized CD47 gene described herein may comprise non-human exons that encode an intracellular portion of a CD47 polypeptide and human exons that encode an extracellular portion of a human CD47 polypeptide. A humanized CD47 gene may also comprise human exons that encode a transmembrane portion of a human CD47 polypeptide. A humanized CD47 gene described herein may comprise non-human exons that encode a signal peptide, in whole or in part, and an intracellular portion of a CD47 polypeptide, and human exons that encode an extracellular portion and optionally a transmembrane portion of a CD47 polypeptide.

[0023] Also described herein is an isolated cell or tissue from a non-human animal as described herein. An isolated cell or tissue is described that comprises a CD47 gene as described herein. A cell may be selected from a dendritic cell, lymphocyte (e.g., a B or T cell), macrophage and a monocyte. A tissue may be selected from adipose, bladder, brain, breast, bone marrow, eye, heart, intestine, kidney, liver, lung, lymph node,

muscle, pancreas, plasma, serum, skin, spleen, stomach, thymus, testis, ovum, and a combination thereof.

[0024] Also described herein is a non-human embryonic stem cell whose genome comprises a CD47 gene as described herein. A non-human embryonic stem cell may be a mouse embryonic stem cell and is from a 129 strain, C57BL/6 strain or a BALB/c strain. A non-human embryonic stem cell may be a mouse embryonic stem cell and may be from a mixture of 129 and C57BL/6 strains.

[0025] Also described herein is the use of a non-human embryonic stem cell as described herein to make a non-human animal. A non-human embryonic stem cell may be a mouse embryonic stem cell and may be used to make a mouse comprising a CD47 gene as described herein. A non-human embryonic stem cell may be a rat embryonic stem cell and may be used to make a rat comprising a CD47 gene as described herein.

[0026] Also described herein is a non-human embryo comprising, made from, obtained from, or generated from a non-human embryonic stem cell comprising a CD47 gene as described herein. A non-human embryo may be a rodent embryo. A rodent embryo may be a mouse embryo. A rodent embryo may be a rat embryo.

[0027] Also described herein is a method of making a non-human animal that expresses a CD47 polypeptide from an endogenous CD47 gene, wherein the CD47 polypeptide comprises a human sequence, the method comprising inserting a genomic fragment into an endogenous CD47 gene in a non-human embryonic stem cell, said genomic fragment comprising a nucleotide sequence that encodes a human CD47 polypeptide in whole or in part; obtaining a non-human embryonic stem cell comprising an endogenous CD47 gene that comprises the nucleotide sequence that encodes a human CD47 polypeptide in whole or in part; and creating a non-human animal using the non-human embryonic stem cell comprising said nucleotide sequence that encodes a human CD47 polypeptide in whole or in part.

[0028] A human sequence may comprise amino acids corresponding to residues 19-141 (or 19-292) of a human CD47 polypeptide. A human sequence may comprise amino acids corresponding to residues 19-127 of a human CD47 polypeptide.

[0029] A nucleotide sequence may comprise exons 2-7 of a human CD47 gene. A nucleotide sequence may comprise one or more selection markers. A nucleotide sequence may comprise one or more site-specific recombination sites.

[0030] The method may further comprise a step of inserting a genomic fragment into an endogenous SIRPα gene of a non-human embryonic stem cell, said genomic fragment comprising a nucleotide sequence that encodes a human SIRPα polypeptide in whole or in part (e.g., encodes an extracellular portion of a human SIRPα polypeptide). A genomic fragment may comprise a nucleotide sequence that encodes a human SIRPα polypeptide in whole or in part (e.g., encodes an extracellular portion of a human SIRPα polypeptide) is inserted into an endogenous SIRPα gene of the non-human embryonic stem cell prior to an insertion into an endogenous CD47 gene.

[0031] The method may further comprise breeding a non-human animal comprising an endogenous CD47 gene that includes a nucleotide sequence that encodes a human CD47 polypeptide, in whole or in part, with a second non-human animal, said second non-human animal having a genome comprising a SIRPα gene that encodes a SIRPα polypeptide comprising an extracellular portion of a human SIRPα polypeptide (e.g., amino acids corresponding to residues 28-362 of a human SIRPα polypeptide) and an intracellular portion of an endogenous SIRPα polypeptide.

[0032] Also described herein is a method of providing a non-human animal whose genome comprises a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide, the method comprising modifying the genome of a non-human animal so

that it comprises a CD47 gene that encodes the extracellular portion of a human CD47 polypeptide linked to the intracellular portion of an endogenous CD47 polypeptide thereby providing said non-human animal. A CD47 gene may encode a CD47 polypeptide that comprises an extracellular portion and a transmembrane portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous non-human CD47 polypeptide. A CD47 gene may encode a CD47 polypeptide that comprises an extracellular portion of a human CD47 polypeptide linked to a transmembrane portion and an intracellular portion of an endogenous non-human CD47 polypeptide.

[0033] The modifying the genome of a non-human animal may be performed in a non-human embryonic stem cell. The non-human embryonic stem cell may be a rodent embryonic stem cell; a mouse embryonic stem cell; or a rat embryonic stem cell.

[0034] The method may further comprise modifying the genome of the non-human animal so that it comprises a SIRP α gene that encodes the extracellular portion of a human SIRP α polypeptide (e.g., amino acids corresponding to residues 28-362 of a human SIRP α polypeptide) linked to the intracellular portion of an endogenous SIRP α polypeptide. The modifying the genome of the non-human animal so that it comprises a SIRP α gene that encodes the extracellular portion of a human SIRP α polypeptide (e.g., amino acids corresponding to residues 28-362 of a human SIRP α polypeptide) linked to the intracellular portion of an endogenous SIRP α polypeptide may be performed prior to modifying the genome of the non-human animal so that it comprises a CD47 gene that encodes the extracellular portion and optionally a transmembrane portion of a human CD47 polypeptide linked to the intracellular portion of an endogenous CD47 polypeptide.

[0035] The method may further comprise breeding a non-human animal whose genome comprises a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide with a second non-human animal, said second non-human animal having a genome comprising a SIRP α gene that encodes a SIRP α polypeptide comprising an extracellular portion of a human SIRP α polypeptide (e.g., amino acids corresponding to residues 28-362 of a human SIRP α polypeptide) and an intracellular portion of an endogenous SIRP α polypeptide.

[0036] Also described herein is a non-human animal obtainable by methods as described herein.

[0037] Also described herein is a method of engrafting human cells into a non-human animal, the method comprising steps of providing a non-human animal whose genome comprises a CD47 gene that encodes the extracellular portion of a human CD47 polypeptide linked to the intracellular portion of an endogenous CD47 polypeptide; and transplanting one or more human cells into said non-human animal. The method may further comprise a step of assaying engraftment of the one or more human cells in said non-human animal. A step of assaying may comprise comparing the engraftment of the one or more human cells to the engraftment in one or more wild-type non-human animals or in one or more non-human animals whose genome does not comprise a CD47 gene that encodes the extracellular portion of a human CD47 polypeptide linked to the intracellular portion of an endogenous CD47 polypeptide.

[0038] Human cells may be hematopoietic stem cells. Human cells may be transplanted intravenously. Human cells may be transplanted intraperitoneally. Human cells may be transplanted subcutaneously.

[0039] Also described herein is a method of assessing the therapeutic efficacy of a drug targeting human cells, the method comprising providing a non-human animal whose genome comprises a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide; transplanting one or more human cells into said non-human animal; administering a drug candidate to said non-human animal; and monitoring the human cells in the non-human animal to determine the therapeutic efficacy of the drug candidate.

[0040] The human cells may be cancer cells and the drug candidate may be an anticancer drug candidate. A drug candidate may be an antibody.

[0041] A non-human animal may further comprise human immune cells. A drug candidate may be a bi-specific antibody that binds human CD47 and an antigen on transplanted human cancer cells.

[0042] Also described herein is a method comprising providing one or more cells whose genome includes a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide; incubating the one or more cells with a labeled substrate; and measuring phagocytosis of the labeled substrate by the one or more cells. The substrate may be fluorescently labeled. The substrate may be labeled with an antibody. The substrate may be one or more red blood cells. The substrate may be one or more bacterial cells. The substrate may be one or more tumor cells.

[0043] Also described herein is a method comprising providing a non-human animal whose genome includes a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide; exposing the non-human animal to an antigen; and measuring phagocytosis of the antigen by one or more cells of the non-human animal. The step of exposing may comprise exposing the non-human animal to an antigen that is fluorescently labeled. The step of exposing may comprise exposing the non-human animal to one or more cells that comprise the antigen. The step of exposing may comprise exposing the non-human animal to one or more human cells comprising the antigen or to one or more bacterial cells comprising the antigen. The step of exposing may comprise exposing the non-human animal to one or more cells that have been transformed with the antigen so that the antigen is expressed on the surface of the one or more transformed cells. The step of exposing may comprise exposing the non-human animal to one or more tumor cells that comprise the antigen.

[0044] Also described herein are methods for identification or validation of a drug or vaccine, the method comprising the steps of delivering a drug or vaccine to a non-human animal whose genome includes a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide, and monitoring one or more of the immune response to the drug or vaccine, the safety profile of the drug or vaccine, or the effect on a disease or condition. Monitoring the safety profile may include determining if the non-human animal exhibits a side effect or adverse reaction as a result of delivering the drug or vaccine. A side effect or adverse reaction may be selected from morbidity, mortality, alteration in body weight, alteration of the level of one or more enzymes (e.g., liver), alteration in the weight of one or more organs, loss of function (e.g., sensory, motor, organ, etc.), increased susceptibility to one or more diseases, alterations to the genome of the non-human animal, increase or decrease in food consumption and complications of one or more diseases.

[0045] Also described herein is use of a non-human animal as described herein in the development of a drug or vaccine for use in medicine, such as use as a medicament.

[0046] Also described herein is use of a non-human animal as described herein in the manufacture of a medicament for the treatment of cancer or a neoplasm.

[0047] Also described herein is use of a non-human animal as described herein to assess the efficacy of a therapeutic drug targeting human cells. A non-human animal described herein may be transplanted with human cells and a drug candidate targeting said human cells may be administered to the animal. Efficacy of the drug may be determined by monitoring the human cells in the non-human animal after the administration of the drug.

[0048] Also described herein is a non-human animal or cell as described herein for use in the development and/or identification of a drug (e.g., an antibody) for therapy or diagnosis.

[0049] Also described herein is a non-human animal or cell as described herein for use in the development and/or identification of a drug (e.g., an antibody) for the treatment, prevention or amelioration of cancer or a neoplasm.

[0050] Also described herein is a method of assessing the pharmacokinetics of a drug targeting human CD47, the method comprising the steps of administering the drug to a non-human animal as described herein, and performing an assay to determine one or more pharmacokinetic properties of the drug targeting human CD47.

[0051] Also described herein is a method of assessing the on-target toxicity of a drug targeting human CD47, the method comprising the steps of administering the drug to a non-human animal as described herein, and performing an assay for one or more parameters associated with on-target toxicity of a drug.

[0052] Also described herein is a method of assessing the off-target toxicity of a drug targeting human CD47, the method comprising the steps of administering the drug to a non-human animal as described herein, and performing an assay for one or more parameters associated with off-target toxicity of a drug.

[0053] A non-human animal as described herein may be a rodent whose genome includes a CD47 gene that encodes an extracellular portion of a human CD47 polypeptide linked to an intracellular portion of an endogenous CD47 polypeptide; a rodent may be a mouse; a rodent may be a rat.

[0054] A drug targeting human CD47 may be a CD47 antagonist. A CD47 antagonist may be an anti-CD47 antibody. A drug targeting human CD47 may be a CD47 agonist.

[0055] A CD47 gene described herein may include a CD47 gene as described herein. A CD47 polypeptide described herein may include a CD47 polypeptide as described herein.

[0056] A non-human animal described herein may not detectably express a full-length endogenous non-human CD47 polypeptide. A non-human animal described herein may not detectably express an extracellular portion of an endogenous CD47 polypeptide. A non-human animal described herein may not detectably express an extracellular portion of both an endogenous CD47 polypeptide and an endogenous SIRP α polypeptide.

[0057] An extracellular portion of a human CD47 polypeptide may comprise amino acids corresponding to residues 19-141 of a human CD47 polypeptide as described herein.

[0058] An N-terminal immunoglobulin V domain of a human CD47 polypeptide may comprise amino acids corresponding to residues 19-127 of a human CD47 polypeptide as described herein.

[0059] Non-human animals, cells, tissues, embryonic stem cells and/or embryos described herein may have a genome that further comprises a SIRP α gene that encodes a SIRP α polypeptide comprising an extracellular portion of a human SIRP α polypeptide (e.g., amino acids corresponding to residues 28-362 of a human SIRP α polypeptide) and an intracellular portion of an endogenous SIRP α polypeptide.

[0060] A non-human animal described herein may be a rodent; a mouse; or a rat.

[0061] As used in this application, the terms "about" and "approximately" are used as equivalents. Any numerals used in this application with or without about/approximately are meant to cover any normal fluctuations appreciated by one of ordinary skill in the relevant art.

[0062] Other features, objects, and advantages described herein are apparent in the detailed description that follows. It should be understood, however, that the detailed description, while indicating embodiments described herein, is given by way of illustration only, not limitation. Various changes and modifications within the scope of the invention will become apparent to those skilled in the art from the detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0063] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0064] The Drawings included herein, which are composed of the following Figures, are for illustration purposes only and not for limitation.

Figure 1 shows a diagram, not to scale, of the genomic organization of a non-human (e.g., mouse) and human Cluster of Differentiation 47 (CD47) genes. Exons are numbered beneath each exon.

Figure 2 shows a diagram, not to scale, of an exemplary method for humanization of a non-human Cluster of Differentiation 47 (CD47) gene.

Figure 3 shows a diagram, not to scale, of the genomic organization of a mouse and human Cluster of Differentiation 47 (CD47) genes. Locations of probes used in an assay described in Example 1 are indicated.

Figure 4 shows an exemplary histogram of CD47 expression in red blood cells from humanized CD47 mice detected by anti-CD47 antibodies. Ab A, Ab B, Ab C, Ab D and Ab E: anti-CD47 antibodies; hIgG4s: human IgG4 of irrelevant specificity with modified Fc region that has reduced effector function; hIgG4: human IgG4 antibody of irrelevant specificity.

Figure 5 shows exemplary hemagglutination of mouse red blood cells from wild-type (n=2) and humanized CD47 (n=2) mice by anti-CD47 antibodies. WT: wild-type; HuCD47: humanized CD47; Ab A, Ab B, Ab C, Ab D and Ab E: anti-CD47 antibodies; hIgG4s: human IgG4 of irrelevant specificity with modified Fc region that has reduced effector function; hIgG4: human IgG4 antibody of irrelevant specificity.

Figure 6 shows exemplary pharmacokinetic profiles of anti-CD47 antibodies in humanized CD47 mice represented as antibody concentration (in $\mu\text{g/mL}$, y-axis) over time (in days, x-axis); Ab F, Ab G, Ab H and Ab I: anti-CD47 antibodies; hIgG4s: human IgG4 antibody of irrelevant specificity with modified Fc region that has reduced effector function.

Figure 7 shows exemplary pharmacokinetic profiles of anti-CD47 antibodies in humanized CD47/SIRP α mice (CD47^{hu/hu}SIRP α ^{hu/hu}) represented as antibody concentration (in mcg/mL , y-axis) over time (in days, x-axis). Ab J, Ab F, Ab G and Ab I: anti-CD47 antibodies; hIgG4s: human IgG4 antibody of irrelevant specificity with modified Fc region that has reduced effector function.

Figure 8 shows exemplary pharmacokinetic profiles of anti-CD47 antibodies in humanized CD47/SIRP α mice (CD47^{hu/hu}SIRP α ^{hu/hu}) represented as antibody concentration (in mcg/mL , y-axis) over time (in days, x-axis). Ab J, Ab F: anti-CD47 antibodies; Ab Fs: Ab F with modified Fc region that has reduced effector function; Ab Fmono: monovalent version of Ab F; hIgG4s: human IgG4 antibody of irrelevant specificity with modified Fc region that has reduced effector function.

Figure 9 shows exemplary pharmacokinetic profiles of anti-CD47 antibodies in wild type mice represented as antibody concentration (in mcg/mL , y-axis) over time (in days, x-axis). Mice demonstrating mouse anti-human antibody response (MAHA) were excluded. Ab J, Ab F, Ab I and Ab G: anti-CD47 antibodies; hIgG4s: human

IgG4 antibody of irrelevant specificity with modified Fc region that has reduced effector function (star: all points after 15 days were excluded from hlgG4s treatment group due to MAHA); Ab J F(ab')₂: F(ab')₂ fragment of Ab J.

DEFINITIONS

[0065] This invention is not limited to particular methods and experimental conditions described herein, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention is defined by the claims.

[0066] Unless defined otherwise, all terms and phrases used herein include the meanings that the terms and phrases have attained in the art, unless the contrary is clearly indicated or clearly apparent from the context in which the term or phrase is used. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, particular methods and materials are now described.

[0067] The term "*approximately*", as applied herein to one or more values of interest, refers to a value that is similar to a stated reference value. The term "*approximately*" or "*about*" may refer to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

[0068] The term "*biologically active*", as used herein, refers to a characteristic of any agent that has activity in a biological system, *in vitro* or *in vivo* (e.g., in an organism). For instance, an agent that, when present in an organism, has a biological effect within that organism, is considered to be biologically active. In particular instances, where a protein or polypeptide is biologically active, a portion of that protein or polypeptide that shares at least one biological activity of the protein or polypeptide may typically be referred to as a "*biologically active*" portion.

[0069] The term "*comparable*", as used herein, refers to two or more agents, entities, situations, sets of conditions, etc. that may not be identical to one another but that are sufficiently similar to permit comparison there between so that conclusions may reasonably be drawn based on differences or similarities observed. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, etc. to be considered comparable.

[0070] The term "*conservative*", as used herein to describe a conservative amino acid substitution, refers to substitution of an amino acid residue by another amino acid residue having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of interest of a protein, for example, the ability of a receptor to bind to a ligand. Examples of groups of amino acids that have side chains with similar chemical properties include: aliphatic side chains such as glycine, alanine, valine, leucine, and isoleucine; aliphatic-hydroxyl side chains such as serine and threonine; amide-containing side chains such as asparagine and glutamine; aromatic side chains such as phenylalanine, tyrosine, and tryptophan; basic side chains such as lysine, arginine, and histidine; acidic side chains such as aspartic acid and glutamic acid; and, sulfur-containing side chains such as cysteine and methionine. Conservative amino acids substitution groups include, for example, valine/leucine/isoleucine, phenylalanine/tyrosine, lysine/arginine, alanine/valine, glutamate/aspartate, and

asparagine/glutamine. A conservative amino acid substitution may be a substitution of any native residue in a protein with alanine, as used in, for example, alanine scanning mutagenesis. A conservative substitution may be made that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Exhaustive Matching of the Entire Protein Sequence Database, Science 256:1443-45. The substitution may be a moderately conservative substitution wherein the substitution has a nonnegative value in the PAM250 log-likelihood matrix.

[0071] The term "*control*", as used herein, refers to the art-understood meaning of a "control" being a standard against which results are compared. Typically, controls are used to augment integrity in experiments by isolating variables in order to make a conclusion about such variables. A control may be a reaction or assay that is performed simultaneously with a test reaction or assay to provide a comparator. As used herein, a "*control*" may refer to a "*control animal*". A "*control animal*" may have a modification as described herein, a modification that is different as described herein, or no modification (i.e., a wild-type animal). In one experiment, the "test" (i.e., the variable being tested) is applied. In the second experiment, the "control," the variable being tested is not applied. A control may be a historical control (i.e., of a test or assay performed previously, or an amount or result that is previously known). A control may be or comprise a printed or otherwise saved record. A control may be a positive control or a negative control.

[0072] The term "*disruption*", as used herein, may refer to the result of a homologous recombination event with a DNA molecule (e.g., with an endogenous homologous sequence such as a gene or gene locus. A disruption may achieve or represent an insertion, deletion, substitution, replacement, missense mutation, or a frame-shift of a DNA sequence(s), or any combination thereof. Insertions may include the insertion of entire genes or fragments of genes, e.g., exons, which may be of an origin other than the endogenous sequence (e.g., a heterologous sequence). A disruption may increase expression and/or activity of a gene or gene product (e.g., of a protein encoded by a gene). A disruption may decrease expression and/or activity of a gene or gene product. A disruption may alter sequence of a gene or an encoded gene product (e.g., an encoded protein). A disruption may truncate or fragment a gene or an encoded gene product (e.g., an encoded protein). A disruption may extend a gene or an encoded gene product; in some such instances, a disruption may achieve assembly of a fusion protein. A disruption may affect level but not activity of a gene or gene product. A disruption may affect activity but not level of a gene or gene product. A disruption may have no significant effect on level of a gene or gene product. A disruption may have no significant effect on activity of a gene or gene product. A disruption may have no significant effect on either level or activity of a gene or gene product.

[0073] The terms "*determining*", "*measuring*", "*evaluating*", "*assessing*", "*assaying*" and "*analyzing*" are used interchangeably herein to refer to any form of measurement, and include determining if an element is present or not. These terms include both quantitative and/or qualitative determinations. Assaying may be relative or absolute. "*Assaying for the presence of*" can be determining the amount of something present and/or determining whether or not it is present or absent.

[0074] The phrase "*endogenous locus*" or "*endogenous gene*", as used herein, refers to a genetic locus found in a parent or reference organism prior to introduction of a disruption, deletion, replacement, alteration, or modification as described herein. The endogenous locus may have a sequence found in nature. The endogenous locus may be a wild type locus. The reference organism may be a wild-type organism. The reference organism may be an engineered organism. The reference organism may be a laboratory-bred organism (whether wild-type or engineered).

[0075] The phrase "*endogenous promoter*" refers to a promoter that is naturally associated, e.g., in a wild-type organism, with an endogenous gene.

[0076] The term "*heterologous*", as used herein, refers to an agent or entity from a different source. For

example, when used in reference to a polypeptide, gene, or gene product or present in a particular cell or organism, the term clarifies that the relevant polypeptide, gene, or gene product: 1) was engineered by the hand of man; 2) was introduced into the cell or organism (or a precursor thereof) through the hand of man (e.g., via genetic engineering); and/or 3) is not naturally produced by or present in the relevant cell or organism (e.g., the relevant cell type or organism type).

[0077] The term "*host cell*", as used herein, refers to a cell into which a heterologous (e.g., exogenous) nucleic acid or protein has been introduced. Persons of skill upon reading this disclosure will understand that such terms refer not only to the particular subject cell, but also is used to refer to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "*host cell*" as used herein. A host cell may be or comprise a prokaryotic or eukaryotic cell. In general, a host cell is any cell that is suitable for receiving and/or producing a heterologous nucleic acid or protein, regardless of the Kingdom of life to which the cell is designated. Exemplary cells include those of prokaryotes and eukaryotes (single-cell or multiple-cell), bacterial cells (e.g., strains of *E. coli*, *Bacillus* spp., *Streptomyces* spp., etc.), mycobacteria cells, fungal cells, yeast cells (e.g., *S. cerevisiae*, *S. pombe*, *P. pastoris*, *P. methanolicus*, etc.), plant cells, insect cells (e.g., SF-9, SF-21, baculovirus-infected insect cells, *Trichoplusia ni*, etc.), non-human animal cells, human cells, or cell fusions such as, for example, hybridomas or quadromas. The cell may be a human, monkey, ape, hamster, rat, or mouse cell. The cell may be eukaryotic and may be selected from the following cells: CHO (e.g., CHO K1, DXB-11 CHO, Veggie-CHO), COS (e.g., COS-7), retinal cell, Vero, CV1, kidney (e.g., HEK293, 293 EBNA, MSR 293, MDCK, HaK, BHK), HeLa, HepG2, WI38, MRC 5, Colo205, HB 8065, HL-60, (e.g., BHK21), Jurkat, Daudi, A431 (epidermal), CV-1, U937, 3T3, L cell, C127 cell, SP2/0, NS-0, MMT 060562, Sertoli cell, BRL 3A cell, HT1080 cell, myeloma cell, tumor cell, and a cell line derived from an aforementioned cell. The cell may comprise one or more viral genes, e.g., a retinal cell that expresses a viral gene (e.g., a PER.C6™ cell). A host cell may be or comprise an isolated cell. A host cell may be part of a tissue, a host cell is part of an organism.

[0078] The term "*humanized*", is used herein in accordance with its art-understood meaning to refer to nucleic acids or proteins whose structures (i.e., nucleotide or amino acid sequences) include portions that correspond substantially or identically with structures of a particular gene or protein found in nature in a non-human animal, and also include portions that differ from that found in the relevant particular non-human gene or protein and instead correspond more closely with comparable structures found in a corresponding human gene or protein. A "*humanized*" gene may be one that encodes a polypeptide having substantially the amino acid sequence as that of a human polypeptide (e.g., a human protein or portion thereof-e.g., characteristic portion thereof). To give but one example, in the case of a membrane receptor, a "*humanized*" gene may encode a polypeptide having an extracellular portion having an amino acid sequence as that of a human extracellular portion and the remaining sequence as that of a non-human (e.g., mouse) polypeptide. A humanized gene may comprise at least a portion of a DNA sequence of a human gene. A humanized gene may comprise an entire DNA sequence of a human gene. A humanized protein may comprise a sequence having a portion that appears in a human protein. A humanized protein may comprise an entire sequence of a human protein and is expressed from an endogenous locus of a non-human animal that corresponds to the homolog or ortholog of the human gene.

[0079] The term "*identity*", as used herein in connection with a comparison of sequences, refers to identity as determined by a number of different algorithms known in the art that can be used to measure nucleotide and/or amino acid sequence identity. Identities as described herein may be determined using a ClustalW v. 1.83 (slow) alignment employing an open gap penalty of 10.0, an extend gap penalty of 0.1, and using a Gonnet similarity matrix (MACVECTOR™ 10.0.2, MacVector Inc., 2008).

[0080] The term "*isolated*", as used herein, refers to a substance and/or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature

and/or in an experimental setting), and/or (2) designed, produced, prepared, and/or manufactured by the hand of man. Isolated substances and/or entities may be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% of the other components with which they were initially associated. Isolated agents may be about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is "*pure*" if it is substantially free of other components. As will be understood by those skilled in the art, a substance may still be considered "*isolated*" or even "*pure*", after having been combined with certain other components such as, for example, one or more carriers or excipients (e.g., buffer, solvent, water, etc.); in such instances, percent isolation or purity of the substance is calculated without including such carriers or excipients. To give but one example, A biological polymer such as a polypeptide or polynucleotide that occurs in nature may be considered to be "*isolated*" when: a) by virtue of its origin or source of derivation is not associated with some or all of the components that accompany it in its native state in nature; b) it is substantially free of other polypeptides or nucleic acids of the same species from the species that produces it in nature; or c) is expressed by or is otherwise in association with components from a cell or other expression system that is not of the species that produces it in nature. Thus, for instance, a polypeptide that is chemically synthesized or is synthesized in a cellular system different from that which produces it in nature may be considered to be an "*isolated*" polypeptide. Alternatively or additionally, a polypeptide that has been subjected to one or more purification techniques may be considered to be an "*isolated*" polypeptide to the extent that it has been separated from other components: a) with which it is associated in nature; and/or b) with which it was associated when initially produced.

[0081] The phrase "*non-human animal*", as used herein, refers to any vertebrate organism that is not a human. A non-human animal may be acyclostome, a bony fish, a cartilaginous fish (e.g., a shark or a ray), an amphibian, a reptile, a mammal, or a bird. A non-human mammal may be a primate, a goat, a sheep, a pig, a dog, a cow, or a rodent. A non-human animal may be a rodent such as a rat or a mouse.

[0082] The phrase "*nucleic acid*", as used herein, in its broadest sense, refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain. A "*nucleic acid*" may be a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage. As will be clear from context, "*nucleic acid*" may refer to individual nucleic acid residues (e.g., nucleotides and/or nucleosides); "*nucleic acid*" may refer to an oligonucleotide chain comprising individual nucleic acid residues. A "*nucleic acid*" may be or comprise RNA; a "*nucleic acid*" may be or comprise DNA. A "*nucleic acid*" may be, comprise, or consist of one or more natural nucleic acid residues. A "*nucleic acid*" may be, comprise, or consist of one or more nucleic acid analogs. A nucleic acid analog may differ from a "*nucleic acid*" in that it does not utilize a phosphodiester backbone. For example, a "*nucleic acid*" may be, comprise, or consist of one or more "*peptide nucleic acids*", which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone. Alternatively or additionally, a "*nucleic acid*" may have one or more phosphorothioate and/or 5'-N-phosphoramidite linkages rather than phosphodiester bonds. A "*nucleic acid*" may be, comprise, or consist of one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine). A "*nucleic acid*" may be, comprise, or consist of one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof). A "*nucleic acid*" may comprise one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) as compared with those in natural nucleic acids. A "*nucleic acid*" may have a nucleotide sequence that encodes a functional gene product such as an RNA or protein. A "*nucleic acid*" may include one or more introns. A "*nucleic acid*" may be prepared by one or more of isolation from a natural source, enzymatic synthesis by polymerization based on a complementary template (*in vivo* or *in*

vitro), reproduction in a recombinant cell or system, and chemical synthesis. A "nucleic acid" may be at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues long. A "nucleic acid" may be single stranded; or a "nucleic acid" may be double stranded. A "nucleic acid" may have a nucleotide sequence comprising at least one element that encodes, or is the complement of a sequence that encodes, a polypeptide. A "nucleic acid" may have enzymatic activity.

[0083] The phrase "*operably linked*", as used herein, refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence "*operably linked*" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. "*Operably linked*" sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. The term "*expression control sequence*", as used herein, refers to polynucleotide sequences, which are necessary to effect the expression and processing of coding sequences to which they are ligated. "*Expression control sequences*" include: appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism. For example, in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence, while in eukaryotes, typically, such control sequences include promoters and transcription termination sequence. The term "*control sequences*" is intended to include components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

[0084] The term "*polypeptide*", as used herein, refers to any polymeric chain of amino acids. A polypeptide may have an amino acid sequence that occurs in nature. A polypeptide may have an amino acid sequence that does not occur in nature, a polypeptide has an amino acid sequence that contains portions that occur in nature separately from one another (i.e., from two or more different organisms, for example, human and non-human portions). A polypeptide may have an amino acid sequence that is engineered in that it is designed and/or produced through action of the hand of man.

[0085] The term "*recombinant*", as used herein, is intended to refer to polypeptides (e.g., CD47 polypeptides as described herein) that are designed, engineered, prepared, expressed, created or isolated by recombinant means, such as polypeptides expressed using a recombinant expression vector transfected into a host cell, polypeptides isolated from a recombinant, combinatorial human polypeptide library (Hoogenboom H. R., (1997) TIB Tech. 15:62-70; Azzazy H., and Highsmith W. E., (2002) Clin. Biochem. 35:425-445; Gavilondo J. V., and Larrick J. W. (2002) BioTechniques 29:128-145; Hoogenboom H., and Chames P. (2000) Immunology Today 21:371-378), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor, L. D., et al. (1992) Nucl. Acids Res. 20:6287-6295; Kellermann S-A., and Green L. L. (2002) Current Opinion in Biotechnology 13:593-597; Little M. et al. (2000) Immunology Today 21:364-370; Murphy, A.J., et al. (2014) Proc. Natl. Acad. Sci. U. S. A. 111(14):5153-5158) or polypeptides prepared, expressed, created or isolated by any other means that involves splicing selected sequence elements to one another. One or more of such selected sequence elements may be found in nature. One or more of such selected sequence elements may be designed *in silico*. One or more such selected sequence elements may result from mutagenesis (e.g., *in vivo* or *in vitro*) of a known sequence element, e.g., from a natural or synthetic source. For example, a recombinant polypeptide may be comprised of sequences found in the genome of a source organism of interest (e.g., human, mouse, etc.). A recombinant polypeptide may have an amino acid sequence that resulted from mutagenesis (e.g., *in vitro* or

in vivo, for example in a non-human animal), so that the amino acid sequences of the recombinant polypeptides are sequences that, while originating from and related to polypeptides sequences, may not naturally exist within the genome of a non-human animal *in vivo*.

[0086] The term "*replacement*" is used herein to refer to a process through which a "*replaced*" nucleic acid sequence (e.g., a gene) found in a host locus (e.g., in a genome) is removed from that locus, and a different, "*replacement*" nucleic acid is located in its place. The replaced nucleic acid sequence and the replacement nucleic acid sequences may be comparable to one another in that, for example, they are homologous to one another and/or contain corresponding elements (e.g., protein-coding elements, regulatory elements, etc.). A replaced nucleic acid sequence may include one or more of a promoter, an enhancer, a splice donor site, a splice receiver site, an intron, an exon, an untranslated region (UTR); a replacement nucleic acid sequence may include one or more coding sequences. A replacement nucleic acid sequence may be a homolog of the replaced nucleic acid sequence. A replacement nucleic acid sequence may be an ortholog of the replaced sequence. A replacement nucleic acid sequence may be or comprise a human nucleic acid sequence. In some instances, including where the replacement nucleic acid sequence is or comprises a human nucleic acid sequence, the replaced nucleic acid sequence may be or comprise a rodent sequence (e.g., a mouse or rat sequence). The nucleic acid sequence so placed may include one or more regulatory sequences that are part of source nucleic acid sequence used to obtain the sequence so placed (e.g., promoters, enhancers, 5'- or 3'-untranslated regions, etc.). For example, the replacement is a substitution of an endogenous sequence with a heterologous sequence that results in the production of a gene product from the nucleic acid sequence so placed (comprising the heterologous sequence), but not expression of the endogenous sequence; the replacement is of an endogenous genomic sequence with a nucleic acid sequence that encodes a protein that has a similar function as a protein encoded by the endogenous sequence (e.g., the endogenous genomic sequence encodes a CD47 protein, and the DNA fragment encodes one or more human CD47 proteins). An endogenous gene or fragment thereof is replaced with a corresponding human gene or fragment thereof. A corresponding human gene or fragment thereof is a human gene or fragment that is an ortholog of, or is substantially similar or the same in structure and/or function, as the endogenous gene or fragment thereof that is replaced.

[0087] The phrase "*cluster of differentiation 47protein*" or "*CD47 protein*", as used herein, refers to a multi-pass transmembrane protein that belongs to the immunoglobulin superfamily and has an extracellular amino-terminal immunoglobulin V domain, five transmembrane domains and a short carboxyl-terminal intracellular tail. CD47 is expressed on the cell surface and is involved in interactions between membrane surface proteins such as, for example, integrins, SIRPα and thrombospondin-1 (TSP-1). CD47 is expressed in normal tissues and up-regulated in many human cancers. CD47 has been shown to be involved in several cellular processes such as, for example, apoptosis, proliferation, adhesion and migration. Several alternatively spliced CD47 isoforms have been identified between mouse and man. By way of illustration, nucleotide and amino acid sequences of mouse and human CD47 genes are provided in Table 3. Persons of skill upon reading this disclosure will recognize that one or more endogenous CD47 genes in a genome (or all) can be replaced by one or more heterologous CD47 genes (e.g., polymorphic variants, subtypes or mutants, genes from another species, humanized forms, etc.).

[0088] A "*CD47-expressing cell*", as used herein, refers to a cell that expresses a CD47 transmembrane protein. A CD47-expressing cell may express a CD47 transmembrane protein on its surface. A CD47 protein may be expressed on the surface of the cell in an amount sufficient to mediate cell-to-cell interactions via the CD47 transmembrane protein expressed on the surface of the cell. Exemplary CD47-expressing cells include neurons, immune cells, keratinocytes, and circulating cells. CD47-expressing cells regulate the interaction of immune cells and circulating cells to regulate various cellular processes such as adhesion, cell proliferation and/or apoptosis, angiogenesis and inflammation. Non-human animals described herein may demonstrate regulation of various cellular processes (as described herein) via humanized CD47 proteins expressed on the surface of one more cells of the non-human animal.

[0089] The term "*reference*" is used herein to describe a standard or control agent, cohort, individual, population, sample, sequence or value against which an agent, animal, cohort, individual, population, sample, sequence or value of interest is compared. A reference agent, cohort, individual, population, sample, sequence or value may be tested and/or determined substantially simultaneously with the testing or determination of the agent, cohort, individual, population, sample, sequence or value of interest. A reference agent, cohort, individual, population, sample, sequence or value may be a historical reference, optionally embodied in a tangible medium. A reference may refer to a control. As used herein, a "*reference*" may refer to a "*reference animal*". A "*reference animal*" may have a modification as described herein, a modification that is different as described herein or no modification (i.e., a wild-type animal). Typically, as would be understood by those skilled in the art, a reference agent, animal, cohort, individual, population, sample, sequence or value is determined or characterized under conditions comparable to those utilized to determine or characterize the agent, animal (e.g., a mammal), cohort, individual, population, sample, sequence or value of interest.

[0090] The term "*substantially*", as used herein, refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term "*substantially*" is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

[0091] The phrase "*substantial homology*", as used herein, refers to a comparison between amino acid or nucleic acid sequences. As will be appreciated by those of ordinary skill in the art, two sequences are generally considered to be "*substantially homologous*" if they contain homologous residues in corresponding positions. Homologous residues may be identical residues. Alternatively, homologous residues may be non-identical residues will appropriately similar structural and/or functional characteristics. For example, as is well known by those of ordinary skill in the art, certain amino acids are typically classified as "*hydrophobic*" or "*hydrophilic*" amino acids, and/or as having "*polar*" or "*non-polar*" side chains. Substitution of one amino acid for another of the same type may often be considered a "*homologous*" substitution. Typical amino acid categorizations are summarized in Table 1 and 2.

TABLE 1

Alanine	Ala	A	Nonpolar	Neutral	1.8
Arginine	Arg	R	Polar	Positive	-4.5
Asparagine	Asn	N	Polar	Neutral	-3.5
Aspartic acid	Asp	D	Polar	Negative	-3.5
Cysteine	Cys	C	Nonpolar	Neutral	2.5
Glutamic acid	Glu	E	Polar	Negative	-3.5
Glutamine	Gln	Q	Polar	Neutral	-3.5
Glycine	Gly	G	Nonpolar	Neutral	-0.4
Histidine	His	H	Polar	Positive	-3.2
Isoleucine	Ile	I	Nonpolar	Neutral	4.5
Leucine	Leu	L	Nonpolar	Neutral	3.8
Lysine	Lys	K	Polar	Positive	-3.9
Methionine	Met	M	Nonpolar	Neutral	1.9
Phenylalanine	Phe	F	Nonpolar	Neutral	2.8
Proline	Pro	P	Nonpolar	Neutral	-1.6
Serine	Ser	S	Polar	Neutral	-0.8
Threonine	Thr	T	Polar	Neutral	-0.7

Tryptophan	Trp	W	Nonpolar	Neutral	-0.9
Tyrosine	Tyr	Y	Polar	Neutral	-1.3
Valine	Val	V	Nonpolar	Neutral	4.2

TABLE 2

Ambiguous Amino Acids	3-Letter	1-Letter
Asparagine or aspartic acid	Asx	B
Glutamine or glutamic acid	Glx	Z
Leucine or Isoleucine	Xle	J
Unspecified or unknown amino acid	Xaa	X

[0092] As is well known in this art, amino acid or nucleic acid sequences may be compared using any of a variety of algorithms, including those available in commercial computer programs such as BLASTN for nucleotide sequences and BLASTP, gapped BLAST, and PSI-BLAST for amino acid sequences. Exemplary such programs are described in Altschul et al. (1990) Basic local alignment search tool, J. Mol. Biol., 215(3): 403-410; Altschul et al. (1997) Methods in Enzymology; Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402; Baxevanis et al. (1998) Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley; and Misener et al. (eds.) (1999) Bioinformatics Methods and Protocols (Methods in Molecular Biology, Vol. 132), Humana Press. In addition to identifying homologous sequences, the programs mentioned above typically provide an indication of the degree of homology. Two sequences may be considered to be substantially homologous if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of their corresponding residues are homologous over a relevant stretch of residues. The relevant stretch may be a complete sequence. The relevant stretch may be at least 9, 10, 11, 12, 13, 14, 15, 16, 17 or more residues. The relevant stretch may include contiguous residues along a complete sequence. The relevant stretch may include discontinuous residues along a complete sequence. The relevant stretch may be at least 10, 15, 20, 25, 30, 35, 40, 45, 50, or more residues.

[0093] The phrase "*substantial identity*", as used herein, refers to a comparison between amino acid or nucleic acid sequences. As will be appreciated by those of ordinary skill in the art, two sequences are generally considered to be "*substantially identical*" if they contain identical residues in corresponding positions. As is well known in this art, amino acid or nucleic acid sequences may be compared using any of a variety of algorithms, including those available in commercial computer programs such as BLASTN for nucleotide sequences and BLASTP, gapped BLAST, and PSI-BLAST for amino acid sequences. Exemplary such programs are described in Altschul et al. (1990) Basic local alignment search tool, J. Mol. Biol., 215(3): 403-410; Altschul et al., Methods in Enzymology; Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402; Baxevanis et al. (1998) Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley; and Misener et al., (eds.) (1999) Bioinformatics Methods and Protocols (Methods in Molecular Biology, Vol. 132), Humana Press. In addition to identifying identical sequences, the programs mentioned above typically provide an indication of the degree of identity. Two sequences may be considered to be substantially identical if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of their corresponding residues are identical over a relevant stretch of residues. The relevant stretch may be a complete sequence. The relevant stretch may be at least 10, 15, 20, 25, 30, 35, 40, 45, 50, or more residues.

[0094] The phrase "*targeting vector*" or "*targeting construct*", as used herein, refers to a polynucleotide molecule that comprises a targeting region. A targeting region comprises a sequence that is identical or substantially identical to a sequence in a target cell, tissue or animal and provides for integration of the targeting construct into a position within the genome of the cell, tissue or animal via homologous

recombination. Targeting regions that target using site-specific recombinase recognition sites (e.g., *loxP* or *Frt* sites) are also included. A targeting construct described herein may further comprise a nucleic acid sequence or gene of particular interest, a selectable marker, control and/or regulatory sequences, and other nucleic acid sequences that allow for recombination mediated through exogenous addition of proteins that aid in or facilitate recombination involving such sequences. A targeting construct described herein may further comprise a gene of interest in whole or in part, wherein the gene of interest is a heterologous gene that encodes a protein, in whole or in part, that has a similar function as a protein encoded by an endogenous sequence. A targeting construct described herein may further comprise a humanized gene of interest, in whole or in part, wherein the humanized gene of interest encodes a protein, in whole or in part, that has a similar function as a protein encoded by the endogenous sequence.

[0095] The term "*variant*", as used herein, refers to an entity that shows significant structural identity with a reference entity, but differs structurally from the reference entity in the presence or level of one or more chemical moieties as compared with the reference entity. A "*variant*" may also differ functionally from its reference entity. In general, whether a particular entity is properly considered to be a "*variant*" of a reference entity is based on its degree of structural identity with the reference entity. As will be appreciated by those skilled in the art, any biological or chemical reference entity has certain characteristic structural elements. A "*variant*", by definition, is a distinct chemical entity that shares one or more such characteristic structural elements. To give but a few examples, a small molecule may have a characteristic core structural element (e.g., a macrocycle core) and/or one or more characteristic pendent moieties so that a variant of the small molecule is one that shares the core structural element and the characteristic pendent moieties but differs in other pendent moieties and/or in types of bonds present (single vs. double, E vs. Z, etc.) within the core, a polypeptide may have a characteristic sequence element comprised of a plurality of amino acids having designated positions relative to one another in linear or three-dimensional space and/or contributing to a particular biological function, a nucleic acid may have a characteristic sequence element comprised of a plurality of nucleotide residues having designated positions relative to one another in linear or three-dimensional space. For example, a "*variant polypeptide*" may differ from a reference polypeptide as a result of one or more differences in amino acid sequence and/or one or more differences in chemical moieties (e.g., carbohydrates, lipids, etc.) covalently attached to the polypeptide backbone. A "*variant polypeptide*" may show an overall sequence identity with a reference polypeptide that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 99%. Alternatively or additionally, a "*variant polypeptide*" may not share at least one characteristic sequence element with a reference polypeptide. The reference polypeptide may have one or more biological activities. A "*variant polypeptide*" may share one or more of the biological activities of the reference polypeptide. A "*variant polypeptide*" may lack one or more of the biological activities of the reference polypeptide. A "*variant polypeptide*" may show a reduced level of one or more biological activities as compared with the reference polypeptide. A polypeptide of interest may be considered to be a "*variant*" of a parent or reference polypeptide if the polypeptide of interest has an amino acid sequence that is identical to that of the parent but for a small number of sequence alterations at particular positions. Typically, fewer than 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% of the residues in the variant are substituted as compared with the parent. A "*variant*" may have 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 substituted residue as compared with a parent. Often, a "*variant*" has a very small number (e.g., fewer than 5, 4, 3, 2, or 1) number of substituted functional residues (i.e., residues that participate in a particular biological activity). Furthermore, a "*variant*" typically has not more than 5, 4, 3, 2, or 1 additions or deletions, and often has no additions or deletions, as compared with the parent. Moreover, any additions or deletions are typically fewer than about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 10, about 9, about 8, about 7, about 6, and commonly are fewer than about 5, about 4, about 3, or about 2 residues. The parent or reference polypeptide may be one found in nature. As will be understood by those of ordinary skill in the art, a plurality of variants of a particular polypeptide of interest may commonly be found in nature, particularly when the polypeptide of interest is an infectious agent polypeptide.

[0096] The term "*vector*", as used herein, refers to a nucleic acid molecule capable of transporting another

nucleic acid to which it is associated. Vectors may be capable of extra-chromosomal replication and/or expression of nucleic acids to which they are linked in a host cell such as a eukaryotic and/or prokaryotic cell. Vectors capable of directing the expression of operatively linked genes are referred to herein as "expression vectors."

[0097] The term "*wild-type*", as used herein, has its art-understood meaning that refers to an entity having a structure and/or activity as found in nature in a "*normal*" (as contrasted with mutant, diseased, altered, etc.) state or context. Those of ordinary skill in the art will appreciate that wild-type genes and polypeptides often exist in multiple different forms (e.g., alleles).

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

[0098] Described herein are among other things, improved and/or engineered non-human animals having humanized genetic material encoding a cluster of differentiation 47 (CD47) gene for determining the therapeutic efficacy of CD47 antagonists (e.g., an anti-CD47 antibody) for the treatment of cancer, and assays in transplant engraftment, activation and phagocytosis and signal transduction. It is contemplated that such non-human animals provide an improvement in determining the therapeutic efficacy of CD47 antagonists and their potential for CD47 blockade. It is also contemplated that such non-human animals provide an improvement in transplant engraftment of human cells. Therefore, the present disclosure is particularly useful for the development of anti-CD47 therapies for the treatment of various cancers, as well as for maintaining human hematopoietic cells in non-human animals. In particular, the present disclosure encompasses the humanization of a murine CD47 gene resulting in expression of a humanized CD47 protein on the surface of cells of the non-human animal. Such humanized CD47 proteins have the capacity to provide a source of human CD47⁺ cells for determining the efficacy of anti-CD47 therapeutics to activate phagocytosis of tumor cells. Further, such humanized CD47 proteins have the capacity to recognize engrafted human cells via engagement of other cell surface proteins and ligands present on the surface of the engrafted human cells (e.g., SIRPα). Non-human animals described herein may be capable of activating phagocytosis via blockade of CD47 signaling through the humanized CD47 protein expressed on the surface of cells of the non-human animal. Non-human animals described herein may be capable of receiving transplanted human hematopoietic cells; such non-human mammals may develop and/or have an immune system comprising human cells. Humanized CD47 proteins may have a sequence corresponding to the N-terminal immunoglobulin V domain of a human CD47 protein. Humanized CD47 proteins may have a sequence corresponding to an N-terminal portion of a human CD47 protein that comprises an extracellular portion and a transmembrane portion of a human CD47 protein, wherein the extracellular portion includes the N-terminal immunoglobulin V domain of the human CD47 protein and the transmembrane portion includes the five transmembrane domains of the human CD47 protein. Humanized CD47 proteins may have a sequence corresponding to the intracytoplasmic tail of a non-human (e.g., murine) CD47 protein. Humanized CD47 proteins may have a sequence corresponding to amino acid residues 19-292 (or 19-141, or 19-127) of a human CD47 protein. Non-human animals described herein may comprise an endogenous CD47 gene that contains genetic material from the non-human animal and a heterologous species (e.g., a human). Non-human animals described herein may comprise a humanized CD47 gene, wherein the humanized CD47 gene comprises exons of a human CD47 gene that encode an extracellular portion including the N-terminal immunoglobulin V domain of a human CD47 gene. The humanized CD47 gene may comprise human CD47 exons, e.g., exons 2-7, encoding an N-terminal portion of a human CD47 protein that comprises an extracellular portion and a transmembrane portion of a human CD47 protein, wherein the extracellular portion includes the N-terminal immunoglobulin V domain of the human CD47 protein and the transmembrane portion includes the five transmembrane domains of the human CD47 protein. The humanized CD47 gene may comprise non-human CD47 exons that encode the signal peptide, in whole or in part, and the intracytoplasmic tail of a non-human CD47 protein. The humanized CD47 gene may comprise non-human CD47 exon 1 and exon(s) downstream of exon 7 that

encode the intracytoplasmic tail and the 3' UTR. Depending on the isoforms, there may be one or more exons downstream of exon 7, with the stop codon and the 3' UTR being present in the last exon for all isoforms. For example, isoform 2 of both mouse and human CD47 shown in Table 3 have two exons downstream of exon 7, designated as exon 8 and 9.

[0099] Various aspects of the invention are described in detail in the following sections. The use of sections is not meant to limit the invention. Each section can apply to any aspect of the invention. In this application, the use of "or" means "and/or" unless stated otherwise.

Cluster of Differentiation 47 (CD47) Gene

[0100] CD47, originally named integrin-associated protein (IAP) for its role in signal transduction from integrins on immune cells, is a transmembrane protein that includes an N-terminal immunoglobulin V (IgV) domain, five transmembrane domains, and a short C-terminal intracytoplasmic tail. The intracytoplasmic tail differs in length according to four alternatively spliced isoforms that have been identified. CD47 (or IAP) was initially described as being expressed on all tissues (isoform 2), neurons (isoform 4) and keratinocytes and macrophages (isoform 1; see Reinhold et al. (1995) J. Cell Sci. 108:3419-3425). Little is known about isoform 3 despite this form having the second longest intracytoplasmic tail among the four isoforms. In addition to integrins, CD47 is known to interact with several other cell surface proteins such as, for example, thrombospondin and members of the SIRP family. Most notably, CD47 interacts with SIRP α and leads to bidirectional signaling that regulates a variety of cell-to-cell responses such as, for example, inhibition of phagocytosis and T cell activation. Indeed, CD47-SIRP α interaction has come into focus in recent years for its role in providing tumor cells with the capacity to evade immune surveillance. CD47 binding to SIRP α normally provides protection through anti-phagocytic signals ("don't eat me") for normal cells. However, it has been discovered that tumors also express anti-phagocytic signals, including CD47, to evade destruction by phagocytosis. Interestingly, CD47 is known to be upregulated in several hematologic cancers and contribute to both the growth and dissemination of tumors (Chao et al. (2012) Curr Opin Immunol.24(2): 225-232).

[0101] The complete effects of targeting CD47 and the CD47-SIRP α pathway as a new treatment for cancer are unknown and some possible toxicities have been explored. A more thorough and detailed understanding of CD47 signaling and the CD47-SIRP α pathway is needed to develop better targeted therapies for cancer treatment of the future.

CD47 Sequences

[0102] Exemplary CD47 sequences for mouse and human are set forth in Table 3. For mRNA sequences, bold font indicates coding sequence, and consecutive exons, where indicated, are separated by alternating underlined text. For mouse and human protein sequences, signal peptides are underlined, extracellular sequences are bold font and intracytoplasmic sequences are italicized. For humanized protein sequences, non-human sequences are indicated in regular font, human sequences are indicated in bold font, and signal peptides are underlined. As shown, the isoforms differ in the number of exons. For example, isoforms 1-4 of the human CD47 gene have a total of 8, 9, 10 and 11 exons, respectively, with exons 2-7 of each isoform encoding the extracellular domain and the five transmembrane domains.

TABLE 3

Mouse CD47 mRNA isoform 1 (XM_006521810.1)
GCCTACACCGGGAGAGCAGGGAGGAGGAGTTGGACTGAGGTTGGGCGGCTC CGAGGTCCAGGGCGAGCTTGGCCAGAGGGAGTAGAGAGCAGCGGGGCTGC GCAGGGACGCGTGCCGTGAGTCCGGTGAGCGTGTGTGTCCCATGCTCCCGT

CTTTCAGGCCGGCCAGGACACGAAGCCGGAAGAGAGCTGGCTGGAGGGAC
 GGGGGCCGTGAGCAGAGAGTGCAACCCGCGCAGCCCCGGGGACAGGCTGA
 TTCTTGGCGCTCTCCGCCGAGCCTGCCAGGGCTGGGTGTGAGGCTGGCGT
 CACGTCAACGAGCAGAGGCGGCCAGGC'GGGGCGGAGTGCGCGTGC'CGG
 GCGGCGAGCACGCGCGCGCGCACCCCCGGGCAGCCTGGGCGGCCGCTCC
 TGCCTGTCACTGCTGCGGCGCTGCTGGTGGTGGTTCCTTGAAGGCAGCA
 GCGGAGGCGGCGGCTGCTCCAGACACCTGCGGCGGCGACCCCCGGCGGCG
 CGGAGATGTGGCCCTTGGCGGCGGCGCTGTTGCTGGGCTCCTGCTGCT
 GCGGTTTCAGCTCAACTACTGTTTAGTAACGTCAACTCCATAGAGTTCAC

TTTCATGCAATGAAACTGTGGTCATCCCTTGTCATCGTCCGTAATGTGGAG
 GCGCAAGCACCAGAAAGAAATGTTTGTGAAGTGGAAGTTGAACAAATCG
 TATATTTTCATCTATGATGGAAATAAAAAATAGCACTACTACAGATCAAA
 ACTTTACCAGTGCAAAAAATCTCAGTCTCAGACTTAATCAATGGCATTGC
 CTCTTTGAAAAATGGATAAGCGCGATGCCATGGTGGGAAACTACACTTGC
 GAAGTGACAGAGTTATCCAGAGAAGGCAAAACAGTTATAGAGCTGAAA
 AACCGCACGGCCTTCAACACTGACCAAGGATCAGCCTGTTCTTACGAGG
 AGGAGAAAGGAGGTTGCAAATTAGTTTCGTGGTTCCTCCAAATGAAAA
 GATCCTCATTGTTATTTTCCCAATTTTGGCTATACCTCTGTTCTGGGGAA
 AGTTTGGTATTTTAACTCAAAATATAAATCCAGCCATACGAATAAGAG
 AATCATTCTGCTGCTCGTTGCCGGGCTGGTGTCTACAGTCATCGTGGTT
 GTTGGAGCCATCCTTCTCATCCCAGGAGAAAAGCCCGTGAAAGATGCTT
 CTGGACTTGGCCTCATGTGAATCTCTACGGGGATATTAATACTACTTCA
 GTACAATGTGTTTATGACAGCTTTTGGAAATGACCTCTTTCACCATTTGCC
 ATATTGATCACTCAAGTGCTGGGCTACGTCCTTGTCTTGGTGGGCTGT
 GTCTCTGCATCATGGCATGTGAGCCAGTGCACGGCCCCCTTTTGATTTC
 AGGTTTGGGGATCATAGCTCTAGCAGAACTACTTGGATTAGTTTATATG
 AAGTTTGTGCAATAGGTGAAGGGAAGTGACGGACTGTAACCTGGAAGTCA
 GAAATGGAAGAATACAGTTGTCTAAGCACCAAGGTCTTACGACTACAGCT
 GGAAGGAACAGACAACAGTAACCTGACTTCCATCCAGGAAAACATGTCACAT
 AAATGATTACTAAGTTTATATTCAAAGCAGCTGTACTTTACATAATAAAAAA
 AATATGATGTGCTGTGTAACCAATTGGAATCCCATTTTCTATTGTTCTACT
 CAACTAGGGGCAACGTTTCAGGGGCAACTTCCAAGAATGATGCTTGTTAG
 ATCTAGAGTCTCTGAACACTGAGTTTAAATTGATTCCGAGTGAGACTCGCC
 AAGCACTAACCTGAGGGTTAGTTACCCAGAGATACCTATGAAAAACAGTGG
 TATCCAGCAAGCCTTAGTAAACTCAGGTTGCCAGCAGCTTTGCCACTTCCGC
 TGCTAGCTGAATAACAAGACTGCCACTTCTGGGTCATAGTGATAGAGACTG
 AAGTAGAAAAACGAATGTGGTTGGGCAATCCCGTGTGGCCCCCTCTGTGTG
 CTATGATATTGATGGCACTGGTGTCTTCTATTCTTGGGGGTTGCCATCATTAC
 ACACACCCCTTTGACATACAGTGCACCCAGTTTGAATACATTTTTTTTGCA
 CCCTGTCCCGTTCTGCTACTTTGATTGCGTTATGATATATATATATATAT
 AATACCTTTTCTCTCTTTAAACATGGTCCTGTGACACAATAGTCAGTTGCA
 GAAAGGAGCCAGACTTATTCGCAAAGCACTGTGCTCAAACCTTTCAGAAAA
 AAAGGAAAAAAAAAAAAAAAAAGCTATAGTTGTAACATATGTATTCCAGACCTCT
 GGTTTAAAGGCAAAAGAAAAAAATCTACAGTGTTCCTTCTCATGTTTCTG
 ATCGGAGGCATGACAAAGCAAGACTGAAATCTGAACTGTGTCTCTGCAATG
 GCAACACGTGTCTCCGTCAGGCCCTCGCAAGGCCCGGGAGGGGGTTCTAC
 GCCTCTTGTCTCTTTGTTGCATGCTGAACACTCATCGCTTCCTACTGTATCC
 TGCCTCTGCAAGCTCCCTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT
 TCCTCTCTCTCTCTCTCAAGTTTGAAGGTCAAACAAAACTACCACATTCC
 CTACCCAGTTAGAAGAAACCACCGTCTGACAGTTGTGATCGCATGGAGT
 ACTTTTAGATTATTAGCACCTGTTTACCTCGTTTGTGGGCGTGTGTGATG
 TGCACATGTATGAAGTCGGCACATGCACCTTCTGTATGGGCAGAGGCGTGG
 CATCTACAGAAGAGCAGATGCCAAGTTTGTGCTTTTAGTGAATACATTAAAA
 AAAAAAAAAACCAACGGTCTTATTGAGTGGAATTCTATTGATGCAAAATATT
 GAGCTCTTAAAGACTTTAAAACTAGATAATGTGCAAGCTTTAGGACTGCT
 CACCAAGTGCCTCTGAAGAAACACCACTACTTTTCCCTGTTTGTGTAATAAA
 GGCATATTTGTATTTGTGTTTGCATCACTAATGGTTATTTCTTCTTAGTCCAC

TGAATGTTTCCATGTGCTCTCGTATGCCAAACTTTTGTATCTTTTCATGTG
 GGGACCAATGGTTTGTCTGTGGCAAACCTAAACCTATGACCTGCTGAGGCC
 TCTCAGAAAACTGACCACAGTACCAAGATAGTACTTCGCAAGAAAAAGTAG
 GTTCCCTCCCTGGTTTGTAGCTGTGCGCAATATTAGCGTAATTCCAAGGAG
 CTGAACGCTTTATATAAATCTGATGGCACCTGATGCTTTTAGTTCTGAAAA
 TATTTACACTCGGATCATGTGTGATGACTTAAACAAAGTTTGTATGAAGA
 GAGCAAAAAAAAAAGCAGGTGGATTGGAACAGTTTCAGGGTTTTTTTGT
 TTTGTTTTTGTTT

[illegible]

TTAATAAAACATTTTAAGCTA (SEQ ID NO: 1)

Mouse CD47 amino acid isoform 1 (XP_006521873.1)

**MWPLAAALLGSCCCGSAQLLFSNVNSIEFTSCNETVTVIPICVRNVEAQSTEE
 MFVKWKLNKSYIFIYDGNKNSTTTDQNFSAKISVSDLINGIASLKMDKRDA
 MVGNYTCEVTELSREGKTVIELKNRTAFNTDQGSACSYEEKGCKLYSW
 FSPNEKILIVIFPILAILFWGKFGILTLKYSKSTNKRILLVAGLVLTIVIVVG
 AILLPEKGPVKNASGLGVLISTGILLQYNVMTAFGMTSTFTAILITQVLGYV
 LALVGLCLCIMACEPVHGPLLISGLGHIALAELLGLVYMKFVE(SEQ ID NO: 2)**

Mouse CD47 mRNA isoform 2 (XM_006521811.1)

GCCTACACCGGGAGAGCAGGGAGGAGGAGTTGGACTGAGGTTGGGCGGCTC
CGAGGTCCAGGGCGAGCTTGGCCAGAGGGAGTAGAGAGCAGCGGGGCTGC
GCAGGGACGCGTGCCGTGAGTTCCGGTGAGCGTGTGTGCCCATGCTCCCGT
CTTTCAGGCCGGCCAGGACACGAAGCCGGAAGAGAGCTGGCTGGAGGGAC
GGGGGCCGTGAGCAGAGAGTGCAACCCGCGCAGCCCCGGGGACAGGCTGA
TTCTTGCGCTCTCCGCCGAGCCTGCCAGGGCTGGGTGTGAGGCTGGCGT
CAGCTCAACGAGCAGAGCGCGGCCAGCGGGGCGGAGTGCGCCTGCGCGGG
CGCGCAGCAGCGCGCGCGCAGCACCCCGGGCAGCCTGGCGCGCCGCTCC
TGCTGTCACTGCTGCGGCGCTGCTGGTGGTGGTTTCCCTTGAAGGCAGCA
GCGGAGGCGGCGGCTGCTCCAGACACCTGCGGCGGCGACCCCCGCGGCG
CGGAGATGTGGCCCTTGGCGGCGGCGCTGTTGCTGGGCTCCTGCTGCT

GCGGTTCAAGTCAACTACGTGTTAGTAACTGCAACTCATAGAGTTCACT
 TTCATGCAATGAACTGTGGTCATCCCTTGCATCGTCCGTAATGTGGAG
 GCGCAAAGCACCGAAGAAATGTTTGTGAAGTGGAAAGTTGAACAAATCG
 TATATTTTCATCTATGATGGAAATAAAAAATAGCACTACTACAGATCAAA
 ACTTTACCAGTGCAAAATCTCAGTCTCAGACTTAATCAATGGCATTGC
 CTCTTTGAAAATGGATAAGCGCGATGCCATGGTGGGAACTACACTTGC
 GAAGTGACAGAGTTATCCAGAGAAGGCCAAAACAGTTATAGAGCTGAAA
 AACCGCACGGTTTCGTGGTTTTCTCCAAATGAAAAGATCCTCATTGTTA
 TTTTCCCAATTTTGGCTATACTCCTGTTCTGGGGAAAGTTTGGTATTTTA
 ACACCTCAAATATAAATCCAGCCATACGAATAAGAGAATCATTCTGCTGC
 TCGTTGCCGGGCTGGTGTCTACAGTCATCGTGGTTGTTGGAGCCATCCT
 TCTCATCCCAGGAGAAAAGCCCGTGAAGAATGCTTCTGGACTTGGCCTC
 ATTGTAATCTCTACGGGGATATTAATACTACTTCAGTACAATGTGTTTAT
 GACAGCTTTTGGAAATGACCTCTTTCACCATTGCCATATTGATCACTCAA
 GTGCTGGGCTACGTCTTGTCTTGGTTCGGGCTGTGTCTCTGCATCATGG
 CATGTGAGCCAGTGACAGGCCCCCTTTTGATTTCAGGTTTGGGGATCAT
 AGCTCTAGCAGAACTTGGATTAGTTTATATGAAGTTTGTGCGTTCC
 AACAGAGGACTATCCAACCTCCTAGGAATAGGTGAAGGGAAGTGACGG
 ACTGTAACCTTGGAAAGTCAGAAATGGAAGAATACAGTTGTCTAAGCACCAG
 TCTTACAGACTCACAGCTGGAAGGAACAGACAACAGTAAGTACTTCCATC
 CAGGAAAACATGTCACATAAATGATTACTAAGTTTATATTCAAAGCAGCTGT
 ACTTTACATAATAAAAAAATATGATGTGCTGTGTAACCAATTGGAATCCCA
 TTTTCTATTGTTTCTACTCACTAGGGGCAAACGTTTCAGGGGCAACTTCCA
 AGAATGATGCTTGTTAGATCCTAGAGTCTCTGAACACTGAGTTTAAATTGAT
 TCCGAGTGAGACTCGCCAAGCACTAACCTGAGGGTTAGTTACCCAGAGATA
 CCTATGAAAAACAGTGGTATCCAGCAAGCCTTAGTAAACTCAGGTTGCCAG

CAGCTTIGCCACTTCCGCTGCTAGCTGAATAACAAGACTGCCACTTCTGGGT
 CATAGTGATAGAGACTGAAGTAGAAAAACGAATGTGGTTGGGCAAATCCCCG
 TGTGGCCCTCTGTGTGCTATGATATTGATGGCACTGGTGTCTTCTATTCTGG
 GGGTTGCCATCATTCACACACCCCTTTGACATACAGTGCACCCCGAGTTT
 GAATACATTTTTTTTGCACCCGTCTCCCGTTCTGCTACTTTGATTGCGTTATG
 ATATATATATATATATAATACCTTTTCTCCTCTTTAAACATGGTCCGTGA
 CACAATAGTCAGTTGCAGAAAGGAGCCAGACTTATTCGCAAAGCACTGTGC
 TCAAACCTCTCAGAAAAAAGGAAAAAAGCTATAGTTGTAACAT
 ATGTATTCCAGACTCTGGTTTAAAGGCAAAAGAAAAAATCTACAGTGT
 TTCTTCTCATGTTTCTGATCGGAGGCATGACAAAGCAAGACTGAAATCTGA
 ACTGTGTCTCCTGCATGGCAACACGTGTCTCCGTCAGGCCCTCGCAAGGCC
 GGGGAGGGGGTTCTACGCCTCTTGTCTTTGTTGCATGCTGAACACTCATC
 GCCTTCTACTGTATCCTGCCTCCTGCAGCCTCCCTCTTCTCTCTCTTCT
 CTTCCT
 AAAACTACCACATTCCCTACCCAGTTAGAAGAAAAACACCGTCTGACAGTT
 GTGATCGCATGGAGTACTTTAGATTATTAGCACCTGTTTTTACCTCGTTTGT
 GGGCGTGTGTATGTGCACATGTATGAAGTCGGCACATGCACCTTCTGTAT
 GGGCAGAGGGCTGGCATCTACAGAAGAGCAGATGCCAACTTTGTGCTTTA
 GTGAATACATTAATAAAAAAACCACCGTCTTATTGAGTGGAAATCTA
 TTTGATGCAAATATTGAGCTCTTTAAGACTTTAAACTAGATAATGTGCCA
 AGCTTTTAGGACTGCTCAGAGTGCCTCTGAAGAAACACAGTACTTTTCT
 CTGTTTGTGTAATAAAGGCATATTTGTAITTTGTGTTTGCATCACTAATGGTTA
 TTTCTCTTAGTCCACTGAATGTTTCCATGTGCCTCTCGTATGCCAACTTTT
 TGTCTCTTTTATGTGGGGACCAAAATGGTTTGTCTGTGGCAAACCTAAACCT
 ATGACCTGCTGAGGCCCTCTCAGAAAACTGACACAGTACCAAGATAGTACT
 TCGCAAAGAAAAGTAGGTTCCCTCCCTGGTTTTGTAGCTGTGCGCAATATTA
 GCGTAATTCCAAGGAGCTGAACGCCCTTATATAAATCTGATGGCACCTGATG
 CTTTATAGTTCTGAAAATATTTACACTCGGATCATGTTGTTGATGACTTAAACA
 AAGTTTGTATGAAGAGAGCAAAAAAAGCAGGTGGATTGGAACAGTTTC
 AGGGTTTTTTTTGTTTTTGTTTTTTGTTTTTTGTTTTTTTTTTTTATTTTTGTTT
 TTCGTCTCTGTAGAAAAGTCAGGTGTTCTCTGTGAGGCTATCTTTATAGT
 CAATTTTTTTTACGAACATAAGTAGTACCTTTAATATGTAGTCAACGCCCT
 CTGCTCGGGGTTTCAGTTTTGGGTCTTAACCAGCTGTCATGTTCTCTATGCTGC
 CTGCCACTTGAGGCACTGAGTGCCTAGACAGTCCCATCGGTGGTAGCCAG
 GGAAACGAAAGACGAACTCAACTCTTGCTCCTAATAATCAACTCTCTGTATG
 AAGGATGGCAGCATTAAGAGTCTCTGCTGGGCAATTATTGGGCCAGTTCA
 CCCTCTTTAAATCAAAACCCGAGTGGCTCCAGTTCTCGTCCCATCAGATTT
 AAATTGCTAACAGTATGGGGGGCACACGCATCTGTTTTGTCCCAATGCG
 CTTTTCTCTCCCAATCCCGATTCTGTGCTGTCATAGCCTCTATTCAATTTTTAT
 TTATTGCTGCCCTCCACTTATACAATCGTAGAGAGCAATGCCATTGTGCACT
 TTCTGCAACAGTTTTTTGAGCCTTTATGGCTGAATCCCATTTTTCTCTCTTTC
 AAAGCTGTTTGTCTCAATTGCTGCTCCCGCAGGCTGTCCGTACAGTCAATCCAT

CCATCTGGGGGCTCTTTCATCTCTCACCCCTCCTGGTGCTTCGTGGATCTCT
GCTTACCTCTGTGGGTTTTTTTTTTTTTTTGGACTTATCTCTCACTGGACT
TTAAGATTACTCCACAGCGAAAGTGCTGCCTCCCTTTTCTGCCCCGAGTGTT
CTGCGTACTTTAGATACTACTCAGTGCTGACATTTGATGGCAAAAGTTGCCT
GCACTTAAATTTCTCTTTTAAATAGGGTGAAGTAGAGTTGGAGTTTTTTCTC
TTTTTCTCTTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT

CCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCTCTCTCTCTTTTTCTTTCTTT
TTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCT
CACAGGCTTTGAGAATTATAAAAGGTGACAGTTCACCTGAAAATCACAGGT
CTGGTCTGTTTAAATTGTTGAGAAATATCCGATTAAAAGCTTGTGGCTGTG
TCCTAATAGGCTCTCTTTCAGGACGTTGTAGTCAATAGAGTGGCTGAACCAT
ACTTGAGTTTATAAAGCTCAAAAACCTGATGCACCCACTCTGCTATTATCGTG
TTAGTAAGAGTTCACTGTATATCATTGTCTAGGTTTATCTTGTCCCTACAGTG
GGTATTCAAATATGGCCACCAGAGGATATGTGTAAATATAAGCACCTGTATT
TGCCTGTTGTTGAGAACTGGAGGGAACAAAAAATGTCTGGCAACCCCTTT
GCCTTTTTAACCCTAATTAATTGACAGTTTATTTAGAGATAAGAGTTTCAA
AAATCTCTTAACTGCCACAACCCACAGAGGGTCTTGTGTTGCCATCTTCAGT
GGCTCACAGATATGATCCAAGTTAACTTGAAAGAGATGAGCAGTACCCAGG
AAATTGTCCTGCCTTTAACTCTGGCTGTCTTAATTATGACTGTTTAAATGCTG
AATTTTCCATCCGCTAGTGTGTTGAGGGTAAAGAAAAGCCTTTTTTAAATAA
GTATTTCTGTAAACGGCATCGGTGGGATCTTCTGTGTTGCTATCACGGGTG
AAAGAGGGAACATTTCTTATTTTATTAAGCAGAGCATTATTTACAGAAAG
CCATTGTTGAGAATTAGTTCCACATCATATAAATATCCATTAACCATTTCTA
AATTGTAAGAGAACTCCAGTGTTGCTATGCACAAGGAACCTCTCCTGGGGGC
CTTTTTTGCATAGCAATTAAGGTATGCTATTTGTCAGTAGCCATTTTTTGC
AGTGATTTAAAGACCAAAGTTGTTTACAGCTGTGTTACCCTTAAAGGTTTT
TTTTTATGATATAATCAATTTATCACTGTTTGAAGCTTTGAATACCTGCAA
TCTTTGCCAAGATACTTTTTTATTTAAAAAATAACTGTGTAAATATTACCCT
GTAATATTATATACTTAATAAAACATTTTAAGCTA (SEQ ID NO: 3)

Mouse CD47 amino acid isoform 2 (XP_006521874.1)

MWPLAAALLLGSCCCGSAQLLFSNVNSIEFTSCNETVVIPCIVRNVEAQSTEE
MFVKWKLNKSYIFIYDGNKNSTTTDQNFSAKISVSDLINGIASLKMDKRDA
MVGNYTCEVTELSREGKTVELKNRTVSWFSPNEKILIVIFPILAILLFWGKFG
ILTLKYKSHTNKRIILLVAGLVLTIVVVGAILLIPGEKPVKNASGLGLIVISTG
ILILLQYNVFMATAFGMTSFTIAILITQVLGYVLALVGLCLCIMACEPVHGPLLISG
LGIIALAEELLGLVYMKFV*ASNQRTIQPPRNR*(SEQ ID NO: 4)

Mouse CD47 mRNA isoform 3 (XM_006521807.1)

GCCTACACCGGGAGAGCAGGGAGGAGGAGTGGACTGAGGTTGGGCGGCTC
CGAGGTCCAGGGCGAGCTTGCCAGAGGGAGTAGAGAGCAGCGGGGCTGC
GCAGGGACGCGTGCCGTGAGTTCCGGTGAGCGTGTGTGTCCCATGCTCCCGT
CTTTCAGGCCGGCCAGGACACGAAGCCGGAAGAGAGCTGGCTGGAGGGAC
GGGGGCCGTGAGCAGAGAGTGCAACCCGCGCAGCCCCGGGGACAGGCTGA
TTCTTGGCGCTCTCCGCCGAGCCTGCCAGGGCTGGGTGTGAGGCTGGCGT
CACGTCAACGAGCAGAGGGCGCCAGGCGGGGCGGAGTGCGCGTGCAGCGG
GCGGCGAGCACGCGCGCGCGCGCACCCCCGGGCAGCCTGGGCGGCGCTCC
TGCCTGTCACTGCTGCGGCGCTGCTGGTCGGTCGTTTCCCTTGAAGGCAGCA
GCGGAGGCGGCGGCTGCTCCAGACACCTGCGGCGGCGACCCCCGGCGGCG
CGGAGATGTGGCCCTTGCGCGGCGCGCTGTTGCTGGGCTCCTGCTGCT
GCGGTTCACTCAACTACTGTTTGTAGTAACGTCAACTCCATAGAGTTCAC
TTCATGCAATGAACTGTGGTCATCCCTTGCATCGTCCGTAATGTGGAG
GCGCAAAGCACCGAAGAAATGTTTGTGAAGTGGAAGTTGAACAAATCG
TATATTTTCACTATGATGGAATAAAAAATAGCACTACTACAGATCAA

ACTTTACCAGTGCAAAAAATCTCAGTCTCAGACTTAATCAATGGCATTGC
CTCTTTGAAAATGGATAAGCGCGATGCCATGGTGGGAACTACACTTGC
GAAGTGACAGGTTATCCAGAGAAGGCAAAACAGTTATAGAGCTGAAA
AACCGCACGGCCTTCAACACTGACCAAGGATCAGCCTGTTCTTACGAGG

AGGAGGAAAGGAGGTTGCAAAATTAGTTTCGTGGTTTTCTCCAAATGAAAA
GATCCTCATTGTTATTTTCCCAATTTTGGCTATACCTCGTTCTGGGGAA
AGTTTGGTATTTTAACTCAAAATATAAATCCAGCCATACGAATAAGAG
AATCATTTCTGCTGCTCGTTCCGCGGGCTGGTCTCACAGTCATCGTGGTT
GTTGAGGCCATCCTTCTCATCCCGAGGAAAAAGCCCGTGAAGAATGCTT
CTGGACTTGGCCCTCATTGTAATCTCTACGGGGATATTAATACTACTTCA
GTACAATGTGTTTATGACAGCTTTTGGGAATGACCTCTTTCACCATTGCC
ATATTGATCACTCAAGTGCTGGGCTACGTCCTTGCCTTGGTCGGGCTGT
GTCTCTGCATCATGGCATGTGAGCCAGTGCACGGCCCCCTTTTGATTTC
AGGTTTGGGGATCATAGCTTACGAGAACTCATTTGGATTAGTTTATATG
AAGTTTGTGCGTTCCCAACAGAGCACTATCCAACCTCCTAGGAAAGCTG
TAGAGGAACCCCTTAAACGAATAGGTGAAGGGAAGTGACGGACTGTAACCT
GGAAAGTCAGAAATGGAAGAATACAGTTGTCTAAGCACCAGGTCTTACGAC
TCACAGCTGGAAGGAACAGACAACAGTAAGTGAAGTCCATCCGACAAAAACA
TGTCACATAAATGATTACTAAGCTTTATTTCAAAGCAGCTGACTTTACATA
ATAAAAAAAATATGATGTGCTGTGTAAACCAATGGAATCCCAATTTTCTAT
GTTTCTACTCAACTAGGGGGCAACGTTTACGGGGCAACTTCCAAGAATGATG
CTTGTTAGATCCTAGAGTCTCTGAACACTGAGTTTAAATTGATTCCGAGTGA
GACTCGCCAAGCACTAACCTGAGGGTTAGTTACCCAGAGATACCTATGAAA
AACAGTGGTATCCAGCAAGCCTTAGTAACTCAGGTGCCAGCAGCTTTGCC
ACTTCGCTGCTAGCTGAATAACAAAGACTGCCACTCTGGGTCATAGTGA
GAGACTGAAGTAGAAAAACGAATGTGGTTGGGCAAAATCCCGTGTGGCCCT
CTGTGTGCTATGATATTGATGGCACTGGTGCTTCACTTCTGGGGGTTGCCAT
CATTCACACACACCCCTTTGACATACAGTGCACCCAGTTTGAATACATTT
TTTTTGACCCCTGTCCCGTTTCTGCTACTTTGATTGTGCGTTATGATATATAT
ATATATAATAATACCTTTTCTCTCTTTAAACATGGTCTGTGACACAATAGTC
AGTTGCAGAAAGGAGCCAGACTTATTTCGCAAGCACTGTGCTCAAACCTTTC
AGAAAAAAAGGAAAAAAGCTATAGTTGTAACATATGTATTCCAG
ACCTCTGGTTTAAAGGCAAAAGAAAAAAATCTACAGTGTTTCTTCTCATGT
TTTCTGATCGGAGGCATGACAAAGCAAGACTGGAATCTGAAGTGTGTCTCCT
GCATGGCAACAGCTGTCTCCGTCAGGCCCTCGCAAGGCCCGGGAGGGGGT
TCTACGCTCTTGTCTTTGTGTGACTGTGAACACTCATCGCTTCTCATCTG
TATCCTGCCTCCTGCAGCCTCCTCTTCTCCTCCTCTTCTCCTCCTCCT
CCTCCTCCTCCTCCTTCTCTCCAAGTTTGAAAGGTCAAACAAAACCTACCAC
ATTCCCTACCCAGTTAGAAGAAACACCGTCTTGACAGTTGTGATCGCATG
GAGTACTTTTAGATTATTAGCACCTGTTTTTACCTCGTTTGTGGGCGTGTG
TATGTGCACATGATGAAGTCGGCAACATGCACCTTCTGTATGGGCGAGGGC
TGGCATCTACAGAAGAGCAGATGCCAACCTTGTGCTTTTAGTGAAATACATTA
AAAAAAGAACCAACGGTCTCTTATTGAGTGGGAATTTCTATTTGATGCAAA
ATTTGAGCTCTTTAAGACTTTTAAACTAGATAATGTGCCAAGCTTTTAGGAC
TGCTCACCAGTGGCCCTCTGAAGAAACACCAAGTACTTTTCTGTTTGTGTAAT
AAAGGCATATTGTATTGTGTTTGATCATCACTAATGGTTATTTCTTCTGATC
CACTGAATGTTTCCATGTGCTCTGATGCAAACTTTTGTACCTTCTTCTAT
GTGGGGACCAAAATGGTTTGTCTGTGGCAACCTAAACCTATGACCTGCTGAG

[illegible]

CCCTCCCTCCCTCCCTCCCTCCCTCTCTCTCTCTTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTTGTACAAATCTCACAGGC
TTTGAGAATTATAAAAAGGTGACAGTTTCACTGAAAAATCACAGGTCCTGGTCTG
TTTAAATTTGTAGAAAATATCCGATTAAAAGTCTTGTGGCTGTGTCCTAATA
GGCTCTCTTTTCAGGACGTTGTAGTCAATAGAGTGGCTGAACCACTACTGTAGT
TTATAAAAGCTCAAAAACTGATGCACCCACTCTGCTATTATCGTGTTAGTAAG
AGTTCAGCTGTATATCATTGTCTAGGTTTATCTTGTCTACAGTGGGTATTCA
AATATGGCCACCAGAGGATATGTGTAATAATAAGCACTGTATTTGCCTGTT
GTTGAGAACTGGAGGGAAAAACAAAAATGTCTGGCAACCCCTTTGCCTTTTTA
ACCGTAATTAATTGACAGTTATTTAGAGATAAGAGTTTCAAAAACTCTT
AACTGCCAACACCCACAGAGGGTCTTGTTTTGCCATCTTCAGTGGCTCACAG
ATATGATCCAAGTTAACTTGAAGAGATGAGCAGTACCCAGGAAATTGTCC
TGCTTTAACTCTGGCTGTCTTAATTATGACTGTTTAAATGCTGAATTTCCA
TCCGTCTAGTGTTTGAGGGTAAAGAAAAGCCTTTTTTAAATAAGTATTTCTG
TAAACCGGCATCGGTGGGATCTTCTGTGTGCTATCACGGGTGAAAGAGGG
AAACATTTCTTATTTTTTAAAGCAGGACATATTATACAGAAAGCAATTGTT
GAGAATTAGTTCACACATCATATAAATATCCATTAAACCATTCTAAATTTGTAA
GAGAACTCCAGTGTGCTATGCACAAGGAACTCTCTGGGGGCCCTTTTTTTG
CATAGCAATTAAAGGTATGCTATTTGTCACTAGCCATTTTGTGCACTGATTT
AAAGACCAAAGTTGTTTTACAGCTGTGTATACCCCTAAAGGTTTTTTTTTATG
TATTAATCAATTTATCACTGTTTGAAGCTTTGAATACCTGCAATCTTTGCCA
AGATACTTTTTTATTTAAAAAAATAACTGTGTGAATATTACCTGTAAATATTA
TATATACTTAATAAAACATTTTAAAGCTA (SEQ ID NO: 5)

Mouse CD47 amino acid isoform 3 (XP_006521870.1)

**MWPLAAALLGSCCCGSAQLLFSNVNSIEFTSCNETVTVIPICVRNVEAQSTEE
MFVKWKLNKSYIFIYDGNKNSTTTDQNFSAKISVSDLINGIASLKMDKRDA
MVGNYTCEVTELSREGKTVIELKNRTAFNTDQGSACSYEEKGKCKLVSW
FSPNEKILIVIFPILAILLFWGKFGILTLKYKSSHTNKRIILLVAGLVLTIVVVVG
AILLPGCEKPVKNASGLGLIVISTGILILLQYNVFMATFGMTSFTIAILITQVLGYV
LALVGLCLIMACEPVHGPGLLISGLGHIALAELLGLVYMKFV.ASNQRTIQPPRKAV
EEPLNE**(SEQ ID NO: 6)

Mouse CD47 mRNA isoform 4 (XM 006521808.1)

GCCTACACCCGGGAGAGCAGGGAGGAGGAGTGGACTGAGGTTGGGCGGCTC
CGAGGTCCAGGGCGAGCTTGGCCAGAGGGAGTAGAGAGCAGCGGGGCTGC
GCAGGGACGCGTGCCGTGAGTTCCGGTGAGCGTGTGTGTCCCATGCTCCCGT
CTTTCAGGCGCGGCCAGGACACGAAGCCGGAAGAGAGCTGGCTGGAGGGAC
GGGGCGGCTGAGCAGGAGAGTGCAACCCGCGCAGCCCGGGACAGGCTGA
TTCTTGGCGTCTCCCGGAGGCTGCCAGGGCTGGGTGTGAGGCTGCGCT
CACGTCAACGAGCAGAGGCGGCGCAGGCGGGGCGGAGTGC GCGTGC GCGGG
GCGGCGAGCACGCGCGCGCGCACCCCCGGGCAGCCTGGGCGGCCGCTCC
TGCCTGTCACTGCTGCGGCGCTGCTGGTGGTTCGTTTCCCTTGAAGGCAGCA
GCGGAGGCGGGCGCTGCTCCAGACACCTGCGGCGGGCAGCCCCCGCGGCG
CGGAGATGTGGCCCTTGGCGGCGGCGCTGTTGCTGGGCTCCTGCTGCT
CGGTTTCAGTCAACTACTGTTTAGTAACGTCAACTCCATAGAGTTCA
TTCAATGCAATGAAACTGTGGTCACTCCCTTGCAATCGTCCGTAATGTGGAG
GCGCAAAGCACCCGAAGAAATGTTTGTGAAGTGGAAGTTGAACAAATCG
TATATTTTCATCTATGATGGAATAAAAAATAGCACTACTACAGATCAAA
ACTTTACCAGTGCAAAAATCTCAGTCTCAGACTTAATCAATGGCATTGC
CTCTTTGAAAATGGATAAAGCGCGATGCCATGGTGGGAAACTACACTTGC
GAAGTGACAGAGTTATCCAGAGAAGGCAAAACAGTTATAGAGCTGAA
AACCGCACGGTTTCGTGGTTTCTCCAAATGAAAGATCCTCATTGTTA
TTTTCCCAATTTTGGCTATACTCCTGTTCTGGGGAAAGTTTGGTATTTTA
ACACTCAAATATAAATCCAGCCATACGAATAAGAGAATCATTCTGCTGC
TCGTTGCCGGGCTGGTGTCTACAGTCATCGTGGTTGTTGGAGCCATCCT
TCTCATCCCAGGAGAAAAGCCCGTGAAGAATGCTTCTGGACTTGGCCTC
ATTGTAATCTCTACGGGGATATTAATACTACTTCAGTACAATGTGTTTAT
GACAGCTTTTGAATGACCTCTTTCACCATTGCCATTTGATCATCTCAA
GTGCTGGGCTACGTCTCTTGTCTGGTGGGCTGTGTCTCTGCATCATGG
CATGTGAGCCAGTGCACGGCCCCCTTTTGATTTCAAGTTTGGGGATCAT
AGCTCTAGCAGAACTACTTGGATTAGTTTATATGAAGTTTGTGCGTTCC
AACCAGGAGACTATCCAACCTCCTAGGAAGCTGTAGAGGAACCCCTTA
ACCGATTATGAGCTCAAAAGCAATGTAATGTAAGCAATGTAAGCTCAAGC

CTCTCTCTCTCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCTCTCTCTCT
TTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTT
TTTGACAAATCTCACAGGCTTTGAGAATTATAAAAGGTGACAGTTCACCTGA
AAATCACAGGCTCTGGTCTGTTTAAATTGTTGAGAAATATCCGATTAAGGTC
TTGTGGCTGTGTCTCTAATAGGCTCTCTTTGAGGACGTTGTAGTCAATAGAGT
GGCTGAACCATCTTGAGTTTATAAAGCTCAAAAACCTGATGCACCCACTCTG
CTATTATCGTATTAGTAAGAGTTTCAGCTGTATATCATTGTCTAGGTTTATCTT
GTCTTACAGTGGGTATTCAAATATGGCCACCAGAGGATATGTGTAAATATA

AGCACCTGATTTGCCCTGTTGTTGAGAACTGGAGGGAAAAACAAAAAATGTC
 TGGCAACCCCTTTGCCCTTTTAAACCGTAATTAATTGACAGTTTATTTAGAGATA
 AGAGTTTTCAAAAATCTTTAACTGCCACAACCCACAGAGGGTCTTGTTTTG
 CCATCTTCAGTGGCTCACAGATATGATCCAAGTTAACTTGAAAGAGATGAGC
 AGTACCCAGGAAATTGTCCTGCCTTTAACTCTGGCTGTCCTTAATTATGACT
 GTTTAATGCTGAATTTTCCATCCGTCTAGTGTGTTGAGGGTAAAGAAAAGCCT
 TTTTAAATAAGTATTTCTGTAAAACGGCATCGGTGGGATCTTCTGTGTTGCT
 ATCACGGGTGAAAGAGGGAAACATTTCTTATTTTTATTAAGCAGAGCATTAT
 TTACAGAAAGCCATTGTTGAGAATTAGTTCACATCATATAAATATCCATT
 AACCATTCTAAATTGTAAGAGAACTCCAGTGTGCTATGCACAAGGAACTCT
 CCTGGGGGCCTTTTTTGCATAGCAATTAAGGTATGCTATTTGTCAGTAGC
 CATTTTTTGCAGTGATTTAAAGACCAAAGTTGTTTTACAGCTGTGTTACCCTT
 AAAGGTTTTTTTTTATGTATTAAATCAATTTATCACTGTTTGAAGCTTTGAA
 TACCTGCAATCTTTGCCAAGATACTTTTTATTTAAAAAAATAACTGTGTAA
 ATATTACCCTGTAATATTATATATACTTAATAAAACATTTTAAGCTA (SEQ ID
 NO: 7)

Mouse CD47 amino acid isoform 4 (XP_006521871.1)

MWPLAAALLLGSCCCGSAQLLFSNVNSIEFTSCNETVVIPCIVRNVEAQSTEE
 MFVKWKLNKSIFYIDGNKNSTTTDQNFSAKISVSDLINGIASLKMDKRDA
 MVGNYTCEVELSREGKTVIELKNRTVSWFSPNEKILVIFPILAILLFWGKFG
 ILTLKYKSSHTNKRILLVAGLVLTIVVVVGAILLIPGEKPVKNASGLGLIVISTG
 ILILLQYNVFMATAFGMTSFTIAILITQVLGYVLALVGLCLCIMACEPVHGPLLISG
 LGIILAELLGLVYMKFVASNQRTIQPPRKAVEEPLNAFKESKGMMNDE (SEQ ID
 NO: 8)

Human CD47 mRNA isoform 1 (XM 005247909.1)

AGTGGGAGCGCGCGTGCAGCGCGGCGGTGCAGCCTGGGCAGTGGGTCCTGCC
 TGTGACGCGCGCGCGCGGTGCGTGCCTGTAACGGCGCGCGCGGTGCT
 GCTCCGGACACCTGCGCGCGCGCGCGGCGACCCGCGCGCGCGCGGAGAT
 GTGGCCCCCTGGTAGCGCGCGCTGTTGCTGGGCTCGGCGTGTGCGGATC
AGCTCAGCTACTATTTAATAAAAAACAAATCTGTAGAATTCACGTTTTGTA
ATGACACTGTCGTCATTCCTATGCTTTGTTACTAATATGGAGGCACAAAA
CACTACTGAAGTATACGTAAGGTGGAAATTTAAAGGAAGAGATATTTAC
ACCTTTGATGGAGCTCTAAACAAGTCCACTGTCCCCACTGACTTTAGTA
GTGCAAAAATTGAAGTCTCACAACTACTAAAAGGAGATGCCTCTTTGAA
GATGGATAAGAGTGATGCTGTCTCACACACAGGAAACTACACTTGTGAA
GTAACAGAAATTAACCAGAGAAGGTGAAACGATCATCGAGCTAAAATATC
GTGTTGTTTCATGGTTTTCTCCAAATGAAAATATTCTTATTGTTATTTTC
CCAATTTTGTCTACTCCTGTTCTGGGGACAGTTTGGTATTAAAACAC

TTAAATATAGATCCGGTGGTATGGATGAGAAAAACAATTGCTTTACTTGT
TGCTGGACTAGTGACTGTCATTGTGTCATTGTTGGAGCCATTCTTTTC
GTCCCAGGTGAATATTCATTAAAGAATGCTACTGGCCTTGGTTTAATIG
TGACTTCTACAGGGATATTAATATTACTTCACTACTATGTGTTTAGTACA
GCGATTGGATTAACTCCCTTCGTCATTGCCATATTGGTTATTCAGGTGA
TAGCCTATATCCTCGCTGTGGTTGGACTGAGTCTCTGTATTGCGGCGTG
TATACCAATGCATGGCCCTCTTCTGATTTCAAGTTTGAGTATCTTAGCT
CTAGCACAAATTACTTGGACTAGTTTATATGAAATTTGTGGAATAACTGAA
GTGAAGTGATGGACTCCGATTTGGAGAGTAGTAAGACGTGAAAGGAATACA
CTIGTGTTTAAGCACCATGGCCTTGATGATTCACTGTTGGGGAGAAGAAACA
AGAAAAGTAACTGGTGTACCTATGAGACCCCTACGTGATTGTTAGTTAAG
TTTTTATTCAAAGCAGCTGTAATTTAGTTAATAAAATAATTATGATCTATGTT
GTTTGCCCAATTGAGATCCAGTTTTTTGTTGTTATTTTTAATCAATTAGGGGC
AATAGTAGAATGGACAATTTCCAAGAATGATGCCTTTCAGGTCTAGGGCCT
CTGGCCTCTAGGTAACCAGTTTAAATTGGTTTCAGGGTGATAACTACTTAGCA
CTGCCCTGGTGATTACCCAGAGATATCTATGAAAACAGTGGCTTCCATCAA
ACCTTTGCCAACTCAGGTTTACAGCAGCTTTGGGCAGTTATGGCAGTATGGC
ATTAGCTGAGAGGTGCTGCCACTTCTGGGTCAATGGAATAATAAATTAAGT
ACAGGCAGGAATTTGGTTGGGAGCATCTTGATGATCTCCGTATGATGTGAT
ATTGATGGAGATAGTGGTCTCATCTTGGGGGTGGCATTCCACATITCCC
CCTTCAACAAACAGTGTAACAGGTCTTCCAGATTTAGGGTACTTTTATTG

AIGGATATGTTTTCCTTTTATTCACATAACCCTTGAACCCTGTTGICTTGICT
CCTGTTACTTGCTTCTGTACAAGATGTAGCACCTTTTCCTCTTTGAAC
ATGGTCTAGTACACGTAGCACCAGTTGCAGGAAGGAGCCAGACTTGTC
TCAGAGCACTGTTCACACTTTCAGCAAAAATAGCTATGGTTGTAACAT
TGTATTCCTTCCTGATTTGAAGGCAAAATCTACAGTGTTCTTCACTTC
TTTTCTGATCTGGGGCATGAAAAAAGCAAGATTGAAATTGAACTATGAGIC
TCCTGCATGGCACAAAATGTGTCACCATCAGGCCAACAGGCCAGCCT
GAATGGGGATTATTACTGTTGTATCTATGTTGCATGATAACATTCAC
CTTCCTGTAGTCCTGCTACTCCCTTCCCTATGATTGAAAGTA
ACAAAACCCACATTTCCTATCTGGTTAGAAAATTAATGTTCTGACAGT
TGTGATCGCTGGAGTACTTTAGACTTTAGACTTTATTGGATTATTG
TTAGTAAAAACATTAAATACAAAGTTCTTTATTGGGTGGATTATTTG
TGCAAATTTGATCACTTAAAACTTTAAAACTTCTAGGTAATTTGCCAG
CTTTTGACTGCTCACCAATACCTGTAAAAATACGTAATTCTCCTGTTG
GTAATAAGATATTTGATTGCATTAATATAGTTGCATTAATATAGTTTC
ATCAGATGTTCCGTGCCTCTTTATGCCAAATTGACCTAAATTATGACT
TTGGGACCAAGTTTGCCAACCTAAATTATGACCTAAATTATGACCTGT
CCTCTCAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AIATGTATACAAATATACGTATATCTATATATACGTATGTATATAC
ACATGTATATTCTTGATTGTAGCTGTCCAAATAATAACATATA
GAGGGAGCTGTATTCCTTATACAAATCGATGGCTCTGCAGCACTTTC
CTTCTGAAAATTTACATTTGCTAACCTAGTTGTACTTTAAAATCAG
TTTGATGAAAGGGAAAAGCAGATGGACTTGAAAAAAGATCCAAGCT
ATTAGAAAAGGTATGAAAATCTTATAGTAAAATTTTAIAAACTAAAG
GIACCTTTAATATGTAGTAAACTCATTATTTGGGTTCGCTTGGAT

TCATCCATCCATTGTTCTCTTAATGCTGCCTTTGAGGCATTCAT
GCCCTAGACAATGCCACCAGATAGTGGGGGAATGCCAGATGAACCA
CTCTTGCTCTCATAGTTGTCAGCTTCTGGATAATGACCAGAGC
GAGTCCTCTGGCATCATTGGGCCAGTTCCTTCTTTAAATCAGAT
TGTATGGCTCCCATCACATCACATTAAATTGCAGACAGTGTT
TGCACATCATGTATCGTTTTGTCCCATAATATGCTTTACTCCTGATCC
AGTTTCGCTGTTGACTTCCATTCAGTTTATTATTGTGTTCTCACA
GACACCATTTGCCTTTCTGCAACACCTTCCAGCTACTTTGCCAATT
TATTTGTCTTCCTTCAAAACATTCCTTGCAGTTCCTCTCATCTGT
GCTGCTCTTTGTCTCTTAACTTACCATTCCTATAGTACTTATGCATCT
TAGTTCTATAGTTTTGGCCTTGCTTCCTTGATTTAAAATTCCT
TATAGAAGCTAAAGTTAAATGATTGAGAGTTGGCTGTATTAGA
TTATCACTTTTAATATAGAGTTTCTTCTTCTTCTTCTTCTTT
TTTTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
AAAAACCTTCAAAGGTGATATTTTCCTTGGAACTCCAGGTCCATTC
TTTAATCCCTAGAATGTCAGAATAAATAACAGGGCTATCCCGTAAT
GAAATATTCTTTTCAGGATGCTATAGTCAATTAGTAAGTGACCA
ATTGTATTTTCTTTCAAAGCTCAAAACAGATAAGTTACTCCTCCAT
TCAGTATAAAAATTAAGCTGTAATCAACCTTCTAGGTTCTCTTGT
AATGGGTATCAAAATGGGATCTGTGGTGTATGTATGGAACATAC
CCTTAATTACTGTTGTTGGAACTGGAAATGATTGTCGGGCAACGT
TATTTTATTGTATTTATTTGGTTGAGGATTTTTATAAACAGTTAC
TGTGTCATATTTAAATTACTAACTGCCATCACCTGCTGGGTCCT
GGTCATTTCAGTATAGGGATATCCAGGTAACTTTGAAGAGATG
GCAGTGATGACCAGGAGTTTCTGCCTTAGCTTGACAGTTCTAAT
AGATCATTGAAGACCAGCTTTCTCATAAATTCTTTTGAAAAAAA
GCATTTGTACTAAGCTCTCTGTAAGACACATCTTAAATCTTAAA
GTTATCATGACTGGTGAGAAAACATTTTGTTTTATTAAATGGA
TTATTT<

MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNT
 TEVYVKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDK
 SDAVSHTGNYTCEVTEL TREGETHELKYRVVSWFSPNENILIVIFPIFAILLFW
 GQFGIKTLKYRSGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLK NATGLGLI
 VTSTGILILLHYVVFSTAIGLTSFVIAILVIQVIAIYILAVVGLSLCIAACIPMHGPLLI
 SGLSILALAQLLGLVYMKFVE
 (SEQ ID NO: 10)

Human CD47 mRNA isoform 2 (NM_198793.2)

GGGAGCAGGCGGGGAGCGGGCGGGAAGCAGTGGGAGCGCGGTGCGCG
 CGGCCGTGCAGCCTGGGCAGTGGGTCCTGCCTGTGACGCGCGGCGCGGTC
 GGTCCTGCCTGTAAACGGCGGCGGCGGCTGCTGCCAGACACCTGCGGCGG
 CGGCGGCGACCCCGCGGCGGGCGGCGGAGATGTGGCCCCGTGGTAGCGGCG
CTGTTGCTGGGCTGGCGTCTGCGGATCAGCTCAGCTACTATTTAATA
AAACAAAATCTGTAGAATTCACGTTTTGTAAATGACACTGTCGTCATTCC
ATGCTTTGTTACTAATATGGAGGCACAAAACACTACTGAAGTATACGTA
AAGTGGAAATTTAAAGGAAGAGATATTTACACCTTTGATGGAGCTCTAA
ACAAGTCCACTGTCCCCACTGACTTTAGTAGTGCAAAAATTGAAGTCTC
ACAATTACTAAAAGGAGATGCCCTCTTTGAAGATGGATAAGAGTGATGCT
GTCTCACACACAGGAAACTACACTTGTGAAGTAACAGAAATTAACCAGAG
AAGGTGAAACGATCATCGAGCTAAAATATCGTGTTGTTTCATGGTTTTTC
TCCAAATGAAAATATTCTTATTGTATTTTCCCAATTTTGTCTATACTCC
TGTTCTGGGGACAGTTTGGTATTAAACACTTAAATATAGATCCGGTGG
TATGGATGAGAAAACAATTGCTTTACTTGTGCTGGACTAGTGATCACT
GTCATTGTCATTGTTGGAGCCATTCTTTTCGTCCCAGGTGAATATTCAAT
AAAGAATGCTACTGGCCTTGGTTTAATTGTGACTTCTACAGGGATATTA
ATATTACTTCACTACTATGTGTTAGTACAGCGATTGGATTAAACCTCCTT
CGTCATTGCCATATTGGTTATTCAGGTGATAGCCTATATCCTCGCTGTG
GTTGGACTGAGTCTCTGTATTGCGGCGGTGTATACCAATGCATGGCCCTC
TTCTGATTTTCAGGTATTGAGTATCTTAGCTCTAGCACAAATTACTTGGACTA
GTTTATATGAAATTTGTGGCTTCCAATCAGAAGACTATACAACCTCCTA
GGAATAACTGAAGTGAAGTGATGGACTCCGATTTGGAGAGTAGTAAGACG
 TGAAAGGAATACACTTGTGTTTAAGCACCATGGCCTTGATGATTCACTGTTG
 GGGAGAAGAAACAAGAAAAGTAACTGGTGTGCACCTATGAGACCCTTACGT
 GATTGTTAGTTAAGTTTTTATTCAAAGCAGCTGTAATTTAGTTAATAAAAATA
 ATTATGATCTATGTTGTTTGGCCCAATTGAGATCCAGTTTTTGTGTTATTTT
 AATCAATTAGGGGCAATAGTAGAATGGACAATTTCCAAGAATGATGCCTTT
 CAGGTCCTAGGGCCTCTGGCCTCTAGGTAACCAGTTTAAATTGGTTCAGGGT
 GATAACTACTTAGCACTGCCCTGGTGATTACCCAGAGATATCTATGAAAACC
 AGTGGCTTCCAATCAAACCTTTGCCAACCTCAGGTTACAGCAGCTTTGGGCAG
 TTATGGCAGTATGGCATTAGCTGAGAGGTGTCTGCCACTTCTGGGTCAATGG
 AATAAATAATTAAAGTACAGGCAGGAATTTGGTTGGGAGCATCTTGATGATC
 TCCGTATGATGTGATATTGATGGAGATAGTGGTCTCATTCTTGGGGGTTC
 CATTCCCACATTCCCCCTTCAACAAACAGTGTAACAGGTCCTTCCCAGATTT
 AGGGTACTTTTATGATGGATATGTTTCCCTTTTATTCACATAACCCCTTGAA
 ACCCTGTCTGTCTCCTGTTACTTGCTTCTGCTGTACAAGATGTAGCACCTT
 TTCTCTCTTTGAACATGGTCTAGTGACACGGTAGCACCAGTTGCAGGAAGG
 AGCCAGACTTGTCTCAGAGCACTGTGTTACACTTTTCAGCAAAAATAGCT
 ATGGTTGTAACATATGATTCCTTCCCTGATTTGAAGGCAAAAATCTACA
 GTGTTTCTCACTTCTTTTCTGATCTGGGGCATGAAAAAAGCAAGATTGAAA
 TTTGAACATAGAGTCTCTGATGGCAACAAAATGTGTGTACCATCAGGCC
 AACAGGCCAGCCCTTGAATGGGGATTATTACTGTTGTATCTATGTTGCATG
 ATAAACATTATCACCTTCCTCCTGAGTCTGCCTCGTACTCCCTTCCCT
 ATGATTGAAAAGTAAACAAACCCACATTTCTATCCTGGTTAGAAGAAAA
 TTAATGTTCTGACAGTTGTGATCGCCTGGAGTACTTTAGACTTTTAGCATT
 GTTTTTACCTGTTTGTGGATGTGTGTTGTATGTGCATACGTATGAGATAGG
 CACATGCATCTTCTGTATGGACAAAGGTGGGGTACCTACAGGAGAGCAAAAG

GTTAATTTTGTGCTTTTATGTAATAAACATTTAAATACAAAGTTCTTTATTGGGT
 GGAATTATATTGATGCAAAATTTGATCACTTAAACTTTTAAACTTCTA
 GGTAATTTGCCACGCTTTTGTACTGCTACCAATACCCGTGAAAAATACGTA
 ATTCTCTCTGTTTGTGTAATAAGATATTCATATTTGTAGTTGCATTAATAATA
 GTTATTCTTAGTCCATCAGATGTTCCCGTGTGCCCTTTTATGCCAAATTGA
 TTGTCATATTTATGTTGGGACCAAGTAGTTTGGCCATGGCAAACCTAAATT
 TATGACCTGTGAGGCTCTCAGAAAACCTGAGCATACTAGCAAGACAGCTC

TTCTTGAAAAAATATGTATACACAAATATATACGTATATCTATATATA
 CGTATGTATATACACACATGTATATTCTTCCTTGATTGTGTAGCTGTCCAAAA
 TAATAACATATATAGAGGGAGCTGTATTCTTTATACAAATCTGATGGCTCC
 TGCAGCACTTTTCTCTGAAAATATTTACATTTTGCTAACCTAGTTTGTTA
 CTTTAAAAATCAGTTTGTATGAAAGGAGGGAAAAGCAGATGGACTTGAAAA
 AGATCCAAAGCTCCTATTAGAAAAGGTATGAAAATCTTTATAGTAAAAATTTT
 TATAAACTAAAGTTGTACCTTTTAAATATGTAGTAACTCTCATTATTTGGGG
 TTCGCTCTTGATCTCATCCATCCATTGTGTTCTCTTAAATGCTGCCTGCCTTT
 TGAGGCATTCACTGCCCTAGACAAATGCCACCAGAGATAGTGGGGGAAATGC
 CAGATGAAACCAACTCTTGCTCTCACTAGTTGTGAGCTTCTCTGGATAAGTG
 ACCACAGAAGCAGGAGTCCCTGCTTGGGCATCATTGGGCCAGTTCCTTCT
 CTTTAAATCAGATTTGTAAATGGCTCCCAAATCCATCACATCACATTTAAAT
 GCAGACAGTGTGTCACATCATGTATCTGTTTTGTCCCATAAATGCTTTTT
 ACTCCCTGATCCAGTTTCTGCTGTTGACTCTCCATTCACTTTTATTATTGT
 GTGTTCTCACAGTGACACCATTTGTCTTTTCTGCAACAACCTTTCCAGCTAC
 TTTTGCCAAATCTATTTGTCTTCTCCTTCAAACATTCTCCTTGCAGTTCT
 CTTCATCTGTGTAGCTGCTCTTTTGTCTCTTAACTTACCATTCTATAGTACTT
 TAGCATCTCTGCTTAGTCTATAGTTTTTTGGCCTTGCTCTCTCCTTGATT
 TAAAAATCTCTTATAGCTAGAGCTTTTCTTCTTCTCTCTCTCTCTGCA
 GTGTTTTGCATACATCAGAAGCTAGGTACATAAGTTAAATGATTGAGAGTTG
 GCTGTATTAGATTTATCACTTTTAAATAGGGTGAGCTTGAGAGTTTTCTTC
 TTTCTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGACTA
 ATTCACATGGCTCTAAAAACCTTCAAAGGTGATTATTTTCTCCTGGAAACTC
 CAGGTCCATTCTGTTTAAATCCCTAAGAATGTCAGAATTAATAACAGGGC
 TATCCCGTAATTGGAAATATTTCTTTTTCAGGATGCTATAGTCAATTTAGTA
 AGTGACCACCAATGTTATTTGCACTAACAAAGCTCAAAACACGATAAGTT
 TACTCCCTCACTCAGTAATAAAAAATTAAGCTGTAATCAACCTTCTAGGTTT
 CTCTTGCTTAAAAATGGGTATTCAAAAATGGGGATCTGTGGTGTATGTATGG
 AAACACATACTCTTAATTTACCTGTTGTTGGAAACTGGAGAAATGATTGTC
 GGGCAACCGTTATTTTTTATTGATTTTATTGGTTGAGGGATTTTTTTATA
 AACAGTTTTACTGTGTCATATTTTAAATTAACCTGCCATCACCTGCTGG
 GGTCTTTGTTAGGTCACTTTTCACTGACTAATAGGGATAATCCAGGTAACCT
 TGAAGAGATGAGCAGTGAGTGACCAGGCAGTTTTTCTGCCTTTAGCTTTGAC
 AGTTCCTAATTAAGATCATTGAAGACCAGCTTTCTCATAAATTTCTTTTTTG
 AAAAAAAGAAAGCATTTGTAAGCTCCTCTGTAAGACAACATCTTAAAT
 CTTAAAAGTGTTGTATCATGACTGGTGAGAGAAGAAAACATTTGTTTTTA
 TTAAATGGAGCATTATTTACAAAAAGCCATTGTTGAGAATTAGATCCCACAT
 CGTATAAATATCTAATAACCATCTAAATAAAGAGAACTCCAGTGTTGCTAT
 GTGCAAGATCCTCTCTGGAGCTTTTTTGCATAGCAATTAAGGTGTGCTAT
 TTGTCAGTAGCCATTTTTTGCAGTGATTGAAGACCAAAGTTGTTTTACAGC
 TGTGTTACCGTTAAAGGTTTTTTTTTTTATATGTATTAATCAATTTACT

GTTTAAAGCTTTGAATATCTGCAATCTTTGCCAAGGTACTTTTTTATTTAAAA
 AAAACATAACTTTGTAAATATTACCTGTAATATTATATACTTAATAAA
 ACATTTTAAAGCTATTTTGTGGGCTATTTCTATTGCTGCTACAGCAGACCACA
 AGCACATTTCTGAAAAATTTAATTTATTAATGTATTTTAAAGTTGCTTATATT
 CTAGGTAACCAATGTAAAGAATGATTTAAATATTAATTAATGAATTTTTTGAG
 TATAATACCAATAAGCTTTTAAATTAGAGCAGAGTTTAAATTAAGTTTAA
 AATCAGTC
 (SEQ ID NO: 11)

Human CD47 amino acid isoform 2 (NP_942088.1)

MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNT
 TEVYVWKFKGRDIYTFDGLNKSIVPTDFSSAKIEVSQLLKGDASLKMDK
 SDAVSHTKNYTCEVTELTREGETHELKRYRVSWFSPNENILIVIFPAILLFW
 GQFGIKTLKYRSGGMDKTIALLVAGLVITVIVVIGAILFVPGEYSLKNATGLGLI
 VTSTGILILLHYVVFSTAIGLTSFVIALVIQVIAYILAVVGLSLCIAACIPMHGPLLI
 SGLSILALAQLLGLVYMKFVASNQKTIQPPRNN(SEQ ID NO: 12)

Human CD47 mRNA isoform 3 (XM_005247908.1)

AGTGGGAGCGCGCGTGCAGCGCGGCCGTGCAGCCTGGGCAGTGGGTCTGCG
 TGTGACGCGCGCGCGCGGTGCGTCTGCGTGTAAACGGCGCGCGCGGTGCT
 GCTCCGGACACCTGCGGCGCGCGCGCGGACCCCGCGCGCGCGCGCGGAGAT

GTGGCCCTGGTAGCGGCGCTGTTGCTGGGCTCGGCGTGCTGCGGATC
 AGCTCAGCTACTATTTAATAAAACAAAATCTGTAGAATTCACGTTTTGTA
 ATGACACTGTCGTCATTCCATGCTTTGTTACTAATATGGAGGCACAAAA
 CACTACTGAAGTATACGTAAAGTGGAAATTTAAAGGAAGAGATATTTAC
 ACCTTTGATGGAGCTCTAAACAAGTCCACTGTCCCCACTGACTTTAGTA
 GTGCAAAATTTGAAGTCTCACAATTACTAAAAGGAGATGCCTCTTTGAA
 GATGGATAAGAGTGATGCTGTCTCACACACAGGAAACTACACTTGTGAA
 GTAACAGAATTAACCAGAGAAGGTGAAACGATCATCGAGCTAAAAATATC
 GTGTTGTTTCATGGTTTTCTCCAAATGAAAATATTCTTATTGTTATTTTC
 CCAATTTTGTCTATACTCCTGTTCTGGGGACAGTTTGGTATTAAAAACAC
 TTAATATAGATCCGGTGGTATGGATGAGAAAAACAATTGCTTTACTTGT
 TGCTGGACTAGTGATCACTGTCAATTGTCAATTGTTGGAGCCATTCTTTTC
 GTCCAGGTGAATATTCTAAAGAATGCTACTGGCCTTGGTTAATTG
 TGACTTCTACAGGGATATTAATATTACTTCACTACTATGTGTTTAGTACA
 GCGATTGGATTAACTCCTTCGTCATTGCCATATTGGTTATTCAGGTGA
 TAGCCTATATCCTCGCTGTGGTTGGACTGAGTCTCTGTATTGCGGCGTG
 TATACCAATGCATGGCCCTCTCTGATTTCAAGTTTGAGTATCTTAGCT
 CTAGCACAAATTACTTGGACTAGTTTATATGAAATTTGTGGCTTCCAATC
 AGAAGACTATACAACCTCCTAGGAAAGCTGTAGAGGAACCCCTTAATGA
 ATAACGTGAAGTGAAGTGATGGACTCCGATTTGGAGAGTAGTAAGACGTGAA
 AGGAATACACTTGTGTTTAAAGCACCATGGCCTTGATGATTCAGTGTGGGGA
 GAAGAAACAAGAAAAGTAACTGGTTGTCACCTATGAGACCCTTACGTGATT
 GTTAGTTAAGTTTTTATTCAAAGCAGCTGTAATTTAGTTAATAAAAATAATTAT
 GATCTATGTTGTTTGCCCAATTGAGATCCAGTTTTTTGTTGTTATTTTAATC
 AATTAGGGGCAATAGTAGAATGGACAATTTCCAAGAATGATGCCCTTCAGG
 TCCTAGGGCCTCTGGCCTCTAGGTAACCAGTTTAAATTGGTTCAGGGTGATA
 ACTACTTAGCACTGCCCTGGTGATTACCCAGAGATATCTATGAAAACCAAGTG

GCTTCCATCAAACCTTTGCCAACTCAGGTTACAGCAGCTTTGGGCAGTTAT
 GGCAGTATGGCATTAGCTGAGAGGTGTCTGCCACTTCTGGGTCAATGGAATA
 ATAAATTAAGTACAGGCAGGAATTTGGTTGGGAGCATCTTGATGATCTCCG
 TATGATGTGATATGATGGAGATAGTGGTCCTCATTCTTGGGGGTGGCCATT
 CCCACATTTCCCTTCAACAAAACAGTGTAACAGGTCTTCCCAGATTTAGGG
 TACTTTTATGATGGATATGTTTCTTTTATTACATAACCCCTTGAAACCC
 TGCTTGTCTCTGTTACTTCTGCTGTACAAGATGTAGCACCTTTTCT
 CCTCTTTGAACATGGTCTAGTGACACGGTAGCACCAGTTGCAGGAAGGAGC
 CAGACTTGTTCTCAGAGCACTGTGTTACACTTTTCAGCAAAAATAGCTATG
 GTTGTAACATATGTATTCCTTCTCTGATTTGAAAGGCAAAAATCTACAGTG
 TTTCTTCACTTCTTTCTGATCTGGGGCATGAAAAAAGCAAGATTGAAATTT
 GAACTATGAGTCTCCTGCATGGCAACAAAATGTGTGTCACCATCAGGCCAA
 CAGGCCAGCCCTTGAATGGGGATTATTACTGTTGTATCTATGTTGCATGAT
 AAACATTTCATACCTTCTCTCTGTAGTCTGCCTCGTACTCCCTTCCCCTAT
 GATTGAAAAGTAAACAAAACCCACATTTCTATCCTGGTTAGAAGAAAATT
 AATGTTCTGACAGTTGTGATCGCCTGGAGTACTTTTAGACTTTTAGCATTCGT
 TTTTACCTGTTGTGGATGTGTGTTGTATGTGCATACGTATGAGATAGGCA
 CATGCATCTTGTATGGACAAAAGGTGGGGTACCTACAGGAGAGCAAAAGGT
 TAATTTTGTGCTTTTAGTAAAAACATTTAAATACAAAGTTCTTTATTGGGTGG
 AATTATATTGATGCAAAATATTGATCACTTAAAACITTTAAAACCTCTAGGT
 AATTGGCCACGCTTTTGACTGCTCACCAATACCTGTAAAAATACGTAATT
 CTTCCTGTTTGTGTAATAAGATATTCATATTGTAGTTGCATTAATAATAGTT
 ATTTCTTAGTCCATCAGATGTTCCCGTGTGCCCTCTTTATGCCAAATTGATTG
 TCATATTTTCATGTTGGGACCAAGTAGTTTGGCCATGGCAAACCTAAATTTAT
 GACCTGCTGAGGCCTCTCAGAAAACCTGAGCATACTAGCAAGACAGCTCTTCT
 TGAAAAAATAATATGTATACACAAATATATACGTATATCTATATATACGTA
 TGTATATACACACATGTATATCTTCTTGTATGTAGCTGTCCAAAAATAAT
 AACATATATAGAGGGAGCTGTATTCCTTTATACAAATCTGATGGCTCCTGCA
 GCACITTTTCTCTGAAAAATATTTACATTTTGCTAACTTAGTTTGTACTTT
 AAAAAATCAGTTTGTATGAAAGGAGGGAAAAGCAGATGGACTTGAAAAAGA
 TCCAAGCTCCTATTAGAAAAGGTATGAAAATCTTTATAGTAAAAATTTTAT
 AAATAAAAGTTGTACCTTTAATATGTAGTAAACTCTCATTTATTTGGGGTTC
 GCCTTGGATCTCATCCATCCATTGTGTTCTCTTAATGCTGCCCTGCCCTTTG
 AGGCATTCACTGCCCTAGACAATGCCACCAGAGATAGTGGGGGAAATGCCA
 GATGAAACCAACTCTTGCTCTCACTAGTTGTGAGCTTCTCTGGATAAGTGAC
 CACAGAAGCAGGAGTCTCCTGCTTGGGCATCATTGGGCCAGTTCCTTCTCT
 TTAATATCAGATTTGTAATGGCTCCCAAAATCCATCACATCACATTTAAATIG
 CAGACAGTGTGTTGCACATCATGTATCTGTTTTGICCCATAATATGCTTTTTA
 CTCCTGATCCAGTTTCTGCTTGACTCTCCATTCAAGTTTATTATTATGTG
 TGTCTCACAGTGACACCATTGTCTTTTCTGCAACAACCTTTCCAGCTACT

TTTGCCAAATCTATTTGTCTTCTCCTTCAAAACATTCTCCTTTCAGTTCCTC
 TTCATCTGTGTAGCTGCTCTTTTGTCTCTTAACCTACCATTCCTATAGTACTTT
 ATGCATCTCTGCTTAGTCTATTAGTTTTTTGGCCTTGCTCTCTCCTTGATTI
 TAAAATTCCTTCTATAGCTAGAGCTTTTCTTCTTTTCAATCTCTCTTCCGCGAG
 TGTTTTGCATACATCAGAAAGCTAGGTACATAAGTTAAATGATTGAGAGTTGG
 CTGTATTTAGATTTATCACTTTTAAATAGGGTGAGCTTGAGAGTTTCTTTCT
 TTCTGTTTTTTTTTTTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGACTAA
 TTTCACATGCTCTAAAAACCTTCAAAGGTGATTATTTTTCTCCTGGAAACTCC

AGGTCCATTCTGTTTAAATCCCTAAGAATGTCAGAATTAATAAACAGGGCT
 ATCCCGTAATTGGAAATATTTCTTTTTTCAGGATGCTATAGTCAATTTAGTAA
 GTGACCACCAAAATGTTATTTGCTACTAACAAGCTCAAAACACGATAAGTTT
 ACTCCTCCATCTCAGTAATAAAAAATTAAGCTGTAATCAACCTTCTAGGTTTC
 TCTTGTCTTAAATGGGTATTCAAAAATGGGGATCTGTGGTGTATGTATGGA
 AACACATACTCCTTAATTTACCTGTTGTTGGAAACTGGAGAAATGATTGTCG
 GGCAACCGTTTATTTTTATTGTATTTATTTGGTTGAGGGATTTTTTATAA
 ACAGTTTTACTTGTGTCAATTTTAAATTAATACTGCCATCACCTGCTGGG
 GTCCTTTGTTAGGTCAATTTTCACTGACTAATAGGGATAATCCAGGTAACTTT
 GAAGAGATGAGCAGTGAGTGACCAGGCAGTTTTTCTGCCTTTAGCTTTGACA
 GTTCTTAAATTAAGATCATTGAAGACCAGCTTCTCATAAATTTCTCTTTTTGA
 AAAAAAGAAAGCATTGTACTAAGCTCCTCTGTAAGACAACATCTTAAATCT
 TAAAAGTGTTGTTATCATGACTGGTGAGAGAAGAAAACATTTGTTTTTATT
 AAATGGAGCATTATTTACAAAAAGCCATTGTTGAGAATTAGATCCCACATCG
 TATAAATATCTATTAACCATCTAAATAAAGAGAACTCCAGTGTTGCTATGT
 GCAAGATCCTCTCTTGGAGCTTTTTTGCATAGCAATTAAGGTGTGCTATTT
 GTCAGTAGCCATTTTTTGCAGTGATTTGAAGACCAAAGTTGTTTTACAGCT
 GTGTTACCGTTAAAGGTTTTTTTTTTTATATGTATTAAATCAATTTATCACTG
 TTTAAAGCTTTGAATATCTGCAATCTTTGCCAAGGTACTTTTTTATTTAAAAA
 AAAACATAACTTTGTAAATATTACCCTGTAATATTATATATACTTAATAAAA
 CATTTTAAGCTA (SEQ ID NO: 13)

Human CD47 amino acid isoform 3 (XP_005247965.1)

MWPLVAALLLGSACCGSAQLLFNKT⁻KSVEFTFCNDTVVIPCFVTNMEAQNT
 TEVYVVKWFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDK
 SDAVSHTGNYTCEVTELTREGETHIELKYRVVSWFSPNENILVIFPIFAILLFW
 GQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNAATGLGLI
 VTSTGILILLHYVVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLI
 SGLSILALAQLLGLVYMKFVAS^{NQ}KTIQPPRKAVEEPLNE (SEQ ID NO: 14)

Human CD47 mRNA isoform 4 (NM_001777.3)

GGGGAGCAGGCGGGGGAGCGGGCGGGAAGCAGTGGGAGCGCGCGTGC GCG
 CGGCCGTGCAGCTGGGCACTGGGTCTGCCTGTGACGCGCGCGCGCGGTC
 GGTCCTGCCTGTAACGGCGGCGGCGGCTGCTGCTCCAGACACCTGCGGCGG
 CGGCGGCGACCCCGCGGCGGCGCGGAGATGTGGCCCCCTGGTAGCGGCG
 CTGTTGCTGGGCTCGGCGTGTGCGGATCAGCTCAGCTACTATTTAATA
 AAACAAAATCTGTAGAATTCACGTTTTGTAATGACACTGTCGTCATTCC
 ATGCTTTGTTACTAATATGGAGGCACAAAACACTACTGAAGTATACGTA
 AAGTGGAATTTAAAGGAAGAGATATTTACACCTTTGATGGAGCTCTAA
 ACAAGTCCACTGTCCCCACTGACTTTAGTAGTGCAAAAATTGAAGTCTC
 ACAATTAATAAAAGGAGATGCCTCTTTGAAGATGGATAAGAGTGATGCT
 GTCTCACACACAGGAACTACACTTGTGAAGTAACAGAATTAACCAGAG
 AAGGTGAAACGATCATCGAGCTAAAATATCGTGTTGTTTCATGGTTTTTC
 TCCAAATGAAAATATTCTTATTGTATTTTCCCAATTTTGTCTATCTCC
 TGTTCTGGGGACAGTTTGGTATTAACCACTTAAATATAGATCCGGTGG
 TATGGATGAGAAAACAATTGCTTTACTTGTGCTGGACTAGTGATCACT
 GTCATTGTCATTGTTGGAGCCATTCTTTTCGTCCCAGGTGAATATTCATT
 AAAGAATGCTACTGGCCTTGGTTTAATTGTGACTTCTACAGGGATATTA

ATATTACTTCACTACTATGTGTTTAGTACAGCGATTGGATTAAACCTCCTT
 CGTCATTGCCATATTGGTTATTCAGGTGATAGCCTATATCCTCGCTGTG

GTTGGACTGAGTCTCTGTATTGCCGGCGTGTATACCAATGCATGGCCCTC
TTCTGATTTTCAGGTTTGAGTATCTTAGCTCTAGCACAACTACTTGGACTA
GTTTATATGAAATTTGTGGCTTCCAATCAGAAGACTATACAACCTCTTA
GGAAAGCTGTAGAGGAACCCCTTAATGCATTCAAAGAATCAAAGGAAT
GATGAATGATGAATAACTGAAGTGAAGTGATGGACTCCGATTGGAGAGT
 AGTAAGACGTGAAAGGAATACACTTGTGTTTAAGCACCATGGCCTTGATGA
 TTCACTGTTGGGGAGAAGAAACAAGAAAAGTAACTGGTTGTCACCTATGAG
 ACCCTIACGTGATTGTTAGTTAAGTTTTATTCAAAGCAGCTGTAATTTAGTT
 AATAAAAATAATTAIGATCTATGTTGTTTGCCCAATTGAGATCCAGTTTTTGT
 TGTATTTTTAATCAATTAGGGGCAATAGTAGAATGGACAATTTCCAAGAAT
 GATGCCTTTCAGGTCTAGGGCCTCTGGCCTCTAGGTAACCAGTTTAAATTG
 GTTCAGGGTGATAACTACTTAGCACTGCCCTGGTGATTACCCAGAGATATCT
 ATGAAAACCAAGTGGCTTCCATCAAACCTTTGCCAACTCAGGTTACACAGCAGC
 TTGGGCGAGTTATGGCAGTATGGCATTAGCTGAGAGGTGCTGCCACTTCTG
 GGTCAATTGGAATAAATAAATTAAGTACAGGCAGGAATTTGGTTGGGAGCATC
 TTGTATGATCTCCGTATGATGTGATATTGATGGAGATAGTGGTCCTCATTCTT
 GGGGGTTGCCATTCCCACATTCCCCCTTCAACAAACAGTGTAACAGGTCCTT
 CCCAGATTTAGGGTACTTTTATTGATGGATATGTTTTCCTTTTATTACATAA
 CCCCTTGAAACCCCTGCTTGTCTCCTGTTACTTGCTTCTGCTGTACAAGATG
 TAGCACCTTTCTCCTCTTTGAACATGGTCTAGTGACCGGTAGCACCAGTT
 GCAGGAAGGAGCCAGACTTGTCTCAGAGCACTGTGTICACACTTTTCAGCA
 AAAATAGCTATGGTTGTAACATATGTATCCCTTCCCTCTGATTTGAAGGCAA
 AAATCTACAGTGTTTCTTCACTTCTTTCTGATCTGGGGCATGAAAAAAGCA
 AGATTGAAATTTGAACTATGAGTCTCCTGCATGGCAACAAAATGTGTGTAC
 CATCAGGCCAACAGGCCAGCCCTGAATGGGGATTATTACTGTTGTATCTA
 TGTTCATGATAAACATTCATCACCTTCCCTCCTGTAGTCCCTGCCTCGTACTCC
 CCTTCCCCTATGATTGAAAAGTAAACAAAACCCACATTTCTATCCTGGTTA
 GAAGAAAATTAATGTTCTGACAGTTGTGATCGCCTGGAGTACTTTTAGACTT
 TTAGCATTCGTTTTTTACCTGTTTGTGGATGTGTGTTTGTATGTGCATACGTA
 TGAGATAGGCACATGCATCTTCTGTATGGACAAAGGTGGGGTACCTACAGG
 AGAGCAAAGGTTAATTTTGTGCTTTTGTAGTAAAAACATTTAAATACAAAGTTC
 TTTATTTGGGTGGAATTAATTTGATGCAAAATTTTGATCACTTAAAACTTTTA
 AAACCTTCTAGGTAATTTGCCACGCTTTTGTACTGCTACCAATACCCTGTAA
 AAATACGTAATCTTCTGTTTGTGTAATAAGATAATTCATATTTGTAGTTGCA
 TTAATAATAGTTATTTCTTAGTCCATCAGATGTTCCCGTGTGCCTCTTTTATG
 CCAAATTGATTGTCATATTTCTATGTTGGGACCAAGTAGTTTGGCCATGGCAA
 ACCTAAATTTATGACCTGCTGAGGCCTCTCAGAAAACCTGAGCATACTAGCAA
 GACAGCTCTTCTTGAAAAAATAATATGTATACACAAATATATACGTATATC
 TATATATACGTATGTATATACACATGTATATTCTTCTTGATTGTGTAGCT
 GTCCAAAATAATAACATATATAGAGGGAGCTGTATTCTTTATACAAATCTG
 AIGGCTCTTCGAGCACCTTTTCTTCTTGAAAAATATTTACATTTTGTCTAACCTA
 GTTTGTTACTTTAAAAATCAGTTTGTATGAAAGGAGGAAAAAGCAGATGGA
 CTTGAAAAAGATCCAAGCTCCTATTAGAAAAAGGTATGAAAATCTTTATAGTA
 AAATTTTTTATAAACTAAAGTTGTACCTTTTAATAAGTAGTAAACTCTCATTT
 ATTTGGGGTTTCGCTCTTGATCTCATCCATCCATTGTGTTCTCTTTAATGCTG
 CCTGCCTTTTGAGGCATTCAGTGCCTTAGACAAATGCCACCAGAGATAGTGGG

GGAAATGCCAGATGAAACCAACTCTTGCTCTCACTAGTTGTCAGCTTCTCTG
 GATAAGTGACCCAGACAGAAGCAGGAGTCTCCTGCTTGGGCATCATTGGGCCA
 GTTCTCTCTCTTTAAATCAGATTTGTAATGGCTCCCAAATTCATCACATCAC
 ATTTAAATTGCAGACAGTGTTTTGCACATCATGTATCTGTTTTGTCCATAAT
 ATGCTTTTTACTCCCTGATCCCAGTTTCTGCTGTTGACTCTTCCATTCACTTTT
 ATTTATTGTGTGTTCTCACAGTGACACCATTGTCTTTTCTGCAACAACCTT
 TCCAGCTACTTTTGCCAAATTCTATTTGTCTTCTCCTTCAAAAACATTCTCCTT
 GCAGTTCTCTTTCATCTGTGTAGCTGCTCTTTTGTCTCTTAACTTACCATTCTT
 ATAGTACTTTATGCATCTCTGCTTAGTTCTATTAGTTTTTTGGCCTTGCTCTTC
 TCCTTGATTTTAAAAATCCCTTCTATAGCTAGAGCTTTTCTTCTTTCATTCTCT
 CTTCTGCAAGTGTGTTTGCATACATCAGAAGCTAGGTACATAAGTTAAATGAT
 TGAGAGTTGGCTGTATTTAGATTTATCACTTTTTAATAGGGTGAGCTTGAGA
 GTTTCTTTCTTCTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
 TTTTGACTAATTTACATGCTCTAAAAACCTTCAAAGGTGATTATTTTCTCC
 TGGAACCTCCAGGTCCATTCTGTTTAAATCCCTAAGAATGTCAGAAATAAAA
 TAACAGGGCTATCCCGTAATTGGAAATATTTCTTTTTTTCAGGATGCTATAGT
 CAATTTAGTAAGTGACCAACCAAAATGTTATTGCACTAACAAAGCTCAAAAC
 ACGATAAGTTTACTCCTCCATCTCAGTAATAAAAAATTAAGCTGTAATCAACC
 TTCTAGGTTTCTCTTGTCTTAAATGGGTATTCAAAAATGGGGATCTGTGGT
 GTATGTATGGAACACATACTCCTTAATTTACCTGTTGTTGGAACTGGAGA
 AATGATTGTCGGGCAACCGTTTATTTTTATTGTATTTTATTGGTTGAGGGA
 TTTTTTATAAAGACTTTTCTCTCTGATATTTTAAATTAAGTAACTGCTGCAAT

TTTTTATAAACAGTTTTACTTGTGTCATATTTAAAAATTACTAAC TGCCAT
CACCTGCTGGGGTCCTTTGTTAGGTCATTTTCAGTGACTAATAGGGATAATC
CAGGTAACCTTTGAAGAGATGAGCAGTGAGTGACCAGGCAGTTTTCTGCCTT
TAGCTTTGACAGTTCTTAATTAAGATCATTGAAGACCAGCTTTCTCATAAAT
TTCTCTTTTTGAAAAAAGAAAGCATTGTACTAAGCTCCTCTGTAAAGACAA
CATCTTAAATCTTAAAGGTGTTGTTATCATGACTGGTGAGAGAAGAAAAACAT
TTTGTTTTTATTAAATGGAGCATTATTTACAAAAAGCCATTGTTGAGAATTA
GATCCCACATCGTATAAATATCTATTAACCATTCTAAATAAAGAGAACTCCA
GTGTTGCTATGTGCAAGATCTCTCTTGGAGCTTTTTTGCATAGCAATTAAA
GGTGTGCTATTTGTCAGTAGCCATTTTTTTGCAGTGATTTGAAGACCAAAGT
TGTTTTACAGCTGTGTTACCGTTAAAGGTTTTTTTTTTTATATGTATTAAATC
AATTTATCACTGTTTAAAGCTTTGAATATCTGCAATCTTTGCCAAGGTACTTT
TTTATTTAAAAAAAACATAACTTTGTAAATATTACCCTGTAAATATTATATAT
ACTTAATAAAACATTTTAAAGCTATTTTGTGGGCTATTTCTATTGCTGCTACA
GCAGACCACAAGCACATTTCTGAAAAATTTAATTTATTAATGTATTTTAAAG
TTGCTTATTTGCTAGTAAACAATGTAAAGAATGATTAAAAATATTAATTATG
AATTTTTTGAGTATAATACCCAATAAGCTTTTAATTAGAGCAGAGTTTAAAT
AAAAGTTTTAAATCAGTC (SEQ ID NO: 15)

Human CD47 amino acid isoform 4 (NP_001768.1)

MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNT
TEVYVWKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDK
SDAVSHTGNYTCEVTEL TREGETHELK YRVVSWFSPNENILIVIFPIFAILLFW
GQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLI
VTSTGILILLHYVVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPILLI
SGLSILALAQLLGLVYMKFVASNQKTIQPPRKAVEEPLNAFKESKGMNDE (SEQ
ID NO: 16)

Humanized CD47 amino acid isoform 1

MWPLAAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNT
TEVYVWKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDK
SDAVSHTGNYTCEVTEL TREGETHELK YRVVSWFSPNENILIVIFPIFAILLF
WGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNAT
GLGLIVTSTGILILLHYVVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACI
PMHGPILLISGLSILALAQLLGLVYMKFV (SEQ ID NO: 17)

Humanized CD47 amino acid isoform 2

MWPLAAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNT
TEVYVWKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDK
SDAVSHTGNYTCEVTEL TREGETHELK YRVVSWFSPNENILIVIFPIFAILLF
WGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNAT
GLGLIVTSTGILILLHYVVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACI
PMHGPILLISGLSILALAQLLGLVYMKFVASNQRTIQPPRNR (SEQ ID NO: 18)

Humanized CD47 amino acid isoform 3

MWPLAAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNT
TEVYVWKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDK
SDAVSHTGNYTCEVTEL TREGETHELK YRVVSWFSPNENILIVIFPIFAILLF
WGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNAT
GLGLIVTSTGILILLHYVVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACI
PMHGPILLISGLSILALAQLLGLVYMKFVASNQRTIQPPRKAVEEPLNE (SEQ ID
NO: 19)

Humanized CD47 amino acid isoform 4

MWPLAAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNT
TEVYVWKWKFKGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDK

```
SDAVSHTGNYTCEVTELTREGETHIELKYRVVSWFSPNENILIVIFPIFAILLF
WGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNAT
GLGLIVTSTGILILLHYVVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACI
PMHGPLLISGLSILALAQLLGLVYMKFVASNQRTIQPPRKAVEEPLNAFKESKG
MMNDE (SEQ ID NO: 20)
```

Humanized CD47 Non-Human Animals

[0103] Non-human animals are provided that express humanized CD47 proteins on the surface of cells of the non-human animals resulting from a genetic modification of an endogenous locus of the non-human animal that encodes a CD47 protein. Suitable examples described herein include rodents, in particular, mice.

[0104] A humanized CD47 gene may comprise genetic material from a heterologous species (e.g., humans), wherein the humanized CD47 gene encodes a CD47 protein that comprises the encoded portion of the genetic material from the heterologous species. A humanized CD47 gene described herein may comprise genomic DNA of a heterologous species that encodes the extracellular portion of a CD47 protein that is expressed on the plasma membrane of a cell. A humanized CD47 gene described herein may comprise genomic DNA of a heterologous species that encodes the extracellular portion and the transmembrane portion of a CD47 protein that is expressed on the plasma membrane of a cell. Non-human animals, embryos, cells and targeting constructs for making non-human animals, non-human embryos, and cells containing said humanized CD47 gene are also provided.

[0105] An endogenous CD47 gene may be deleted. An endogenous CD47 gene may be altered, wherein a portion of the endogenous CD47 gene is replaced with a heterologous sequence (e.g., a human CD47 sequence, in whole or in part). All or substantially all of an endogenous CD47 gene may be replaced with a heterologous gene (e.g., a human CD47 gene). A portion of a heterologous CD47 gene may be inserted into an endogenous non-human CD47 gene at an endogenous CD47 locus. The heterologous gene may be a human gene. The modification or humanization may be made to one of the two copies of the endogenous CD47 gene, giving rise to a non-human animal that is heterozygous with respect to the humanized CD47 gene. A non-human animal may be provided that is homozygous for a humanized CD47 gene.

[0106] A non-human animal described herein may contain a human CD47 gene, in whole or in part, at an endogenous non-human CD47 locus. Thus, such non-human animals can be described as having a heterologous CD47 gene. The replaced, inserted, modified or altered CD47 gene at the endogenous CD47 locus can be detected using a variety of methods including, for example, PCR, Western blot, Southern blot, restriction fragment length polymorphism (RFLP), or a gain or loss of allele assay. The non-human animal may be heterozygous with respect to the humanized CD47 gene. The non-human animal may be homozygous for the humanized CD47 gene.

[0107] A humanized CD47 gene described herein includes a CD47 gene that has a second, third, fourth, fifth, sixth and seventh exon each may have a sequence at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to a second, third, fourth, fifth, sixth and seventh exon that appear in a human CD47 gene of Table 3.

[0108] A humanized CD47 gene described herein may include a CD47 gene that has a first exon and exon(s) downstream of exon 7 (e.g., eighth and ninth exons of isoform 2) each having a sequence at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to a respective exon that appears in a mouse CD47 gene of Table 3.

[0109] A humanized CD47 gene described herein may include a CD47 gene that has a 5' untranslated region and a 3' untranslated region each having a sequence at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to a 5' untranslated region and a 3' untranslated region that appear in a mouse CD47 gene of Table 3.

[0110] A humanized CD47 gene described herein may include a CD47 gene that has a nucleotide coding sequence (e.g., a cDNA sequence) at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to a nucleotide coding sequence that appears in a human CD47 nucleotide coding sequence of Table 3.

[0111] A humanized CD47 protein produced by a non-human animal described herein may have an extracellular portion having an amino acid sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to an extracellular portion of a human CD47 protein that appears in Table 3.

[0112] A humanized CD47 protein produced by a non-human animal described herein may have an extracellular portion having an amino acid sequence that is identical to amino acid residues 19-141 that appear in a human CD47 protein of Table 3.

[0113] A humanized CD47 protein produced by a non-human animal described herein may have an N-terminal immunoglobulin V domain having an amino acid sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to an N-terminal immunoglobulin V domain of a human CD47 protein that appears in Table 3.

[0114] A humanized CD47 protein produced by a non-human animal described herein may have an N-terminal immunoglobulin V domain having an amino acid sequence that is identical to amino acid residues 19-127 that appear in a human CD47 protein of Table 3.

[0115] A humanized CD47 protein produced by a non-human animal described herein may have an N-terminal immunoglobulin V domain and five transmembrane domains each having a sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to an N-terminal immunoglobulin V domain and five transmembrane domains of a human CD47 protein that appears in Table 3.

[0116] A humanized CD47 protein produced by a non-human animal described herein may have an intracytoplasmic tail having a sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to an intracytoplasmic tail of a mouse CD47 protein that appears in Table 3.

[0117] A humanized CD47 protein produced by a non-human animal described herein may have an amino acid sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to amino acid residues 16-292 that appear in a human CD47 protein of Table 3.

[0118] A humanized CD47 protein produced by a non-human animal described herein may have an amino acid sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to amino acid residues 19-292 that appear in a human CD47 protein of Table 3.

[0119] A humanized CD47 protein produced by a non-human animal described herein may have an amino acid sequence that is identical to amino acid residues 19-292 (or 16-292) that appear in a human CD47

protein of Table 3.

[0120] A humanized CD47 protein produced by a non-human animal described herein may have an amino acid sequence that is at least 50% (e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to an amino acid sequence of a humanized CD47 protein that appears in Table 3.

[0121] A humanized CD47 protein produced by a non-human animal described herein may have an amino acid sequence that is identical to an amino acid sequence of a humanized CD47 protein that appears in Table 3.

[0122] Compositions and methods for making non-human animals that express a humanized CD47 protein, including specific polymorphic forms, allelic variants (e.g., single amino acid differences) or alternatively spliced isoforms, are provided, including compositions and methods for making non-human animals that express such proteins from a human promoter and a human regulatory sequence. Compositions and methods for making non-human animals that express such proteins from an endogenous promoter and an endogenous regulatory sequence may also be provided. The methods include inserting the genetic material encoding a human CD47 protein in whole or in part at a precise location in the genome of a non-human animal that corresponds to an endogenous CD47 gene thereby creating a humanized CD47 gene that expresses a CD47 protein that is human in whole or in part. The methods may include inserting genomic DNA corresponding to exons 2-7 of a human CD47 gene into an endogenous CD47 gene of the non-human animal thereby creating a humanized gene that encodes a CD47 protein that contains a human portion containing amino acids encoded by the inserted exons.

[0123] Where appropriate, the coding region of the genetic material or polynucleotide sequence(s) encoding a human CD47 protein in whole or in part may be modified to include codons that are optimized for expression in the non-human animal (e.g., see U.S. Patent No.'s 5,670,356 and 5,874,304). Codon optimized sequences are synthetic sequences, and preferably encode the identical polypeptide (or a biologically active fragment of a full length polypeptide which has substantially the same activity as the full length polypeptide) encoded by the non-codon optimized parent polynucleotide. The coding region of the genetic material encoding a human CD47 protein, in whole or in part, may include an altered sequence to optimize codon usage for a particular cell type (e.g., a rodent cell). For example, the codons of the genomic DNA corresponding to exons 2-7 of a human CD47 gene to be inserted into an endogenous CD47 gene of a non-human animal (e.g., a rodent) may be optimized for expression in a cell of the non-human animal. Such a sequence may be described as a codon-optimized sequence.

[0124] A humanized CD47 gene approach employs a relatively minimal modification of the endogenous gene and results in natural CD47-mediated signal transduction in the non-human animal, because the genomic sequence of the CD47 sequences are modified in a single fragment and therefore retain normal functionality by including necessary regulatory sequences. Thus, in such instances, the CD47 gene modification does not affect other surrounding genes or other endogenous CD47-interacting genes (e.g., thrombospondin, SIRPs, integrins, etc.). Further, the modification does not affect the assembly of a functional CD47 transmembrane protein on the plasma membrane and maintains normal effector functions via binding and subsequent signal transduction through the cytoplasmic portion of the protein which is unaffected by the modification.

[0125] A schematic illustration (not to scale) of the genomic organization of an endogenous murine CD47 gene and a human CD47 gene is provided in Figure 1. An exemplary method for humanizing an endogenous murine CD47 gene using a genomic fragment containing exons 2-7 of a human CD47 gene is provided in Figure 2. As illustrated, genomic DNA containing exons 2-7 of a human CD47 gene is inserted into an endogenous murine CD47 gene locus by a targeting construct. This genomic DNA includes the portion of the gene that encodes an extracellular portion and transmembrane domains (e.g., amino acid residues 16-292) of

a human CD47 protein responsible for ligand binding.

[0126] A non-human animal (e.g., a mouse) having a humanized CD47 gene at the endogenous CD47 locus can be made by any method known in the art. For example, a targeting vector can be made that introduces a human CD47 gene in whole or in part with a selectable marker gene. Figure 2 illustrates an endogenous CD47 locus of a mouse genome comprising an insertion of exons 2-7 of a human CD47 gene. As illustrated, the targeting construct contains a 5' homology arm containing sequence upstream of exon 2 of an endogenous murine CD47 gene (~39 Kb), followed by a genomic DNA fragment containing exons 2-7 of a human CD47 gene (~23.9 Kb), a drug selection cassette (e.g., a neomycin resistance gene flanked on both sides by *loxP* sequences; ~5 Kb), and a 3' homology arm containing sequence downstream of exon 7 of an endogenous murine CD47 gene (~99 Kb). The targeting construct contains a self-deleting drug selection cassette (e.g., a neomycin resistance gene flanked by *loxP* sequences; see U.S. Patent No.'s 8,697,851, 8,518,392 and 8,354,389). Upon homologous recombination, exons 2-7 of an endogenous murine CD47 gene are replaced by the sequence contained in the targeting vector (i.e., exons 2-7 of a human CD47 gene). A humanized CD47 gene is created resulting in a cell or non-human animal that expresses a humanized CD47 protein that contains amino acids encoded by exons 2-7 of a human CD47 gene. The drug selection cassette is removed in a development-dependent manner, i.e., progeny derived from mice whose germ line cells containing the humanized CD47 gene described above will shed the selectable marker from differentiated cells during development.

[0127] The non-human animals described herein may be prepared as described above, or using methods known in the art, to comprise additional human or humanized genes, oftentimes depending on the intended use of the non-human animal. Genetic material of such additional human or humanized genes may be introduced through the further alteration of the genome of cells (e.g., embryonic stem cells) having the genetic modifications as described above or through breeding techniques known in the art with other genetically modified strains as desired. Non-human animals described herein may be prepared to further comprise one or more human or humanized genes selected from SIRPα (CD172a), IL-3, M-CSF, GM-CSF and TPO. Non-human animals described herein may be prepared by introducing a targeting vector, as described herein, into a cell from a modified strain. To give but one example, a targeting vector, as described above, may be introduced into a mouse that is Rag2-deficient and IL-2Rγ-deficient and include four human cytokines (Rag2^{-/-} IL2Rγ^{-/-}; M-CSF^{Hu}; IL-3/GM-CSF^{Hu}; hSIRPα^{tg}; TPO^{Hu}). Non-human animals described herein may be prepared to further comprise a human or humanized signal-regulatory protein alpha (SIRPα) gene. Non-human animals described herein may comprise a humanized CD47 gene, as described herein, and genetic material from a heterologous species (e.g., humans), wherein the genetic material encodes, in whole or in part, one or more heterologous proteins selected from SIRPα (CD172a), IL-3, M-CSF, GM-CSF and TPO. Non-human animals described herein may comprise a humanized CD47 gene as described herein and genetic material from a heterologous species (e.g., humans), wherein the genetic material encodes, in whole or in part, a heterologous (e.g., human) SIRPα (CD172a) protein. Non-human animals described herein may further comprise a SIRPα gene that comprises an endogenous portion and a human portion (e.g., exons 2-4 of a human SIRPα gene), wherein the human portion encodes the extracellular domain of a SIRPα protein (e.g., amino acids corresponding to residues 28-362 of a human SIRPα protein) and the endogenous portion encodes the intracellular domain of an endogenous SIRPα protein; the human portion and the endogenous portion may be operably linked to an endogenous SIRPα promoter.

[0128] For example, as described herein, non-human animals comprising a humanized CD47 gene may further comprise (e.g., via cross-breeding or multiple gene targeting strategies) one or more modifications as described in PCT/US2010/051339, filed October 4, 2010; PCT/US2013/058448, filed September 6, 2013; PCT/US2013/045788, filed June 14, 2013; PCT/US2014/056910, filed September 23, 2014; PCT/US2014/060568, filed October 15, 2014; the PCT/US2012/025040, filed February 14, 2014; PCT/US2012/062379, filed October 29, 2012; PCT/US2014/064806, filed November 10, 2014; and PCT/US2014/064810, filed November 10, 2014. A rodent comprising a humanized CD47 gene (i.e., exons 2-7

of a human CD47 gene operably linked to exon 1 and exon 8 (and hence any downstream exons) of an endogenous rodent CD47 gene so that the humanized CD47 gene encodes a CD47 polypeptide having an extracellular portion from a human CD47 protein and an intracellular portion from a rodent CD47 protein) may be crossed to a rodent comprising a humanized SIRP α gene (e.g., exons 2-4 of a human SIRP α gene operably linked to exons 1 and 5-8 of an endogenous rodent SIRP α gene so that the humanized SIRP α gene encodes a SIRP α polypeptide having an extracellular portion from a human SIRP α protein (e.g., amino acids corresponding to residues 28-362) and an intracellular portion from a rodent SIRP α protein; see, e.g., PCT/US2014/056910, filed September 23, 2014).

[0129] Although embodiments employing a humanized CD47 gene in a mouse (i.e., a mouse with a CD47 gene that encodes a CD47 protein that includes a human portion and a mouse portion) are extensively discussed herein, other non-human animals that comprise a humanized CD47 gene are also described. Such non-human animals may comprise a humanized CD47 gene operably linked to an endogenous CD47 promoter. Such non-human animals may express a humanized CD47 protein from an endogenous locus, wherein the humanized CD47 protein comprises amino acid residues 16-292 (or 19-141 or 19-127) of a human CD47 protein. Such non-human animals include any of those which can be genetically modified to express a CD47 protein as disclosed herein, including, e.g., mammals, e.g., mouse, rat, rabbit, pig, bovine (e.g., cow, bull, buffalo), deer, sheep, goat, chicken, cat, dog, ferret, primate (e.g., marmoset, rhesus monkey), etc. For example, for those non-human animals for which suitable genetically modifiable ES cells are not readily available, other methods are employed to make a non-human animal comprising the genetic modification. Such methods include, e.g., modifying a non-ES cell genome (e.g., a fibroblast or an induced pluripotent cell) and employing somatic cell nuclear transfer (SCNT) to transfer the genetically modified genome to a suitable cell, e.g., an enucleated oocyte, and gestating the modified cell (e.g., the modified oocyte) in a non-human animal under suitable conditions to form an embryo.

[0130] Methods for modifying a non-human animal genome (e.g., a pig, cow, rodent, chicken, etc. genome) include, e.g., employing a zinc finger nuclease (ZFN) or a transcription activator-like effector nuclease (TALEN) to modify a genome to include a humanized CD47 gene.

[0131] A non-human animal described herein may be a mammal. A non-human animal described herein may be a small mammal, e.g., of the superfamily Dipodoidea or Muroidea. A genetically modified animal described herein may be a rodent. A rodent described herein may be selected from a mouse, a rat, and a hamster. A rodent described herein may be selected from the superfamily Muroidea. A genetically modified animal described herein may be from a family selected from Calomyscidae (e.g., mouse-like hamsters), Cricetidae (e.g., hamster, New World rats and mice, voles), Muridae (true mice and rats, gerbils, spiny mice, crested rats), Nesomyidae (climbing mice, rock mice, with-tailed rats, Malagasy rats and mice), Placanthomyidae (e.g., spiny dormice), and Spalacidae (e.g., mole rats, bamboo rats, and zokors). A genetically modified rodent described herein may be selected from a true mouse or rat (family Muridae), a gerbil, a spiny mouse, and a crested rat. A genetically modified mouse described herein may be from a member of the family Muridae. A non-human animal described herein may be a rodent. A rodent described herein may be selected from a mouse and a rat. A non-human animal described herein may be a mouse.

[0132] A non-human animal described herein may be a rodent that is a mouse of a C57BL strain selected from C57BL/A, C57BL/An, C57BL/GrFa, C57BL/KaLwN, C57BL/6, C57BL/6J, C57BL/6ByJ, C57BL/6NJ, C57BL/10, C57BL/10ScSn, C57BL/10Cr, and C57BL/Ola. A mouse described herein may be a 129 strain selected from the group consisting of a strain that is 129P1, 129P2, 129P3, 129X1, 129S1 (e.g., 129S1/SV, 129S1/SvIm), 129S2, 129S4, 129S5, 129S9/SvEvH, 129/SvJae, 129S6 (129/SvEvTac), 129S7, 129S8, 129T1, 129T2 (see, e.g., Festing et al., 1999, Mammalian Genome 10:836; Auerbach, W. et al., 2000, Biotechniques 29(5):1024-1028, 1030, 1032). A genetically modified mouse described herein may be a mix of an aforementioned 129 strain and an aforementioned C57BL/6 strain. A mouse described herein may be a mix of aforementioned 129 strains, or a mix of aforementioned BL/6 strains. A 129 strain of the mix as described

herein may be a 129S6 (129/SvEvTac) strain. A mouse described herein may be a BALB strain, e.g., BALB/c strain. A mouse described herein may be a mix of a BALB strain and another aforementioned strain.

[0133] A non-human animal described herein may be a rat. a rat described herein is selected from a Wistar rat, an LEA strain, a Sprague Dawley strain, a Fischer strain, F344, F6, and Dark Agouti. A rat strain as described herein may be a mix of two or more strains selected from the group consisting of Wistar, LEA, Sprague Dawley, Fischer, F344, F6, and Dark Agouti.

Methods Employing Non-Human Animals Having Humanized CD47 Genes

[0134] CD47 mutant and transgenic non-human animals (e.g., miniature swine) and cells have been reported (Koshimizu H. et al. (2014) PLoS One, 9(2):e89584; Lavender, K.J. et al. (2014) J. Immunol. Methods, 407:127-134; Tena, A. et al. (2014) Am. J. Transplant.doi: 10.1111/ajt.12918; Lavender K.J. et al. (2013) Blood, 122(25):4013-4020; Tena, A. et al. (2012) Transplantation 94(10S):776; Wang, C. et al. (2011) Cell Transplant. 20(11-12):1915-1920; Johansen, M.L. and Brown, E.J. (2007) J. Biol. Chem. 282:24219-24230; Wang, H. et al. (2007) Proc. Nat. Acad. Sci. U.S.A. 104:13744-13749; Tulasne D. et al. (2001) Blood, 98(12):3346-52; Oldenburg, P. et al. (2000) Science 288:2051-2054; Verdrengh, M. et al. (1999) Microbes Infect. 1(10):745-751; Chang, H.P. et al. (1999) Learn Mem. 6(5):448-457; Wang, X.Q. et al. (1999) J. Cell Biol. 147(2):389-400; Lindberg, F.P. et al. (1996) Science 274(5288):795-798). Such animals have been employed in a variety of assays to determine, for example, the molecular aspects of CD47 expression, function and regulation. Considerable species differences have been discovered. Indeed, nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice express a SIRP α protein that is capable of interacting with human CD47 and, therefore, have been used extensively for the development of mouse models with components of the human immune system (e.g., see Takenaka, K. et al. (2007) Nat. Immunol. 8(12):1313-1323). The SIRP α allele present in these mice is not representative of the SIRP α allele present in other mouse strains and, generally, there is little cross-reaction between CD47 and SIRP α between species. Also, CD47 on mouse cells has been reported to have a near-complete mobility, while CD47 on human cells demonstrate only about 30-40% (Bruce, L. et al. (2003) Blood 101:4180-4188; Mouro-Chanteloup, L. et al. (2000) VoxSanguinis 78:P030; Mouro-Chanteloup, L. et al. (2003) Blood 101:338-344). Thus, NOD/SCID mice are not without limitation. For example, although multi-lineage human hematopoietic development can be supported in some genetic backgrounds (e.g., BALB/c Rag2^{-/-}IL-2R γ ^{-/-}), homeostasis of other cell types remains inefficient (e.g., T and NK cells; see e.g., Gimeno, R. et al. (2004) Blood 104:3886-3893; Traggiai, E. et al. (2004) Science 304:104-107; Legrand, N. et al. (2006) Blood 108:238-245). Further, CD47 is also known to interact with other cell surface proteins and provide bidirectional signaling. Thus, existing mice represent an inefficient *in vivo* system for elucidation of CD47-dependent functions in various biological processes such as, for example, engraftment and phagocytosis. Further, existing mice represent a suboptimal *in vivo* system for development of CD47 targeted therapies.

[0135] Non-human animals described herein may provide an improved *in vivo* system and source of biological materials (e.g., cells) expressing human CD47 that are useful for a variety of assays. Non-human animals described herein may be used to develop therapeutics that target CD47 and/or modulate CD47-SIRP α signaling. Non-human animals described herein may be used to screen and develop candidate therapeutics (e.g., antibodies) that bind human CD47. Non-human animals described herein may be used to screen and develop candidate therapeutics (e.g., antibodies) that block interaction of human CD47 with human SIRP α . Non-human animals described herein may be used to determine the binding profile of antagonists and/or agonists of a humanized CD47 on the surface of a cell of a non-human animal as described herein. Non-human animals described herein may be used to determine the epitope or epitopes of one or more candidate therapeutic antibodies that bind human CD47.

[0136] Non-human animals described herein may be used to determine the pharmacokinetic profiles of anti-CD47 antibodies. One or more non-human animals described herein and one or more control or reference non-human animals may be each exposed to one or more candidate therapeutic anti-CD47 antibody at various doses (e.g., 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 7.5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 40 mg/kg, or 50 mg/kg or more). Candidate therapeutic antibodies may be dosed via any desired route of administration (e.g., subcutaneously, intravenously, intramuscular, intraperitoneal, etc.). Blood is isolated from non-human animals (humanized and control) at various time points (e.g., 0 hr, 6 hr, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, or up to 30 or more days). Various assays may be performed to determine the pharmacokinetic profiles of administered candidate therapeutic antibodies using samples obtained from non-human animals as described herein including, but not limited to, total IgG, anti-therapeutic antibody response, agglutination, etc.

[0137] Non-human animals described herein may be used to measure the therapeutic effect of blocking or modulating CD47 signaling and the effect on gene expression as a result of cellular changes. A non-human animal described herein or cells isolated therefrom may be exposed to a candidate therapeutic that binds to a humanized CD47 protein (or a human portion of a CD47 protein) on the surface of a cell of the non-human animal and, after a subsequent period of time, analyzed for effects on CD47-dependent processes, for example, adhesion, angiogenesis, apoptosis, inflammation, migration, phagocytosis, proliferation and clearance of tumors (or tumor cells).

[0138] Non-human animals described herein may express humanized CD47 protein, thus cells, cell lines, and cell cultures can be generated to serve as a source of humanized CD47 for use in binding and functional assays, e.g., to assay for binding or function of a CD47 antagonist or agonist, particularly where the antagonist or agonist is specific for a human SIRP α sequence or epitope. CD47 epitopes bound by candidate therapeutic antibodies can be determined using cells isolated from non-human animals described herein.

[0139] Cells from non-human animals described herein may be isolated and used on an ad hoc basis, or can be maintained in culture for many generations. Cells from a non-human animal described herein may be immortalized and maintained in culture indefinitely (e.g., in serial cultures).

[0140] Cells and/or non-human animals described herein may be used in a survival and/or proliferation assay (e.g., employing B or T cells) to screen and develop candidate therapeutics that modulate human CD47 signaling. Activation or loss of CD47 can play an important role in the regulation of cell proliferation, and induction of apoptosis by CD47 may result from the activation of specific epitopes of the extracellular domain of CD47, therefore, candidate CD47 modulators (e.g., antagonists or agonists) may be identified, characterized and developed using cells of non-human animals described herein and/or a non-human animal as described herein. Cells and/or non-human animals described herein may be used in survival or death assay(s) to determine the effect on proliferation or apoptosis of a specific cell(s) (e.g., cancer cells) in the presence and absence of CD47.

[0141] Cells and/or non-human animals described herein may be used in xenotransplantation of heterologous (e.g., human) cells to determine the CD47-mediated functions in the physiological (e.g., immune) response to the transplanted human cells. Candidate therapeutics that bind, or block one or more functions of, human CD47 may be characterized in a non-human animal described herein. Suitable measurements include various cellular assays, proliferation assays, serum immunoglobulin analysis (e.g., antibody titer), cytotoxicity assays, and characterization of ligand-receptor interactions (immunoprecipitation assays). Non-human animals described herein may be used to characterize the CD47-mediated functions regulating an immune response to an antigen. The antigen may be associated with a neoplasm. The antigen may be associated with an autoimmune disease or condition. The antigen may be a target associated with a disease or condition suffered by one or more human patients in need of treatment.

[0142] Non-human animals described herein may be used in transplantation or adoptive transfer experiments to determine the therapeutic potential of compounds or biological agents to modulate CD47-dependent regulation of new lymphocytes and their immune function. Non-human animals described herein may be transplanted with human B cells.

[0143] Cells of non-human animals described herein may be used in a cell migration or spreading assay to screen and develop candidate therapeutics that modulate human CD47. Such processes are necessary for many cellular processes including wound healing, differentiation, proliferation and survival.

[0144] Cells of non-human animals described herein may be used in phagocytosis assays to determine the therapeutic potential of compounds or biological agents to modulate CD47-dependent regulation of phagocytosis.

[0145] Cells of non-human animals described herein may be used in tumor cell growth (or proliferation) assays to determine the therapeutic potential of compounds or biological agents to modulate CD47-dependent regulation and/or apoptosis of tumor cells.

[0146] An inflammatory disease or condition may be induced in one or more non-human animals described herein to provide an *in vivo* system for determining the therapeutic potential of compounds or biological agents to modulate CD47-dependent regulation of one or more functions of the inflammatory disease or condition. The inflammatory disease or condition may be associated with a neoplasm.

[0147] An anti-angiogenic condition may be induced in one or more non-human animals described herein to provide an *in vivo* system for determining the therapeutic potential of compounds or biological agents to modulate CD47-dependent regulation of one or more functions of the anti-angiogenic condition. Exemplary functions that can be evaluated to determine therapeutic efficacy include chemokine expression, nitric oxide (NO)-stimulated responses and blood flow recovery.

[0148] Non-human animals described herein may provide an *in vivo* system for the analysis and testing of a drug or vaccine. A candidate drug or vaccine may be delivered to one or more non-human animals described herein, followed by monitoring of the non-human animals to determine one or more of the immune response to the drug or vaccine, the safety profile of the drug or vaccine, or the effect on a disease or condition. Exemplary methods used to determine the safety profile include measurements of toxicity, optimal dose concentration, efficacy of the drug or vaccine, and possible risk factors. Such drugs or vaccines may be improved and/or developed in such non-human animals.

[0149] Non-human animals described herein may provide an *in vivo* system for assessing the pharmacokinetic properties of a drug targeting CD47. A drug targeting CD47 may be delivered or administered to one or more non-human animals described herein, followed by monitoring of, or performing one or more assays on, the non-human animals (or cells isolated therefrom) to determine the effect of the drug on the non-human animal. Pharmacokinetic properties include, but are not limited to, how an animal processes the drug into various metabolites (or detection of the presence or absence of one or more drug metabolites, including, toxic metabolites), drug half-life, circulating levels of drug after administration (e.g., serum concentration of drug), anti-drug response (e.g., anti-drug antibodies), drug absorption and distribution, route of administration, routes of excretion and/or clearance of the drug. Pharmacokinetic and pharmacodynamic properties of drugs (e.g., CD47 modulators) may be monitored in or through the use of non-human animals described herein.

[0150] Non-human animals described herein may provide an *in vivo* system for assessing the on-target toxicity of a drug targeting CD47. A drug targeting CD47 may be delivered or administered to one or more

non-human animals described herein, followed by monitoring of or performing one or more assays on the non-human animals (or cells isolated therefrom) to determine the on-target toxic effect of the drug on the non-human animal. Typically, drugs are intended to modulate one or more functions of their targets. To give but one example, a CD47 modulator is intended to modulate CD47-mediated functions (e.g., CD47 induced apoptosis) through interacting in some way with the CD47 molecule on the surface of one or more cells. Such a modulator may have an adverse effect that is an exaggeration of the desired pharmacologic action(s) of the modulator. Such effects are termed on-target effects. Exemplary on-target effects include too high of a dose, chronic activation/inactivation, and correct action in an incorrect tissue. On-target effects of a drug targeting CD47 identified in or through the use of non-human animals described herein may be used to determine a previously unknown function(s) of CD47.

[0151] Non-human animals described herein may provide an *in vivo* system for assessing the off-target toxicity of a drug targeting CD47. A drug targeting CD47 may be delivered or administered to one or more non-human animals described herein, followed by monitoring of or performing one or more assays on the non-human animals (or cells isolated therefrom) to determine the off-target toxic effect of the drug on the non-human animal. Off-target effects can occur when a drug interacts with an unintended target (e.g., cross-reactivity to a common epitope). Such interactions can occur in an intended or unintended tissue. To give but one example, mirror image isomers (enantiomers) of a drug can lead to off-target toxic effects. Further, a drug can inappropriately interact with and unintentionally activate different receptor subtypes. Exemplary off-target effects include incorrect activation/inhibition of an incorrect target regardless of the tissue in which the incorrect target is found. Off-target effects of a drug targeting CD47 may be determined by comparing the effects of administering the drug to non-human animals described herein to one or more reference non-human animals.

[0152] Performing an assay may include determining the effect on the phenotype (e.g., change in body weight) and/or genotype of the non-human animal to which the drug is administered. Performing an assay may include determining lot-to-lot variability for a CD47 modulator (e.g., an antagonist or an agonist). Performing an assay may include determining the differences between the effects of a drug targeting CD47 administered to a non-human animal described herein and a reference non-human animal. Reference non-human animals may have a modification as described herein, a modification that is different as described herein (e.g., one that has a disruption, deletion or otherwise non-functional CD47 gene) or no modification (i.e., a wild-type non-human animal).

[0153] Exemplary parameters that may be measured in non-human animals (or in and/or using cells isolated therefrom) for assessing the pharmacokinetic properties, on-target toxicity, and/or off-target toxicity of a drug targeting CD47 include, but are not limited to, agglutination, autophagy, cell division, cell death, complement-mediated hemolysis, DNA integrity, drug-specific antibody titer, drug metabolism, gene expression arrays, hematocrit levels, hematuria, metabolic activity, mitochondrial activity, oxidative stress, phagocytosis, protein biosynthesis, protein degradation, protein secretion, stress response, target tissue drug concentration, non-target tissue drug concentration, transcriptional activity and the like. Non-human animals described herein may be used to determine a pharmaceutically effective dose of a CD47 modulator.

[0154] Non-human animals described herein may provide an improved *in vivo* system for the development and characterization of candidate therapeutics for use in cancer. Non-human animals described herein may be implanted with a tumor, followed by administration of one or more candidate therapeutics. Candidate therapeutics may include a multi-specific antibody (e.g., a bi-specific antibody) or an antibody cocktail; candidate therapeutics may include combination therapy such as, for example, administration of mono-specific antibodies dosed sequentially or simultaneously. The tumor may be allowed sufficient time to be established in one or more locations within the non-human animal. Tumor cell proliferation, growth, etc. may be measured both before and after administration with the candidate therapeutic(s). Cytotoxicity of candidate therapeutics may also be measured in the non-human animal as desired.

[0155] Non-human animals described herein may provide improved *in vivo* system elucidating mechanisms of human cell-to-cell interaction through adoptive transfer. Non-human animals described herein may be implanted with a tumor xenograft, followed by a second implantation of tumor infiltrating lymphocytes could be implanted in the non-human animals by adoptive transfer to determine the effectiveness in eradication of solid tumors or other malignancies. Such experiments may be done with human cells due to the exclusive presence of human CD47 without competition with endogenous CD47 of the non-human animal. Alternatively, such experiments may include the use of mouse cells from a NOD/SCID or BRG (BALB/c Rag2^{-/-}IL-2Rγ^{-/-}) background. Further, therapies and pharmaceuticals for use in xenotransplantation can be improved and/or developed in such non-human animals.

[0156] Non-human animals described herein may provide an improved *in vivo* system for maintenance and development of human hematopoietic stem cells through engraftment. Non-human animals described herein may provide improved development and maintenance of human stem cells within the non-human animal. Increased populations of differentiated human B and T cells may be observed in the blood, bone marrow, spleen and thymus of the non-human animal. Optimal T and NK cell homeostasis may be observed in cells in the blood, bone marrow, spleen and thymus of the non-human animal. Non-human animals described herein may demonstrate an increase in the level or amount of red blood cells (RBCs) as compared to one or more reference non-human animals.

[0157] Non-human animals described herein may be employed to assess the efficacy of a therapeutic drug targeting human cells. A non-human animal described herein may be transplanted with human cells, and a drug candidate targeting such human cells is administered to such non-human animal. The therapeutic efficacy of the drug is then determined by monitoring the human cells in the non-human animal after the administration of the drug. Drugs that can be tested in the non-human animals include both small molecule compounds, i.e., compounds of molecular weights of less than 1500 kD, 1200 kD, 1000 kD, or 800 daltons, and large molecular compounds (such as proteins, e.g., antibodies), which have intended therapeutic effects for the treatment of human diseases and conditions by targeting (e.g., binding to and/or acting on) human cells.

[0158] The drug is an anti-cancer drug, and the human cells are cancer cells, which can be cells of a primary cancer or cells of cell lines established from a primary cancer. In these instances, a non-human animal described herein may be transplanted with human cancer cells, and an anti-cancer drug is given to the non-human animal. The efficacy of the drug can be determined by assessing whether growth or metastasis of the human cancer cells in the non-human animal is inhibited as a result of the administration of the drug.

[0159] The anti-cancer drug may be an antibody molecule, which binds to an antigen on human cancer cells. The anti-cancer drug may be a bi-specific antibody that binds to an antigen on human cancer cells, and to an antigen on other human cells, for example, cells of the human immune system (or "human immune cells") such as B cells and T cells.

[0160] A non-human animal described herein may be engrafted with human immune cells or cells that differentiate into human immune cells. Such non-human animal with engrafted human immune cells is transplanted with human cancer cells, and is administered an anti-cancer drug, such as a bi-specific antibody that binds to an antigen on human cancer cells and to an antigen on human immune cells (e.g., T cells). The therapeutic efficacy of the bi-specific antibody can be evaluated based on its ability to inhibit growth or metastasis of the human cancer cells in the non-human animal. The non-human animal described herein may be engrafted with human CD34⁺ hematopoietic progenitor cells which give rise to human immune cells (including T cells, B cells, NK cells, among others). Human B cell lymphoma cells (e.g., Raji cells) are transplanted into such non-human animal with engrafted human immune cells, which is then administered with a bi-specific antibody that binds to tumor antigen (e.g., an antigen on normal B cells and certain B cell

malignancies such as CD20) and to the CD3 subunit of the T cell receptor, to test the ability of the bi-specific antibody to inhibit tumor growth in the non-human animal.

EXAMPLES

[0161] The following examples are provided so as to describe to those of ordinary skill in the art how to make and use methods and compositions of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Unless indicated otherwise, temperature is indicated in Celsius, and pressure is at or near atmospheric.

Example 1. Humanization of an endogenous Cluster of Differentiation 47 (CD47) gene.

[0162] This example illustrates exemplary methods of humanizing an endogenous gene encoding cluster of differentiation 47 (CD47) in a non-human mammal such as a rodent (e.g., a mouse). The methods described in this example can be employed to humanize an endogenous CD47 gene of a non-human animal using any human sequence, or combination of human sequences (or sequence fragments) as desired. In this example, a human CD47 gene that appears in bacterial artificial chromosome (BAC) clone RP11-69A17 is employed for humanizing an endogenous CD47 gene of a mouse.

[0163] A targeting vector for humanization of the genetic material encoding an extracellular N-terminal IgV domain and five transmembrane domains of an endogenous CD47 gene was constructed using VELOCIGENE® technology (see, e.g., U.S. Patent No. 6,586,251 and Valenzuela et al. (2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis, Nature Biotech. 21(6):652-659).

[0164] Briefly, mouse bacterial artificial chromosome (BAC) clone RP23-230L20 (Invitrogen) was modified to delete the sequence containing exons 2-7 of an endogenous CD47 gene and insert exons 2-7 of a human CD47 gene using human BAC clone RP11-69A17 (Invitrogen), which encodes amino acids 16-292 of a human CD47 polypeptide. Endogenous DNA containing genomic DNA corresponding to exons 1, 8 and 9 of isoform 2 as well as the 5' and 3' untranslated regions (UTRs) were retained. Sequence analysis of the human CD47 sequence contained in BAC clone RP11-69A17 confirmed all CD47 exons and splicing signals. Sequence analysis revealed that the sequence matched the reference genome and CD47 transcripts NM_001777.3 and NM_198793.2. The genomic DNA corresponding to exons 2-7 of an endogenous CD47 gene (~30.8 kb) was replaced in BAC clone RP23-230L20 by homologous recombination in bacterial cells to insert a DNA fragment containing ~23.9 kb of genomic human DNA corresponding to exons 2-7 of a human CD47 gene from BAC clone RP11-69A17 and ~4995 bp corresponding to a self-deleting neomycin cassette flanked by recombinase recognition sites (*loxP*-hUb1-em7-Neo-pA-mPrm1-Crei-*loxP*; see U.S. Patent No.'s 8,697,851, 8,518,392 and 8,354,389). The self-deleting neomycin cassette was added to the end of the ~23.9 kb human DNA fragment containing exons 2-7 of the human CD47 gene (Figure 2). The targeting vector contained, from 5' to 3', a 5' homology arm containing ~39 kb of mouse genomic DNA from BAC clone RP23-230L20, ~29.3 kb of human genomic DNA from BAC clone RP11-69A17 (containing exons 2-7 of a human CD47 gene), a self-deleting neomycin cassette flanked by *loxP* sites, and ~98.8 kb of mouse genomic DNA from BAC clone RP23-230L20. After homologous recombination in bacterial cells with the targeting vector described above, a modified RP23-230L20 BAC clone was created that resulted in a humanized CD47 gene which contained a mouse 5' UTR, a mouse exon 1, human exons 2-7, mouse exons 8-9 and a mouse 3'UTR. Protein sequences of four projected alternatively spliced isoforms of humanized CD47 are provided in Table 3 which indicate the resulting mouse and human amino acids encoded by the mouse and human DNA, respectively.

[0165] The modified BAC clone described above was used to electroporate F1H4 (50% 129/S6/SvEv/Tac, 50% C57BL/6NTac; Auerbach, W. et al. (2000) *Biotechniques* 29(5):1024-8, 1030, 1032) mouse embryonic stem (ES) cells to create modified ES cells comprising an endogenous CD47 gene that is humanized from exons 2-7. Positively targeted ES cells containing a humanized CD47 gene were identified by an assay (Valenzuela *et al.*, *supra*) that detected the presence of the human CD47 sequences (e.g., exons 2-7) and confirmed the loss and/or retention of mouse CD47 sequences (e.g., exons 1, 8 and 9 and/or exons 2-7). Table 4 sets forth the primers and probes that were used to confirm humanization of an endogenous CD47 gene as described above (Figure 3). The nucleotide sequence across the upstream insertion point included the following, which indicates endogenous mouse sequence upstream of the insertion point (contained within the parentheses below with an *Asi*I restriction site italicized) linked contiguously to a human CD47 sequence present at the insertion point: (GCAGACATGA TTA~~CTTC~~CAGA GCTTTCAAAG CTAGATACTG TACCTTGCAT ATTCCAACAC) GCGATCGC ATTTTAAGAT TTTCCATCCT AGTGGAAGA TATGATTTGA TTCATCCTAT TTA~~CTTT~~GTGTA TATTAAAGTA CAGTAGAACC TGCCACTTTT (SEQ ID NO: 33). The nucleotide sequence across the downstream insertion point at the 5' end of the self-deleting neomycin cassette included the following, which indicates human CD47 genomic sequence contiguous with cassette sequence downstream of the insertion point (contained within the parentheses below with *loxP* sequence italicized): GGATCCATTT TAAGTAATAG AATAGGATTT TTAATTGTTT CAGTGTCTCT GTGATAGAGC TGTCCTGCAC AGACCTGTTT (CTCGAGATAA CTTCGTATAA TGTATGCTAT ACGAAGTTAT ATGCATGGCC TCCGCGCCGG GTTTTGGCGC CTCCGCGGG) (SEQ ID NO: 34). The nucleotide sequence across the downstream insertion point at the 3' end of the neomycin cassette included the following, which indicates cassette sequence contiguous with mouse genomic sequence 3' of exon 7 of an endogenous CD47 gene (contained within the parentheses below with *loxP* sequence italicized): CATGTCTGGA ATA~~CTTC~~GT ATAATGTATG CTATACGAAG TTATGCTAGT AACTATAACG GTCCTAAGGT AGCGACTAGC (ATTAGTATGG AAGGTCCGTC CACTGTCCAG GTTCCTCTTG CGGAGCTCTT TGTCTCTCTG GACTCTGTAT AACTGCTTG) (SEQ ID NO: 35). The nucleotide sequence across the downstream insertion point after deletion of the neomycin cassette (76 bp remaining) included the following, which indicates human and mouse genomic sequence juxtaposed with remaining cassette sequence *loxP* sequence (contained within the parentheses below with *loxP* sequence italicized): GGATCCATTT TAAGTAATAG AATAGGATTT TTAATTGTTT CAGTGTCTCT GTGATAGAGC TGTCCTGCAC AGACCTGTTT (CTCGAGATAA CTTCGTATAA TGTATGCTAT ACGAAGTTAT GCTAGTAACT ATAACGGTCC TAAGGTAGCG ACTAGC)ATT AGTATGGAAG GTCCGTCCAC TGTCAGGTT CCTCTTGCGG AGCTCTTGT CTCTCTGGAC TCTGTATACA CTGCTTGCAT (SEQ ID NO: 36).

[0166] Positive ES cell clones were then used to implant female mice using the VELOCIMOUSE® method (see, e.g., U.S. Pat. No. 7,294,754 and Poueymirou et al., F0 generation mice that are essentially fully derived from the donor gene-targeted ES cells allowing immediate phenotypic analyses, 2007, Nature Biotech. 25(1):91-99) to generate a litter of pups containing an insertion of exons 2-7 of a human CD47 gene into an endogenous CD47 gene of a mouse. Mice bearing the humanization of exons 2-7 of an endogenous CD47 gene were again confirmed and identified by genotyping of DNA isolated from tail snips using a modification of allele assay (Valenzuela *et al.*, *supra*) that detected the presence of the human CD47 gene sequences. Pups are genotyped and cohorts of animals heterozygous for the humanized CD47 gene construct are selected for characterization.

TABLE 4

Name	Primer	Sequence (5'-3')	
7190mTU	Forward	TGCAGAAAGTCACTAGGAGGAAT	(SEQ ID NO:21)
	Probe	TCAGTCAACTTCTTCTGGGTTGTTT CC	(SEQ ID NO:22)
	Reverse	GTGCCAGACTCACTTTCTATCCA	(SEQ ID NO:23)
	Forward	TGCTGCCAATATACGGCTTCTG	(SEQ ID NO:24)

Name	Primer	Sequence (5'-3')	
7190mTD	Probe	CAGCTCTCATAGCCAACTATGGTG CC	(SEQ ID NO:25)
	Reverse	TCAAGCAGAGCCTGGTTATCTG	(SEQ ID NO:26)
	Forward	GTCGTCATTCCATGCTTTGTTAC	(SEQ ID NO:27)
7190hTU	Probe	TGGAGGCACAAAACACTACTGAAG TATACG	(SEQ ID NO:28)
	Reverse	GGACAGTGGACTTGTTTAGAGC	(SEQ ID NO:29)
	Forward	GGCTTGGTGGCTGATTGTTCT	(SEQ ID NO:30)
7190hTD	Probe	AGCACCCAACTGATATGCCTGTA TTTG	(SEQ ID NO:31)
	Reverse	TGGGAACTGGTGTTCAGTCTA	(SEQ ID NO:32)

Example 2. Expression of humanized CD47 polypeptide by mouse red blood cells.

[0167] This Example demonstrates that non-human animals (e.g., rodents) modified to contain a humanized CD47 gene according to Example 1 can be used to screen CD47 modulators (e.g., anti-CD47 antibodies) and determine various characteristics such as, for example, pharmacokinetics and safety profiles. In this Example, several anti-CD47 antibodies are screened on mouse red blood cells (RBCs) isolated from rodents made in accordance with Example 1, which rodents express a humanized CD47 polypeptide as described herein.

[0168] Briefly, 2 mL of whole blood from humanized CD47 mice (n=2) was transferred to a 15 mL tube and centrifuged at 200xg for 10 minutes at 4°C. The plasma and buffy coat were aspirated and then 15 mL of PBS was added and the cells were mixed gently. The mixture was centrifuged again at 200xg for five minutes at 4°C. The supernatant was aspirated and the cells were washed two additional times. Pelleted RBCs were resuspended to a final volume in 10 mL of PBS. The resuspended RBCs were centrifuged a final time at 200xg for 10 minutes at 4°C. The volume of packed RBCs was estimated 0.5 mL and diluted to a concentration of 0.5% with PBS (0.5 mL packed RBC/100 mL PBS). Actual RBC concentration was determined with a Cellometer Auto T4 (1.5×10^7 /mL; Nexcelom Bioscience).

[0169] Eighty (80) μ L of 0.5% mouse RBCs were added to each well of a 96-well V-bottom plate. Anti-CD47 antibodies were added into each well (20 μ L at 33 nM). The plate was gently tapped to mix and incubated on ice for 30 minutes. The plate was then washed twice with staining buffer (PBS with 2% FBS). Secondary antibody Fab-488 (Alexa Fluor 488-conjugated AffiniPure mouse anti-human IgG, F(ab')₂ fragment specific, Jackson Immuno Research) was added to each well at a concentration of 10 μ g/mL. The plate was incubated again on ice for 30 minutes, followed by washing once with staining buffer. The cells in each well were resuspended in 200 μ L of staining buffer and filtered through a 96-well filter plate. The cells in the plate were analyzed using the BD ACCURI™ C6 system (BD Biosciences). Exemplary results are shown in Figure 4. The mean fluorescence intensity (MFI) above isotype control for each tested antibody is shown in Table 5.

TABLE 5

Antibody	MFI	Fold above isotype control
Ab A, hlgG4s	28898	258
Ab B, hlgG4s	27545	246
Ab C, hlgG4s	24620	220
Ab D, hlgG1	29882	267
Ab E, hlgG4	33423	298
Control, hlgG4s	112	-
Control, hlgG4	112	-
<i>hlgG4s: human IgG4 with modified Fc region that has reduced effector function</i>		

[0170] As shown in Figure 4, all anti-CD47 antibodies bound to RBCs from humanized CD47 mice. Taken together, this Example demonstrates that (1) non-human animals (e.g., rodents) engineered to contain a humanized CD47 gene as described herein express a humanized CD47 polypeptide on the surface of cells (e.g., RBCs) of the non-human animal, and (2) such cells are useful for screening CD47 modulators (e.g., CD47 antibodies) and determining the pharmacokinetic profiles of such modulators.

Example 3. Hemagglutination of mouse red blood cells expressing humanized CD47 polypeptide.

[0171] This Example further demonstrates that non-human animals (e.g., rodents) modified to contain a humanized CD47 gene according to Example 1 can be used in various assays (e.g., hemagglutination assay) to screen CD47 modulators (e.g., anti-CD47 antibodies) and determine various characteristics such as, for example, pharmacokinetics and safety profiles. In this Example, several anti-CD47 antibodies are screened on mouse red blood cells (RBCs) that express a humanized CD47 polypeptide as described herein to determine antibody concentration that promotes hemagglutination.

[0172] Briefly, RBCs from wild-type and humanized CD47 mice ($n = 2$) were prepared as described in Example 2. Twenty (20) μ L of anti-CD47 antibody (at 5-fold serial dilution) was added into wells 1-12 across a 96-well V-bottom plate followed by the addition of 80 μ L of 0.5% mouse RBCs to all wells of the plate. The plates were tapped gently to mix and incubated at room temperature (24-27°C) for 30 minutes. Agglutination endpoint was observed visually (i.e., RBCs settle to the bottom in negative samples, while RBCs agglutinate in positive samples). Exemplary results are shown in Figure 5, with boxes to outline the wells that show hemagglutination.

[0173] As shown in Figure 5, only lectin caused agglutination in wild-type mice. However, two anti-CD47 antibodies (Ab E and Ab C) in addition to lectin induced agglutination in RBCs from two humanized CD47 rodents made according to Example 1. The concentration at which these two antibodies induced agglutination started from 11 nM. Taken together, this Example demonstrates that non-human animals (e.g., rodents) engineered to contain a humanized CD47 gene as describe herein can be used to assess one or more properties (e.g., hemagglutination) of CD47 modulators (e.g., CD47 antibodies).

Example 4. Pharmacokinetic clearance of CD47 modulators in humanized CD47 rodents.

[0174] This Example illustrates a method of assessing the pharmacokinetic clearance of CD47 modulators (e.g., anti-CD47 antibodies) in non-human animals (e.g., rodents) modified to contain a humanized CD47 gene according to Example 1. In this Example, wild-type and humanized CD47 rodents (e.g., mice) were

administered anti-CD47 antibodies and serum levels of antibodies were determined using an ELISA assay.

[0175] Briefly, wild-type (n=5) or mice homozygous for humanized CD47 (n=5; as described above) were administered four anti-CD47 antibodies (Ab F, Ab G, Ab H and Ab I) and an IgG4s isotype control antibody (IgG4s). The genetic background of the mice were 75% CD57BL/6 and 25% 129Sv. Each antibody was tested in five humanized CD47 rodents. All antibodies were administered subcutaneously at a dose of 50 mg/kg. One pre-bleed was collected one day prior to administration of antibody (day 0). Post-injection bleeds were collected at 6 hours, 1 day, 2 days, 3 days, 4 days, 7 days, 10 days and 14 days. Serum fractions from bleeds were separated and subjected to total human antibody analysis using an ELISA immunoassay.

[0176] Briefly, a goat anti-human IgG polyclonal antibody (Jackson ImmunoResearch) was coated onto 96-well plates to capture the tested human antibodies in the sera, and then plate bound antibodies were detected using a goat anti-human IgG polyclonal antibody conjugated with horseradish peroxidase (Jackson ImmunoResearch) and TMB substrate (BD Pharmingen). The serum samples were in six-dose serial dilutions and reference standards of the respective antibodies in 12-dose serial dilutions. Drug antibody concentrations in the sera were calculated based on the reference standard curve generated using Graphpad Prism software. Exemplary results are shown in Figure 6 and Table 6.

[0177] The data demonstrated that the antibodies administered to wild-type and humanized mice as described herein were well tolerated. Taken together, this Example demonstrates that non-human animals described herein can be used to assess one or more pharmacokinetic properties of a drug targeting CD47 (e.g., an anti-CD47 antibody) such as, for example, circulating drug levels. Moreover, non-human animals described herein can be used to assess the toxicity of a drug targeting CD47 by determining adverse effects after administration.

TABLE 6

Serum antibody concentrations ($\mu\text{g/mL} \pm \text{SEM}$)							
Antibody	6 hour	Day 1	Day 2	Day 3	Day 4	Day 7	Day 10
Ab F	116.7 $\pm$ 14.0	196.4 $\pm$ 10.6	96.0 $\pm$ 13.3	24.7 $\pm$ 7.0	3.7 $\pm$ 0.42	<0.35	<0.35
Ab G	115.0 $\pm$ 22.1	198.8 $\pm$ 23.4	118.4 $\pm$ 20.9	48.3 $\pm$ 16.0	2.9 $\pm$ 1.97	<0.35	<0.35
Ab H	64.5 $\pm$ 3.85	108.0 $\pm$ 5.13	32.0 $\pm$ 6.08	1.0 $\pm$ 0.2	0.4 $\pm$ 0.03	0.06 $\pm$ 0.03	0.05 $\pm$ 0.02
Ab I	51.1 $\pm$ 16.6	115.2 $\pm$ 14.8	63.8 $\pm$ 8.3	11.1 $\pm$ 4.2	0.5 $\pm$ 0.1	0.1 $\pm$ 0.02	<0.35
IgG4s Isotype control	458.2 $\pm$ 34.4	702.5 $\pm$ 32.3	616.6 $\pm$ 27.0	567.1 $\pm$ 39.5	488.9 $\pm$ 45.0	357.0 $\pm$ 51.1	307.6 $\pm$ 61.1

Example 5. Pharmacokinetic profiles of CD47 modulators in humanized CD47/SIRP α rodents.

[0178] This Example illustrates a method of assessing the pharmacokinetic clearance of CD47 modulators (e.g., anti-CD47 antibodies) in non-human animals (e.g., rodents) modified to contain humanized CD47 (according to Example 1) and SIRP α genes. In particular, humanized CD47 rodents described herein were modified to further contain a humanized SIRP α gene that contains an endogenous portion and a human portion, which human portion encodes the extracellular domain of a human SIRP α protein (e.g., amino acids 28-362 of a human SIRP α protein) and which endogenous portion encodes an intracellular domain of an endogenous SIRP α protein (e.g., amino acids encoding transmembrane and intracellular portions of a murine SIRP α protein) as described in PCT/US14/56910, filed September 23, 2014. Double humanized CD47/SIRP α mice were made by breeding humanized SIRP α mice to humanized CD47 mice. In this Example, double humanized CD47/SIRP α rodents (e.g., mice) were administered various anti-CD47 antibodies and their

corresponding pharmacokinetic profiles were determined.

[0179] Briefly, groups of wild type (n=5) and mice homozygous for humanized CD47 and SIRP α genes (CD47^{hu/hu}SIRP α ^{hu/hu}; n=5 per group) were administered selected anti-CD47 antibodies and an IgG4 isotype control antibody (hIgG4s). The genetic background of the mice were 75% CD57BL/6 and 25% 129Sv. All antibodies were administered in a single subcutaneous dose of 50 mg/kg. One pre-bleed was collected one day prior to administration of antibody (day 0). Post-injection bleeds were collected at 6 hours, 1 day, 2 days, 3 days, 4 days, 7 days and 10 days. Serum fractions from bleeds were separated and subjected to total human antibody analysis using an ELISA immunoassay (described above). Additionally, hematocrit levels were measured at 6 hours, 1 day, 2 days, 3 days, 4 days, 7 days and 10 days and a urine test was performed as needed (at 6 hours and when urine color deviated from yellow color) to determine red blood cell counts. Exemplary results are shown in Figures 7-9.

[0180] As shown in Figures 7 and 8, all anti-CD47 antibodies demonstrated target-mediated clearance in CD47^{hu/hu}SIRP α ^{hu/hu} mice and, in particular, many demonstrated similar pharmacokinetic profiles. Further, a monovalent version of one anti-CD47 antibody (Ab F) demonstrated greater bioavailability than its bivalent equivalent (Figure 8). The inventors observed similar pharmacokinetic profiles for the antibodies among multiple experiments with humanized CD47 and double humanized animals (i.e., CD47^{hu/hu}SIRP α ^{hu/hu} mice).

[0181] Ab J had less of an effect on hematocrit levels than other anti-CD47 antibodies tested (Ab F, Ab G, Ab I, etc.) and comparable changes in hematocrit levels to control (hIgG4s) in CD47^{hu/hu}SIRP α ^{hu/hu} mice. Measurements of hematocrit on days 2-4 showed the largest drop from normal range (~38.5-45.1%), which included groups administered Abs F, G and I. In particular, a monovalent form of Ab F demonstrated a delayed lowering effect on hematocrit as compared to other antibodies tested. The inventors reasoned that differences in hematocrit levels among the various treatment groups could be attributed to a difference in epitope recognized by the various antibodies. Also, mice dosed with selected anti-CD47 antibodies demonstrated positive urine dipstick tests for heme at 6 hours. For example, Ab J and Ab F treatment groups each had one mouse positive for heme on day 1, while all other timepoints were negative. No significant weight loss (>20%) was observed in any treatment group.

[0182] Taken together, this Example demonstrates that non-human animals described herein provide an *in vivo* system for assessing the pharmacokinetic properties and/or profiles of one or more drugs targeting CD47 (e.g., one or more anti-CD47 antibodies) such as, for example, circulating drug levels. Moreover, non-human animals as described herein engineered to further contain other humanized genes (e.g., humanized SIRP α) can be used to assess the target-mediated clearance of one or more drugs targeting CD47.

EQUIVALENTS

[0183] Having thus described several aspects of at least one embodiment of this invention, it is to be appreciated by those skilled in the art that various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the scope of the invention. Accordingly, the foregoing description and drawing are by way of example only and the invention is described in detail by the claims that follow.

[0184] Use of ordinal terms such as "first," "second," "third," etc., in the claims to modify a claim element does not by itself connote any priority, precedence, or order of one claim element over another or the temporal order in which acts of a method are performed, but are used merely as labels to distinguish one claim element having a certain name from another element having a same name (but for use of the ordinal term) to distinguish the claim elements.

[0185] The articles "a" and "an" as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to include the plural referents. Claims or descriptions that include "or" between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention also includes embodiments in which more than one, or the entire group members are present in, employed in, or otherwise relevant to a given product or process. Furthermore, it is to be understood that the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the listed claims is introduced into another claim dependent on the same base claim (or, as relevant, any other claim) unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise. Where elements are presented as lists, (e.g., in Markush group or similar format) it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements, features, etc., certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements, features, etc. For purposes of simplicity those embodiments have not in every case been specifically set forth in so many words herein. It should also be understood that any embodiment or aspect of the invention can be explicitly excluded from the claims, regardless of whether the specific exclusion is recited in the specification.

[0186] Those skilled in the art will appreciate typical standards of deviation or error attributable to values obtained in assays or other processes described herein.

SEQUENCE LISTING

[0187]

<110> REGENERON PHARMACEUTICALS, INC.

<120> NON-HUMAN ANIMALS HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION
47 GENE

<130> 32584 (10108WO01)

<140>

<141>

<150> 62/087,992

<151> 2014-12-05

<160> 36

<170> PatentIn version 3.5

<210> 1

<211> 5591

<212> DNA

<213> Mus musculus

<400> 1

gcctacaccg ggagagcagg gaggaggagt tggactgagg ttgggcggct ccgaggtcca

gggcgagctt ggccagaggg agtagagagc agcggggctg cgcagggacg cgtgccgtga	120
gttcgggtga gcgtgtgtgt cccatgtcc cgtctttcag gccggcccag gacacgaagc	180
cggaagagag ctggctggag ggacgggggc cgtgagcaga gagtgcacc cgcgcagccc	240
cggggacagg ctgattcttg gcgtctccg ccggagcctg cccagggctg ggtgtgaggc	300
tggcgtcaog tcaacgagca gaggcggcca ggcggggcgg agtgcgctg cgcggggcgg	360
cgagcacgag cgcgcgcgca ccccgggca gcctgggcgg ccgctcctgc ctgtcactgc	420
tgcggcgtg ctggtcggtc gtttcccttg aaggcagcag cggaggcggc ggctgtcca	480
gacacctgcg gcggcgaccc cccggcgggc cggagatgtg gcccttggcg gcggcgtgt	540
tgctgggctc ctgctgtgc ggttcagctc aactactgtt tagtaacgtc aactccatag	600
agttcacttc atgcaatgaa actgtggtca tcccttgcat cgtccgtaat gtggaggcgc	660
aaagcaccga agaaatgttt gtgaagtgga agttgaacaa atcgtatatt ttcactctatg	720
atggaaataa aaatagcact actacagatc aaaactttac cagtgcacaa atctcagtct	780
cagacttaat caatggcatt gcctctttga aaatggataa gcgcgatgcc atggtgggaa	840
actacacttg cgaagtgaca gaggttatcca gagaaggcaa aacagttata gagctgaaaa	900
accgcacggc cttcaacact gaccaaggat cagcctgttc ttacgaggag gagaaaggag	960
gttgcaaat agtttcgtgg ttttctccaa atgaaaagat cctcattgtt attttcccaa	1020
ttttggctat actcctgttc tggggaagt ttggtatttt aacactcaaa tataaatcca	1080
gccatacgaa taagagaatc attctgtgc tcgttgccgg gctggtgctc acagtcatcg	1140
tggttgttg agccatcctt ctcacccag gagaaaagcc cgtgaagaat gcttctggac	1200
ttggcctcat tgtaactctc acggggatat taatactact tcagtacaat gtgtttatga	1260
cagcttttg aatgacctct ttcaccattg ccatattgat cactcaagtg ctgggctacg	1320
tccttgcttt ggtcgggctg tgtctctgca tcattggcatg tgagccagtg cgcggcccc	1380
ttttgatttc aggtttgggg atcatagctc tagcagaact acttgatta gtttatatga	1440
agtttgtcga ataggtaag ggaagtgacg gactgtaact tggaagtcag aaatggaaga	1500
atacagttgt ctaagacca ggtcttcacg actcacagct ggaaggacaa gacaacagta	1560
actgacttcc atccaggaaa acatgtcaca taaatgatta ctaagtttat attcaaagca	1620
gctgtacttt acataataaa aaaaatatga tgtgtgtgtt aaccaattgg aatcccattt	1680
ttctattgtt tctactcaac taggggcaaa cgtttcaggg gcaacttcca agaattgtgc	1740
ttgttagatc ctgagctc tgaacactga gtttaaattg attccgagtg agactcgcca	1800
agcactaacc tgagggttag ttaccagag atacctatga aaaacagtggt tatccagcaa	1860
gccttagtaa actcaggttg ccagcagctt tgccacttcc gctgctagct gaataacaag	1920
actgccactt ctgggtcata gtgatagaga ctgaagtaga aaaacgaatg tggttgggca	1980
aatcccggtg gggccctctg tgtgtatga tattgatggc actggtgtct tcattcttgg	2040
gggttgccat cattcacaca ccccccttg acatacagtg cccccagtt ttgaatacat	2100
tttttttgca cctgtcccg ttctgtact ttgatttgcg ttatgatata tatatatata	2160
tataatacct tttctcctct ttaaactggt tcctgtgaca caatagtcag ttgcagaaag	2220
gagccagact tattcgcaaa gactgtgct caaactctc agaaaaaag gaaaaaaa	2280
aaaagctata gttgtaacat atgtattcca gacctctggt ttaaaggcaa aagaaaaaa	2340
atctacagtg tttcttctca tgtttctga tcggaggcat gacaaagca gactgaaatc	2400
tgaactgtgt ctctgcatg gcaacacgtg tctcgtcag gccctcgcaa ggcggggga	2460
gggggttcta cgcctcttgt ctcttgttg catgctgaac actcatcgcc ttcctactgt	2520
atcctgcctc ctgcagcctc cctcttctc ctctcttcc tcttctctc ctctctctc	2580
ctctctctct tctccaagt ttgaaaggtc aaacaaaact accacattcc ctaccagtt	2640
aaaaaaaac caccctctc acattctga tccatgga tacttttga ttattaacac	2700

ctgtttttac ctcgtttgtg ggcgtgtttg tatgtgcaca tqtatgaagt cggcacatgc	2760
accttctgta tgggcagagg cgtggcatct acagaagagc agatgccaac tttgtgcttt	2820
tagtgaatac attaaaaaaa aaaaccaaac ggtccttatt gagtggattt ctatttgatg	2880
caaatatttg agctctttaa gactttaaaa ctagataatg tgccaagctt ttaggactgc	2940
tcaccagtgc cctctgaaga aacaccagta ctttttctctg tttgtgtaat aaaggcatat	3000
ttgtatttgt gtttgcata ctaatggtta tttctcttta gtccactgaa tgtttccatg	3060
tgcctctcgt atgccaaact ttttgtcatc tttcatgtgg ggaccaaag gtttgtctgt	3120
ggcaaaccta aacctatgac ctgctgaggc ctctcagaaa actgaccaca gtaccaagat	3180
agtacttcgc aaagaaaagt aggttccttc cctggttttg tagctgtcgc caatattagc	3240
gtaattccaa ggagctgaac gcctttatat aaatctgatg gcacctgatg ctttttagttc	3300
tgaatatatt tacactcgga tcatgttgtt gatgacttaa acaaagtttt gatgaagaga	3360
gcaaaaaaaaa agcaggtgga tttggaacag tttcagggtt ttttttgttt tttgtttttt	3420
gtttttgttt tttttttttt atttttgttt ttctgttctc tgttagaaaa gtcaggtgtt	3480
ctctgtcagg ctatctttat agtcaatttt ttttacgaac taaagtagta ctttttaata	3540
tgtagtcaac gcccctctgc tcgggggttca gttttgggtc ttaaccagct gtcagtgtct	3600
ctatgctgcc tgccacttga ggcactgagt gccctagaca gtcccatcgg tggtagccag	3660
ggaacgaaa gacgaactca actcttgctc ctaataatca actctctgta tgaaggatgg	3720
cagcattaag agtcctctcg cctgggcatt attgggccag ttcacctctt ttaaatcaaa	3780
cccgcagtgg ctcccagttc tcgtcccatc agatttaaat tgetaacagt atggggggca	3840
ccacgcactc gttttgtccc acaatgcgct tttctctccc aaatcccgat ttctgctgtc	3900
atagcctcta ttcaattttt atttattgtc tgccctccac ttatacaatc gtagagagca	3960
atgccatttg tcactttctg caacagtttt ttgagccttt atggctgaat cccatttttc	4020
ttctctttca aactgtttgc tccattgtct ccccgccagc gctgtccgta cagtcatccc	4080
atccatctgg gggcctcttt catctctcac ccttcctggt gcttcgtgga tctctgctta	4140
cctctgtggg tttttttttt tttttttgac ttattcttct cactggactt taagattact	4200
tccacagcga aagtgtgccc tcccttttct gcccgcagtg ttctgcgtac tttagatact	4260
actcagtgtc gacatttgat ggcaaaagt gcttgcactt aaatttctct ttttaatagg	4320
gtgaactaga gttggagttt ttttctcttt tttctctttt ctctctctct ctctctctct	4380
ctctctctct ctctctctct ctccctccct cctccctcc ctccctccct cctctctct	4440
ctctttttct ttctttcttt cttttcttct ttctttcttt ctttctttct ttctttcttt	4500
ttttgacaaa tctcacaggc tttgagaatt ataaaagggt acagttccac tgaaatcac	4560
aggtctggtc tgtttaaatt gttgagaaat atccgattaa aagtcttgtg gctgtgtcct	4620
aataggctct ctttcaggac gttgtagtca atagagtgc tgaaccatac ttgagtttat	4680
aaagctcaaa aactgatgca cccactctgc tattatctgt ttagtaagag ttcagctgta	4740
tatcattgtc taggtttatc ttgtcctaca gtgggtatcc aaatatggcc accagaggat	4800
atgtgtaaat ataagcacct gtatttgcct gttgttgaga actggaggga aaacaaaaaa	4860
tgtctggcaa ccctttgcct ttttaaccgt aattaattga cagtttattt agagataaga	4920
gttttcaaaa atctcttaac tgccacaacc cacagagggg cttgttttgc catcttcagt	4980
ggctcacaga tatgatccaa gttaacttga aagagatgag cagtaccag gaaattgtcc	5040
tgcctttaac tctggctgtc cttaattatg actgtttaat gctgaatttt ccatccgtct	5100
agtgtttgag ggtaagaaa agcctttttt aaataagtat ttctgtaaaa cggcatcggg	5160
gggatcttct gtgttgctat cacgggtgaa agagggaaac atttcttatt tttattaagc	5220
agagcattat ttacgaaa cctttcttga gaattagttc cggcatcata taaatatcca	5280

```

agagcattat ttacagaaag ccatgtgtga gaattagttt ccaatcata taaatattca 5200
ttaaccatttc taaattgtaa gagaactcca gtgttgctat gcacaaggaa ctctcctggg 5340
ggcctttttt tgcataagcaa ttaaaggtat gctatttgtc agtagccatt ttttgcagtg 5400
atttaaagac caaagttggt ttacagctgt gttaccctta aaggtttttt ttttatgtat 5460
taaatcaatt tatcactggt tgaagctttg aatacctgca atctttgccca agatactttt 5520
ttatttaaaa aaataactgt gtaaataatta cctgttaata ttatatatac ttaataaaac 5580
attttaagct a 5591

```

<210> 2
 <211> 312
 <212> PRT
 <213> Mus musculus

<400> 2
 Met Trp Pro Leu Ala Ala Ala Leu Leu Leu Gly Ser Cys Cys Gly
 1 5 10 15

Ser Ala Gln Leu Leu Phe Ser Asn Val Asn Ser Ile Glu Phe Thr Ser
 20 25 30

Cys Asn Glu Thr Val Val Ile Pro Cys Ile Val Arg Asn Val Glu Ala
 35 40 45

Gln Ser Thr Glu Glu Met Phe Val Lys Trp Lys Leu Asn Lys Ser Tyr
 50 55 60

Ile Phe Ile Tyr Asp Gly Asn Lys Asn Ser Thr Thr Thr Asp Gln Asn
 65 70 75 80

Phe Thr Ser Ala Lys Ile Ser Val Ser Asp Leu Ile Asn Gly Ile Ala
 85 90 95

Ser Leu Lys Met Asp Lys Arg Asp Ala Met Val Gly Asn Tyr Thr Cys
 100 105 110

Glu Val Thr Glu Leu Ser Arg Glu Gly Lys Thr Val Ile Glu Leu Lys
 115 120 125

Asn Arg Thr Ala Phe Asn Thr Asp Gln Gly Ser Ala Cys Ser Tyr Glu
 130 135 140

Glu Glu Lys Gly Gly Cys Lys Leu Val Ser Trp Phe Ser Pro Asn Glu
 145 150 155 160

Lys Ile Leu Ile Val Ile Phe Pro Ile Leu Ala Ile Leu Leu Phe Trp
 165 170 175

Gly Lys Phe Gly Ile Leu Thr Leu Lys Tyr Lys Ser Ser His Thr Asn
 180 185 190

Lys Arg Ile Ile Leu Leu Leu Val Ala Gly Leu Val Leu Thr Val Ile
 195 200 205

Val Val Val Gly Ala Ile Leu Leu Ile Pro Gly Glu Lys Pro Val Lys
 210 215 220

Asn Ala Ser Gly Leu Gly Leu Ile Val Ile Ser Thr Gly Ile Leu Ile
 225 230 235 240

Leu Leu Gln Tyr Asn Val Phe Met Thr Ala Phe Gly Met Thr Ser Phe
 245 250 255

Thr Ile Ala Ile Leu Ile Thr Gln Val Leu Gly Tyr Val Leu Ala Leu
 260 265 270

Val Gly Leu Cys Leu Cys Ile Met Ala Cys Glu Pro Val His Gly Pro
275 280 285

Leu Leu Ile Ser Gly Leu Gly Ile Ile Ala Leu Ala Glu Leu Leu Gly
290 295 300

Leu Val Tyr Met Lys Phe Val Glu
305 310

<210> 3
<211> 5560
<212> DNA
<213> Mus musculus

<400> 3
gcctacaccg ggagagcagg gaggaggagt tggactgagg ttgggcggct ccgagggtcca 60
gggcgagctt ggccagaggg agtagagagc agcggggctg cgcagggacg cgtgccgtga 120
gttcgggtga gcgtgtgtgt cccatgctcc cgtctttcag gccggcccag gacacgaagc 180
cggaagagag ctggctggag ggacgggggc cgtgagcaga gagtgcaccc cgcgcagccc 240
cggggacagg ctgattcttg gcgctctccg ccggagcctg ccagggctg ggtgtgaggc 300

tggcgtcacg tcaacgagca gaggcggcca ggccggggcg agtgcgcgtg cgcggggcg 360
cgagcacgcg cgcgcgcgca ccccccggga gcctggggcg ccgctcctgc ctgtcactgc 420
tgccgcgctg ctggtcggtc gtttcccttg aaggcagcag cggagggcgc ggctgctcca 480
gacacctgcg gcggcgaccc cccggcggcg cggagatgtg gcccttggcg gcggcgctgt 540
tgctgggctc ctgctgtctc gggtcagctc aactactgtt tagtaacgtc aactccatag 600
agttcacttc atgcaatgaa actgtggtca tcccttgcac cgtccgtaat gtggaggcgc 660
aaagcaccca agaaatgttt gtgaagtgga agttgaacaa atcgtatatt ttcacttatg 720
atggaaataa aaatagcact actacagatc aaaactttac cagtgcacaa atctcagtct 780
cagacttaat caatggcatt gcctctttga aaatggataa gcgcgatgcc atggtgggaa 840
actacacttg cgaagtgaca gagttatcca gagaaggcaa aacagttata gagctgaaaa 900
accgcacggt ttcgtggttt tctccaaatg aaaagatcct cattgttatt ttcccaattt 960
tggctatact cctgttcttg ggaaagtttg gtattttaac actcaaatat aaatccagcc 1020
atacgaataa gagaatcatt ctgctgctcg ttgccgggct ggtgctcaca gtcactgtgg 1080
ttgttgagc catccttctc atcccaggag aaaagcccgt gaagaatgct tctggacttg 1140
gcctcattgt aatctctacg gggatattaa tactacttca gtacaatgtg tttatgacag 1200
cttttggaat gacctcttcc accattgcca tattgatcac tcaagtgtg ggctacgtcc 1260
ttgcttttgt cgggctgtgt ctctgcatca tggcatgtga gccagtgcac ggcccccttt 1320
tgatttcagg tttggggatc atagctctag cagaactact tggattagtt tatatgaagt 1380
ttgtcgcttc caaccagagg actatccaac ctccataggaa taggtgaagg gaagtgcagg 1440
actgtaactt ggaagtcaga aatggaagaa tacagttgtc taagcaccag gtcttcacga 1500
ctcacagctg gaaggaacag acaacagtaa ctgacttcca tccaggaaaa catgtcacat 1560
aaatgattac taagtattata ttcaaagcag ctgtacttta cataataaaa aaaatatgat 1620
gtgctgtgta accaattgga atcccatttt tctattgttt ctactcaact aggggcaaac 1680
gtttcagggg caacttccaa gaatgatgct tgttagatcc tagagtctct gaacactgag 1740
tttaaattga ttccgagtga gactcgccaa gcaactaacct gagggtagt taccagaga 1800
tacctatgaa aaacagtggg atccagcaag ccttagtaaa ctcaggttgc cagcagcttt 1860
gccacttccg ctgctagctg aataacaaga ctgccacttc tgggtcatag tgatagagac 1920
tgaagtagaa aaacgaatgt ggttgggcaa atcccgtgtg gccctctctg gtgctatgat 1980
attgatggca ctggtgtctt cattcttggg ggttgccatc attcacacac acccctttga 2040
catacaotcc accccaottt toaatacatt ttttttccac cctotcccot tctctactt 2100

tgatttgcgt tatgatatat atatatatat ataatacctt ttctctctt taaacatggt 2160

cctgtgacac aatagtcagt tgcagaaagg agccagactt attcgcaaag caactgtgctc 2220
 aaactcttca gaaaaaaagg aaaaaaaaaa aaagctatag ttgtaacata tgtattccag 2280
 acctctgggt taaaggcaaa agaaaaaaa tctacagtgt ttcttctcat gttttctgat 2340
 cggaggcatg acaaagcaag actgaaatct gaactgtgtc tctgcatgg caacacgtgt 2400
 ctccgtcagg cctcgcgaag gcccggggag ggggttctac gcctcttgct tctttgttgc 2460
 atgctgaaca ctcatgcct tctactgta tctgcctcc tgcagcctcc ctcttctcc 2520
 tctcttctct ctctctctct tctctctctc tctctctctt cctccaagtt tgaaaggcca 2580
 aacaaaacta ccacattccc taccagttta gaagaaaacc accgtcctga cagtgtgat 2640
 cgcattggagt acttttagat tatttagcacc tgtttttacc tctgttggg gcgtgttgt 2700
 atgtgcacat gtatgaagtc ggcacatgca ccttctgtat gggcagaggc gtggcatcta 2760
 cagaagagca gatgccaact ttgtgctttt agtgaataca ttaaaaaaa aaaaccaacg 2820
 gtccttattg agtggaaatc tatttgatgc aaatatgtga gctctttaag actttaaaac 2880
 tagataatgt gccaaagctt taggactgct caccagtgcc ctctgaagaa acaccagtac 2940
 ttttctctgt ttgtgtaata aaggcatatt tgtatttggg ttgcatcac taatggttat 3000
 ttcttcttag tccactgaat gtttccatgt gcctctctga tgccaaactt ttgtcatct 3060
 ttcatgtggg gaccaaagtg ttgtctgtg gcaaacctaa acctatgacc tgcagaggcc 3120
 tctcagaaaa ctgaccacag taccaagata gtacttcgca aagaaaagta gggtccctcc 3180
 ctggttttgt agctgtgcc aatattagcg taattccaag gagctgaacg cctttatata 3240
 aatctgatgg cacctgatgc ttttagttct gaaaatattt aactcggat catgttgttg 3300
 atgacttaaa caaagttttg atgaagagag caaaaaaaa gcaggtggat ttggaacagt 3360
 ttcagggttt tttttgtttt ttgtttttt tttttgttt tttttttta tttttgttt 3420
 tctgttctct gtagaaaaag tcaggtgttc tctgtcaggc tatctttata gtcaattttt 3480
 tttacgaact aaagtagtac cttttaatat gtagtcaacg cccctctgct cgggggtcag 3540
 ttttgggtct taaccagctg tcatgttctc tatgtgcct gccacttgag gcactgagtg 3600
 cccatagacag tcccatcggg ggtagccagg gaaacgaaag acgaactcaa ctcttgctcc 3660
 taataatcaa ctctctgtat gaaggatggc agcatthaaga gtccctctgc ctgggcatta 3720
 ttgggccagt tcacctctt taaatcaaac ccgcagtggc tcccagttct cgtcccatca 3780
 gatttaaat gctaacagta tggggggcac cagcatctg tttgtccca caatgcgctt 3840
 ttctctccca aatcccgatt tctgtgtca tagcctctat tcaattttta tttattgtct 3900
 gccctccact tatacaatcg tagagagcaa tgccatttgt cactttctgc aacagttttt 3960
 tgagccttta tggtgaatc ccatttttct tctctttcaa actgtttgct ccattgtctc 4020
 tcccgacagg ctgtccgtac agtcatccca tccatctggg ggctctttc atctctcacc 4080

cttctgggtg ctctgtgat ctctgttac ctctgtgggt ttttttttt ttttttgact 4140
 tattcttctc actggacttt aagattactt ccacagcga agtgctgctt ccttttctg 4200
 cccgcagtgt tctgcgtact ttagatacta ctcagtctg acatttgatg gcaaaagttg 4260
 octgcactta aattctctt ttaatatagg tgaactagag ttggagtttt tttctctttt 4320
 ttctcttttc tctctctctc tctctctctc tctctctctc tctctctctc tccctccctc 4380
 cctccctccc tccctccctc cctctctctc tcttttctt tctttcttc tttcttctt 4440
 tctttcttct tttcttctt ttttctttt ttgacaaat ctcacaggct ttgagaatta 4500
 taaaagtgga cagttcacct gaaaatcaca ggtctggtct gtttaaattg ttgagaata 4560
 tccgattaaa agtcttggg ctgtgtcta ataggctctc ttccaggacg ttgtagtcaa 4620
 tagagtggct gaaccatact tgagtttata aagctcaaaa actgatgcac ccactctgct 4680

```

attatcgtgt tagtaagagt tcagctgtat atcattgtct aggtttatct tgtcctacag      4740
tgggtattca aatatggcca ccagaggata tgtgtaaata taagcacctg tatttgctg      4800
ttgttgagaa ctggagggaa aacaaaaaat gtctggcaac cctttgcctt ttaaccgta      4860
attaattgac agtttattta gagataagag ttttcaaaaa tctcttaact gccacaacc      4920
acagagggtc ttgttttgcc atcttcagtg gctcacagat atgatccaag ttaacttgaa      4980
agagatgagc agtaccagc aaattgtcct gcctttaact ctggctgtcc ttaattatga      5040
ctgtttaatg ctgaattttc catccgtcta gtgtttgagg gtaaagaaaa gcctttttta      5100
aataagtatt tctgtaaaac ggcacggtg ggatcttctg tgttgctatc acgggtgaaa      5160
gagggaaaca tttcttattt ttattaagca gagcattatt tacagaaagc cattgttgag      5220
aattagttec cacatcatat aaatatccat taaccattct aaattgtaag agaactccag      5280
tgttgctatg cacaaggaac tctcctgggg gccttttttt gcatagcaat taaaggatg      5340
ctatttgtea gtagccattt ttgcagtgga tttaaagacc aaagttgttt tacagctgtg      5400
ttacccttaa aggttttttt tttatgtatt aaatcaattt atcactgttt gaagctttga      5460
atacctgcaa tctttgcaa gatacttttt tatttaaaaa aataactgtg taaatattac      5520
cctgtaatat tatatatact taataaaaca ttttaagcta      5560

```

<210> 4

<211> 303

<212> PRT

<213> Mus musculus

<400> 4

```

Met Trp Pro Leu Ala Ala Ala Leu Leu Leu Gly Ser Cys Cys Cys Gly
1           5           10          15

```

```

Ser Ala Gln Leu Leu Phe Ser Asn Val Asn Ser Ile Glu Phe Thr Ser
                20                25                30

```

```

Cys Asn Glu Thr Val Val Ile Pro Cys Ile Val Arg Asn Val Glu Ala
35           40           45

```

```

Gln Ser Thr Glu Glu Met Phe Val Lys Trp Lys Leu Asn Lys Ser Tyr
50           55           60

```

```

Ile Phe Ile Tyr Asp Gly Asn Lys Asn Ser Thr Thr Thr Asp Gln Asn
65           70           75           80

```

```

Phe Thr Ser Ala Lys Ile Ser Val Ser Asp Leu Ile Asn Gly Ile Ala
85           90           95

```

```

Ser Leu Lys Met Asp Lys Arg Asp Ala Met Val Gly Asn Tyr Thr Cys
100          105          110

```

```

Glu Val Thr Glu Leu Ser Arg Glu Gly Lys Thr Val Ile Glu Leu Lys
115          120          125

```

```

Asn Arg Thr Val Ser Trp Phe Ser Pro Asn Glu Lys Ile Leu Ile Val
130          135          140

```

```

Ile Phe Pro Ile Leu Ala Ile Leu Leu Phe Trp Gly Lys Phe Gly Ile
145          150          155          160

```

```

Leu Thr Leu Lys Tyr Lys Ser Ser His Thr Asn Lys Arg Ile Ile Leu
165          170          175

```

```

Val Val Val Ala Glu Val Val Val Val Val Val Val Val Val Val

```

Leu Leu Val Ala Gly Leu Val Leu Thr Val Ile Val Val Val Gly Ala
180 185 190

Ile Leu Leu Ile Pro Gly Glu Lys Pro Val Lys Asn Ala Ser Gly Leu
195 200 205

Gly Leu Ile Val Ile Ser Thr Gly Ile Leu Ile Leu Leu Gln Tyr Asn
210 215 220

Val Phe Met Thr Ala Phe Gly Met Thr Ser Phe Thr Ile Ala Ile Leu
225 230 235 240

Ile Thr Gln Val Leu Gly Tyr Val Leu Ala Leu Val Gly Leu Cys Leu
245 250 255

Cys Ile Met Ala Cys Glu Pro Val His Gly Pro Leu Leu Ile Ser Gly
260 265 270

Leu Gly Ile Ile Ala Leu Ala Glu Leu Leu Gly Leu Val Tyr Met Lys
275 280 285

Phe Val Ala Ser Asn Gln Arg Thr Ile Gln Pro Pro Arg Asn Arg
290 295 300

<210> 5

<211> 5648

<212> DNA

<213> Mus musculus

<400> 5

gcctacaccg ggagagcagg gaggaggagt tggactgagg ttgggaggct ccgaggtcca	60
gggcgagcgt ggccagaggg agtagagagc agcggggctg cgcagggacg cgtgccgtga	120
gttccggtga gcgtgtgtgt cccatgctcc cgtctttcag gccggcccag gacacgaagc	180
cggaaagagag ctggctggag ggacgggggc cgtgagcaga gagtgcgaacc cgcgcagccc	240
cggggacagg ctgattcttg gcgctctccg ccggagcctg ccaggggctg ggtgtgaggc	300
tggcgtcacg tcaacgagca gaggcggcca ggcggggcgg agtgcgcgtg cgcggggcgg	360
cgagcacgcg cgcgcgcgca cccccgggca gcctgggcgg ccgctcctgc ctgtcactgc	420
tgcggcgtg ctggctggtc gtttcccttg aaggcagcag cggaggcggc ggctgtctca	480
gacacctgag gcggcgaccc ccggcgggcg cggagatgtg gcccttggcg gcggcgctgt	540
tgctggggctc ctgctgctgc ggttcagctc aactactgtt tagtaacgtc aactccatag	600
agttcacttc atgcaatgaa actgtggtca tcccttgcat cgtccgtaat gtggaggcgc	660
aaagcacoga agaaatgttt gtgaagtgga agttgaacaa atcgtatatt ttcactctatg	720
atggaaataa aatatgact actacagatc aaaaactttac cagtgcacaaa atctcagtct	780
cagacttaat caatggcatt gcctctttga aaatggataa gcgcgatgcc atggtgggaa	840
actacacttg cgaagtgaca gatttatcca gagaaggcaa aacagttata gagctgaaaa	900
accgcacggc cttcaacact gaccaaggat cagcctgttc ttacgaggag gagaaaggag	960
gttgcaaat agtttcgtgg ttttctccaa atgaaaagat cctcattgtt attttcccaa	1020
ttttggctat actcctgttc tggggaaagt ttggtatttt aacctcaaaa tataaatcca	1080
gccatacgaa taagagaatc attctgctgc tcgttgccgg gctggtgctc acagtcacgc	1140
tgggtgttgg agccatcctt ctcatcccag gagaaaagcc cgtgaagaat gcttctggac	1200
ttggcctcat tgtaactctt acggggatat taatactact tcagtacaat gtgtttatga	1260
cagcttttgg aatgacctct ttcaccattg ccatattgat cactcaagtg ctgggctacg	1320
tccttgcttt ggtcgggctg tgtctctgca tcatggcatg tgagccagtg cagggccccc	1380

ttttgatttc aggtttgggg atcatagctc tagcagaact acttgatta gtttatatga	1440
agtttgcgc ttccaaccag aggactatcc aacctcctag gaaagctgta gaggaacccc	1500
ttaacgaata ggtgaaggga agtgacggac tgtaacttgg aagtcagaaa tggaagaata	1560
cagttgtcta agcaccaggt cttcacgact cacagctgga aggaacagac aacagtaact	1620
gacttccatc caggaaaaca tgtcacataa atgattacta agtttatatt caaagcagct	1680
gtactttaca taataaaaaa aatatgatgt gctgtgtaac caattggaat cccatttttc	1740
tattgtttct actcaactag gggcaaactt ttcaggggca acttccaaga atgatgcttg	1800
ttagatccta gagtctctga acactgagtt taaattgatt ccgagtgaga ctgcgaagc	1860
actaacctga gggttagtta cccagagata cctatgaaaa acagtggat ccagcaagcc	1920
ttagtaaaact caggttgcca gcagctttgc cacttccgct gctagctgaa taacaagact	1980
gccacttctg ggtcatagtg atagagactg aagtagaaaa acgaatgtgg ttgggcaaat	2040
cccggtgtgc cctctgtgt gctatgatat tgatggcact ggtgtcttca ttcttggggg	2100
ttgccatcat tcacacacac cctttgaca tacagtgcac cccagttttg aatacathtt	2160
ttttgcaccc tgtcccgctc tgctactttg atttgcgtta tgatatatat atatatatat	2220
aatacctttt ctctcttcta aacatggtcc tgtgacacaa tagtcagttg cagaaaggag	2280
ccagacttat tcgcaaagca ctgtgctcaa actcttcaga aaaaaaggaa aaaaaaaaaa	2340
agctatagtt gtaacatatg tattccagac ctctggttta aaggcaaaag aaaaaaatc	2400
tacagtgttt cttctcatgt tttctgatcg gaggcagac aaagcaagac tgaaatctga	2460
actgtgtctc ctgcagtgca acacgtgtct ccgtcaggcc ctgcgaagcc ccggggaggg	2520
ggttctacgc ctcttgtctc tttgttgcat gctgaacact catcgcttc ctactgtatc	2580
ctgcctctg cagcctccct ctctctctc ctctctctc tctctctct cctcctctc	2640
ctctctctc tccaagtttg aaaggtaaaa caaaactacc acattcccta cccagttaga	2700
agaaaaccac cgtctgaca gttgtgatcg catggagtac ttttagatta ttagcacctg	2760
tttttacctc gtttgtgggc gtgtttgtat gtgcacatgt atgaagtcgg cacatgcacc	2820
ttctgtatgg gcagaggcgt ggcactctaca gaagagcaga tgccaacttt gtgcttttag	2880
tgaatacatt aaaaaaaaaa aaccaacggt ccttattgag tggaattcta tttgatgcaa	2940
atatttgagc tctttaagac tttaaaacta gataatgtgc caagctttta ggactgctca	3000
ccagtgcct ctgaagaaac accagtactt tttctgttt gtgtaataaa ggcataattg	3060
tatttgtgtt tgcatcacta atggttattt cttcttagtc cactgaatgt ttccatgtgc	3120
ctctcgtatg ccaaactttt tgtcatcttt catgtgggga ccaaagggtt tgtctgtggc	3180
aaacctaaac ctatgacctg ctgaggcctc tcagaaaact gaccacagta ccaagatagt	3240
acttcgaaa gaaaagtagg ttccctccct ggttttgtag ctgtcgcaa tattagcgta	3300
attccaagga gctgaacgcc tttatataaa tctgatggca cctgatgctt ttagttctga	3360
aaatatttac actcgatca tgttgtgat gacttaaaaa aagttttgat gaagagagca	3420
aaaaaaaaagc aggtggattt ggaacagttt cagggttttt tttgtttttt gttttttgtt	3480
tttgtttttt tttttttatt tttgtttttc tgttctctgt tagaaaagtc aggtgttctc	3540
tgtcaggcta tctttatagt caattttttt tacgaactaa agtagtacct tttaatatgt	3600
agtcaacgcc cctctgctcg gggttcagtt ttgggtctta accagctgtc atgttctcta	3660
tgtgcctgc cacttgaggc actgagtgcc ctgacagtc ccatcggtgg tagccaggga	3720
aacgaaagac gaactcaact ctgctccta ataatacaact ctctgtatga aggatggcag	3780
cattaagagt cctcctgctt gggcattatt gggccagttc accctcttta aatcaaaccc	3840
gcagtggctc ccagttctcg tcccatcaga tttaaattgc taacagtatg gggggcacca	3900
cgcactctgt ttgtccaca atgcgctttt ctctcccaaa tcccgatttc tgctgtcata	3960

```

gcctctattc aatttttatt tattgtctgc cctccactta tacaatcgta gagagcaatg      4020
ccattttgtca cttttctgcaa cagtttttttg agcctttatg gctgaatccc atttttcttc      4080
tctttcaaac tgtttgctcc attgtctctc ccgcacggct gtccgtacag tcatcccatc      4140
catctggggg cctcttcoat ctctcaccct tcttgggtgt tegtggatct ctgcttacct      4200
ctgtgggttt tttttttttt ttttgactta ttctctctac tggactttaa gattacttcc      4260
acagcgaaag tctgcctcc cttttctgcc cgcagtgttc tgcgtacttt agatactact      4320
cagtgtctgac atttgatggc aaaagttgcc tgcacttaaa tttctctttt taatagggtg      4380
aactagagtt ggagtttttt tctctttttt ctctttttct tctctctctc tctctctctc      4440
tctctctctc tctctctctc cctccctccc tccctccctc cctccctccc tctctctctc      4500
ttttcttttc tttctttctt tctttctttc tttctttctt tctttctttc tttctttttt      4560
tgacaaatct cacaggcttt gagaattata aaagtgaca gttcacctga aaatcacagg      4620
tctgtgtctgt ttaaattggt gagaaatctc cgattaaaag tcttgtggct gtgtcctaatt      4680
aggtctctct tcaggacgtt gtagtcaata gagtggctga accatacttg agtttataaa      4740
gctcaaaaac tgatgcaccc actctgctat tctctgttta gtaagagttc agctgtatat      4800
cattgtctag gtttatcttg tcctacagtg ggtattcaaa tatggccacc agaggatatg      4860
tgtaaatata agcacctgta ttgcctgtt gttgagaact ggagggaaaa caaaaaatgt      4920
ctggcaaccc tttgcctttt taaccgtaat taattgacag tttatttaga gataagagtt      4980
ttcaaaaatc tcttaactgc cacaaccac agagggctct gttttgccat cttcagtggc      5040
tcacagatat gatccaagtt aacttgaaag agatgagcag taccaggaa attgtcctgc      5100
ctttaactct ggtgtcctt aattatgact gtttaatgct gaattttcca tccgtctagt      5160
gtttgagggg aaagaaaagc cttttttaa taagtatttc tgtaaaacgg catcggtggg      5220
atcttctgtg ttgctatcac ggtgaaaga gggaaacatt tcttattttt attaaagcaga      5280

gcattattta cagaaagcca ttgttgagaa ttagttccca catcatataa atatccatta      5340
accattctaa attgtaagag aactccagtg ttgctatgca caagggaactc tctggggggc      5400
ctttttttgc atagcaatta aaggtatgct atttgtcagt agccattttt tgcagtgatt      5460
taaagaccaa agttgtttta cagctgtgtt acccttaaag gttttttttt tatgtattaa      5520
atcaatttat cactgtttga agctttgaat acctgcaatc ttgccaaga tactttttta      5580
tttaaaaaaa taactgtgta aatattacc tgaatatta tatatactta ataaaacatt      5640
ttaagcta                                          5648

```

<210> 6

<211> 331

<212> PRT

<213> Mus musculus

<400> 6

```

Met Trp Pro Leu Ala Ala Ala Leu Leu Leu Gly Ser Cys Cys Cys Gly
1          5          10          15

```

```

Ser Ala Gln Leu Leu Phe Ser Asn Val Asn Ser Ile Glu Phe Thr Ser
          20          25          30

```

```

Cys Asn Glu Thr Val Val Ile Pro Cys Ile Val Arg Asn Val Glu Ala
          35          40          45

```

```

Gln Ser Thr Glu Glu Met Phe Val Lys Trp Lys Leu Asn Lys Ser Tyr
          50          55          60

```

```

Ile Phe Ile Tyr Asp Gly Asn Lys Asn Ser Thr Thr Thr Asp Gln Asn
65          70          75          80

```

Phe Thr Ser Ala Lys Ile Ser Val Ser Asp Leu Ile Asn Gly Ile Ala
 85 90 95
 Ser Leu Lys Met Asp Lys Arg Asp Ala Met Val Gly Asn Tyr Thr Cys
 100 105 110
 Glu Val Thr Glu Leu Ser Arg Glu Gly Lys Thr Val Ile Glu Leu Lys
 115 120 125
 Asn Arg Thr Ala Phe Asn Thr Asp Gln Gly Ser Ala Cys Ser Tyr Glu
 130 135 140
 Glu Glu Lys Gly Gly Cys Lys Leu Val Ser Trp Phe Ser Pro Asn Glu
 145 150 155 160
 Lys Ile Leu Ile Val Ile Phe Pro Ile Leu Ala Ile Leu Leu Phe Trp
 165 170 175
 Gly Lys Phe Gly Ile Leu Thr Leu Lys Tyr Lys Ser Ser His Thr Asn
 180 185 190
 Lys Arg Ile Ile Leu Leu Leu Val Ala Gly Leu Val Leu Thr Val Ile
 195 200 205
 Val Val Val Gly Ala Ile Leu Leu Ile Pro Gly Glu Lys Pro Val Lys
 210 215 220
 Asn Ala Ser Gly Leu Gly Leu Ile Val Ile Ser Thr Gly Ile Leu Ile
 225 230 235 240
 Leu Leu Gln Tyr Asn Val Phe Met Thr Ala Phe Gly Met Thr Ser Phe
 245 250 255
 Thr Ile Ala Ile Leu Ile Thr Gln Val Leu Gly Tyr Val Leu Ala Leu
 260 265 270
 Val Gly Leu Cys Leu Cys Ile Met Ala Cys Glu Pro Val His Gly Pro
 275 280 285
 Leu Leu Ile Ser Gly Leu Gly Ile Ile Ala Leu Ala Glu Leu Leu Gly
 290 295 300
 Leu Val Tyr Met Lys Phe Val Ala Ser Asn Gln Arg Thr Ile Gln Pro
 305 310 315 320
 Pro Arg Lys Ala Val Glu Glu Pro Leu Asn Glu
 325 330

<210> 7

<211> 5618

<212> DNA

<213> Mus musculus

<400> 7

gcctacaccg ggagagcagg gaggaggagt tggactgagg ttgggoggct ccgaggtcca	60
gggcgagctt ggccagaggg agtagagagc agcggggctg cgcagggacg cgtgccgtga	120
gttccggtga gcgtgtgtgt cccatgctcc cgtctttcag gccggcccag gacacgaagc	180
cggaagagag ctggctggag ggacgggggc cgtgagcaga gagtgcaacc cgcgcagccc	240
cggggacagg ctgattcttg gcgctctccg ccggagcctg cccagggctg ggtgtgaggg	300

tggcgctcacg tcaacgagca gaggcgccca ggcggggcgg agtgcgctg cgcggggcgg	360
cgagcacgcg cgcgcgcgca cccccgggca gcctgggcgg ccgctcctgc ctgtcactgc	420
tgcggcgctg ctggtcggtc gtttccttg aaggcagcag cggaggcggc ggctgctcca	480
gacacctgcg gcggcgaccc cccggcggcg cggagatgtg gcccttggcg gcggcgctgt	540
tgctgggctc ctgctgctgc ggttcagctc aactactgtt tagtaacgtc aactccatag	600
agttcacttc atgcaatgaa actgtggtca tcccttgcat cgtccgtaat gtggaggcgc	660
aaagcaccga agaaatgttt gtgaagtgga agttgaacaa atcgtatatt ttcctctatg	720
atggaaataa aaatagcact actacagatc aaaactttac cagtgcacaa atctcagctc	780
cagacttaat caatggcatt gcctctttga aaatggataa gcgcgatgcc atggtgggaa	840
actacacttg cgaagtgaca gagttatcca gagaaggcaa aacagttata gagctgaaaa	900
accgcacggt ttcgtgggtt tctccaaatg aaaagatcct cattgttatt tccccaattt	960
tggctatact cctgttcttg ggaagtttg gtattttaac actcaaatat aaatccagcc	1020
atagcaataa gagaatcatt ctgctgctcg ttgccgggct ggtgctcaca gtcctcgttg	1080
ttgttgagc catccttctc atcccaggag aaaagcccg gaagaatgct tctggacttg	1140
gcctcattgt aatctctacg gggatattaa tactacttca gtacaatgtg tttatgacag	1200
cttttggaat gacctcttcc accattgcc aattgtatc tcaagtgtg ggctacgtcc	1260
ttgctttggt cgggctgtgt ctctgcatca tggcatgtga gccagtgca gcccccctt	1320
tgatttcagg tttggggatc atagctctag cagaactact tggattagt tatatgaagt	1380
ttgtcgcttc caaccagagg actatccaac ctccataggaa agctgtagag gaaccctta	1440
acgcatttaa agagtcaaaa ggaatgatga atgacgaata ggtgaaggga agtgacggac	1500
tgtaaacttg aagtcagaaa tggagaata cagttgtcta agcaccaggt ctccacgact	1560
cacagctgga aggaacagac aacagtaact gacttccatc caggaaaaca tgtcacataa	1620
atgattacta agtttatatt caaagcagct gtactttaca taataaaaaa aatatgatgt	1680
gctgtgtaac caattggaat cccatttttc tattgtttct actcaactag gggcaaacgt	1740
ttcaggggca acttccaaga atgatgcttg ttagatccta gagtctctga aactgagtt	1800
taaattgatt ccgagtgaga ctgcgcaagc actaacctga gggttagtta ccagagata	1860
cctatgaaaa acagtggat ccagcaagcc ttagtaaaact caggttgcca gcagctttgc	1920
cacttccgct gctagctgaa taacaagact gccacttctg ggtcatagt atagagactg	1980
aagtagaaaa acgaatgtg tttgggcaat cccgtgtggc cctctgtgt gctatgatat	2040
tgatggcact ggtgtcttca ttcttggggg ttgccatcat tcacacacac ccttttgaca	2100
tacagtgcac cccagttttg aatacatttt ttttgacccc tgtcccgctc tgctactttg	2160
atttgcgtta tgatatatat atatatatat aatacctttt ctctcttcta aacatggctc	2220
tgtgacacaa tagtcagttg cagaaaggag ccagacttat tcgcaaagca ctgtgctcaa	2280
actcttcaga aaaaaaggaa aaaaaaaaaa agctatagtt gtaacatatg tattccagac	2340
ctctggttta aaggcaaaaag aaaaaaaatc tacagtgttt ctctctcatgt tttctgatcg	2400
gaggcatgac aaagcaagac tgaaatctga actgtgtctc ctgcatggca acacgtgtct	2460
ccgtcaggcc ctgcgaaggc cgggggaggg ggttctacgc ctcttgtctc tttgttgcat	2520
gctgaacact catcgcttc ctactgtatc ctgcctcctg cagcctccct ctctcctc	2580
ctcttctctc tctcctctt cctcctcctc ctctctctc tccaagtttg aaaggtcaaa	2640
caaaactacc acattcccta cccagttaga agaaaaccac cgtcctgaca gttgtgatcg	2700
catggagtac ttttagatta ttagcacctg tttttacctc gtttgtgggc gtgtttgtat	2760
gtgcacatgt atgaagtcgg cacatgcacc ttctgtatgg gcagaggcgt ggcactctaca	2820
gaagagcaga tgccaacttt gtgcttttag tgaatacatt aaaaaaaaaa aaccaacggt	2880
ccttattgag tggaaattcta tttgatgcaa atatttgagc tctttaagac tttaaaacta	2940

gataatgtgc caagctttta ggactgctca ccagtgccct ctgaagaaac accagtactt	3000
tttcctgttt gtgtaataaa ggcataattg tatttgtgtt tgcatacta atggttattt	3060
cttccttagtc cactgaatgt ttccatgtgc ctctcgtatg ccaaactttt tgtcatcttt	3120
catgtgggga ccaaatgggt tgtctgtggc aaacctaaac ctatgacctg ctgaggcctc	3180
tcagaaaact gaccacagta ccaagatagt acttcgcaa gaaaagtagg ttccctccct	3240
ggttttgtag ctgtcgccaa tattagcgta attccaagga gctgaacgcc tttatataaa	3300
tctgatggca cctgatgctt ttagttctga aaatatttac actcggatca tgttgttgat	3360
gacttaaaaca aagttttgat gaagagagca aaaaaaagc aggtggattt ggaacagttt	3420
cagggttttt tttgtttttt gttttttgtt tttgtttttt tttttttatt tttgtttttc	3480
tgttctctgt tagaaaagtc aggtgttctc tgtcaggcta tctttatagt caattttttt	3540
tacgaactaa agtagtacct tttaatatgt agtcaacgcc cctctgctcg gggttcagtt	3600
ttgggtctta accagctgtc atgttctcta tgctgcctgc caettgaggc actgagtgcc	3660
ctagacagtc ccatcggttg tagccaggga aacgaaagac gaactcaact ctgtctccta	3720
ataatcaact ctctgtatga aggatggcag cattaagagt cctcctgcct gggcattatt	3780
gggccagttc accctcttta aatcaaaccc gcagtggctc ccagtctctg tcccatcaga	3840
tttaaattgc taacagtatg gggggcacca cgcactctgt ttgtcccaca atgcgctttt	3900
ctctcccaaa tcccgatttc tgctgtcata gcctctattc aatttttatt tattgtctgc	3960
cctccactta tacaatcgta gagagcaatg ccatttgtca ctttctgcaa cagttttttg	4020
agcctttatg gctgaatccc atttttcttc tctttcaaac tgtttgtccc attgtcctc	4080
ccgcacgget gtccgtacag tcatcccatc catctggggg cctctttcat ctctcaccct	4140
tcctgggtgt tcgtggatct ctgcttacct ctgtgggttt tttttttttt ttttgactta	4200
ttcttctcac tggactttaa gattacttcc acagcgaaag tgctgcctcc cttttctgcc	4260
cgcagtgttc tgcgtacttt agatactact cagtgcctgac atttgatggc aaaagttgcc	4320
tgcacttaaa tttctctttt taataggggt aactagagtt ggagtttttt tctctttttt	4380
ctcttttctc tctctctctc tctctctctc tctctctctc tctctctctc cctccctccc	4440
tccctccctc cctccctccc tctctctctc tttttcttcc tttctttctt tctttctttc	4500
tttctttctt tctttcttcc tttctttttt tgacaaatct cacaggcttt gagaattata	4560
aaaggtgaca gttcacctga aaatcacagg tctgggtctgt ttaaattggt gagaaatctc	4620
cgattaaaag tcttggtggc gtgtccta at aggtctctct tcaggacgtt gtagtcaata	4680
gagtggctga accatacttg agttttataa gtcacaaaac tgatgcaccc actctgctat	4740
tatcgtgtta gtaagagttc agctgtatat cattgtctag gtttatcttg tccacagtg	4800
ggtattcaaa tatggccacc agaggatat gttaaataata agcacctgta ttgacctgtt	4860
gttgagaact ggagggaaaa caaaaaatgt ctggcaaccc tttgcctttt taaccgtaat	4920
taattgacag tttattttaga gataagagtt ttcaaaaatc tcttaactgc cacaaccac	4980
agagggctct gttttgcat cttcagtggt tcacagatat gatccaagtt aacttgaaag	5040
agatgagcag taccaggaa attgtcctgc ctttaactct ggctgtcctt aattatgact	5100
gtttaatgct gaattttcca tccgtctagt gtttgagggt aaagaaaagc ctttttttaa	5160
taagtatttc tgtaaaacgg catcggtggg atcttctgtg ttgctatcac gggtgaaaga	5220
gggaaacatt tcttattttt attaaagcaga gcattattta cagaaagcca ttgttgagaa	5280
ttagttccca catcatataa atatccatta accattctaa attgtaagag aactccagtg	5340
ttgctatgca caaggaaact tcctgggggc ctttttttgc atagcaatta aaggatagct	5400
atttgtcagt agccattttt tgcagtgatt taaagaccaa agttgtttta cagctgtgtt	5460
agcctttaaag attttttttt tctctattaa atgaaattat agctattttg agcctttgaa	5520

```

acccctaaag gctctctctt cagtattaa atcaattat cactgttga agctctgaat 5520
acctgcaatc ttgtccaaga tactttttta tttaaaaaaa taactgtgta aatattaccc 5580
tgtaatatta tatatactta ataaaacatt ttaagcta 5618

```

<210> 8

<211> 321

<212> PRT

<213> Mus musculus

<400> 8

```

Met Trp Pro Leu Ala Ala Ala Leu Leu Leu Gly Ser Cys Cys Cys Gly
1          5          10          15

Ser Ala Gln Leu Leu Phe Ser Asn Val Asn Ser Ile Glu Phe Thr Ser
20          25          30

Cys Asn Glu Thr Val Val Ile Pro Cys Ile Val Arg Asn Val Glu Ala
35          40          45

Gln Ser Thr Glu Glu Met Phe Val Lys Trp Lys Leu Asn Lys Ser Tyr
50          55          60

Ile Phe Ile Tyr Asp Gly Asn Lys Asn Ser Thr Thr Thr Asp Gln Asn
65          70          75          80

Phe Thr Ser Ala Lys Ile Ser Val Ser Asp Leu Ile Asn Gly Ile Ala
85          90          95

Ser Leu Lys Met Asp Lys Arg Asp Ala Met Val Gly Asn Tyr Thr Cys
100         105         110

Glu Val Thr Glu Leu Ser Arg Glu Gly Lys Thr Val Ile Glu Leu Lys
115         120         125

Asn Arg Thr Val Ser Trp Phe Ser Pro Asn Glu Lys Ile Leu Ile Val
130         135         140

Ile Phe Pro Ile Leu Ala Ile Leu Leu Phe Trp Gly Lys Phe Gly Ile
145         150         155         160

Leu Thr Leu Lys Tyr Lys Ser Ser His Thr Asn Lys Arg Ile Ile Leu
165         170         175

Leu Leu Val Ala Gly Leu Val Leu Thr Val Ile Val Val Val Gly Ala
180         185         190

Ile Leu Leu Ile Pro Gly Glu Lys Pro Val Lys Asn Ala Ser Gly Leu
195         200         205

Gly Leu Ile Val Ile Ser Thr Gly Ile Leu Ile Leu Leu Gln Tyr Asn
210         215         220

Val Phe Met Thr Ala Phe Gly Met Thr Ser Phe Thr Ile Ala Ile Leu
225         230         235         240

Ile Thr Gln Val Leu Gly Tyr Val Leu Ala Leu Val Gly Leu Cys Leu
245         250         255

Cys Ile Met Ala Cys Glu Pro Val His Gly Pro Leu Leu Ile Ser Gly
260         265         270

Leu Gly Ile Ile Ala Leu Ala Glu Leu Leu Gly Leu Val Tyr Met Lys
275         280         285

Phe Val Ala Ser Asn Gln Arg Thr Ile Gln Pro Pro Arg Lys Ala Val

```

290

295

300

Glu Glu Pro Leu Asn Ala Phe Lys Glu Ser Lys Gly Met Met Asn Asp
 305 310 315 320

Glu

<210> 9

<211> 5021

<212> DNA

<213> Homo sapiens

<400> 9

```

agtgggagcg cgcggtgcgcg cgcccggtgca gcctgggcag tgggtcctgc ctgtgacgcg      60
cggcgggcggg cggtcctgcc tgtaacggcg gcgcgcgctg ctgctccgga cacctgcggc      120
ggcgcgcgcg accccgcggc gggcgcggag atgtggcccc tggtagcggc gctgttgctg      180
ggctcggcgt gctgcggatc agctcagcta ctatttaata aaacaaaatc tgtagaattc      240
acgttttcta atgacactgt cgtcattcca tgctttgtta ctaatatgga ggcacaaaac      300
actactgaag tatacgtaaa gtggaatttt aaaggaagag atatttacac ctttgatgga      360
gctctaaaca agtccactgt cccactgac tttagtagtg caaaaattga agtctcacia      420
ttactaaaag gagatgcctc ttgaagatg gataagagtg atgctgtctc acacacagga      480
aactacactt gtgaagtaac agaattaacc agagaagggt aaacgatcat cgagctaaaa      540
tactgtgttg ttctatggtt ttctccaaat gaaaatattc ttattgttat ttcccaatt      600
tttctatac tcctgttctg gggcagcttt ggtattaaaa cacttaaata tagatccggt      660
ggtatggatg agaaaacaat tgctttactt gttgctggac tagtgatcac tgtcattgtc      720
attgttgtag ccattctttt cgtcccagggt gaattattcat taaagaatgc tactggcctt      780
ggtttaattg tgacttctac agggatatta atattacttc actactatgt gtttagtaca      840
gcgattggat taacctcctt cgtcattgcc atattgggta ttcagggtgat agcctatatc      900
ctcgtctgtg ttggactgag tctctgtatt gcgcggtgta taccaatgca tggccctctt      960
ctgatttcag gtttgagtat cttagctcta gcacaattac ttggactagt ttatatgaaa     1020
tttgtggaat aactgaagtg aagtgatgga ctccgatttg gagagtagta agacgtgaaa     1080
ggaatacact tgtgtttaag caccatggcc ttgatgattc actgttgggg agaagaaaca     1140
agaaaagtaa ctggttgtca cctatgagac ccttacgtga ttgttagtta agtttttatt     1200
caaagcagct gtaatttagt taataaaata attatgatct atgttgtttg cccaattgag     1260
atccagtttt ttgttgttat ttttaataca ttaggggcaa tagtagaatg gacaatttcc     1320

aagaatgatg cctttcagggt ctagggcct ctggcctcta ggtaaccagt ttaaattggt      1380
tcagggtgat aactacttag cactgcccgt gtgattaccc agagatatct atgaaaacca      1440
gtggcttcca tcaaaccctt gccaaactcag gttcacagca gctttgggca gttatggcag      1500
tatggcatta gctgagaggt gtctgccact tctgggtcaa tggaataata aattaagtac      1560
aggcaggaat ttggttggga gcatcttgta tgatctccgt atgatgtgat attgatggag      1620
atagtgtgac tcattcttgg gggttgccat tcccacattc ccccttcaac aaacagtgtg      1680
acaggtcctt cccagattta gggtaacttt attgatggat atgttttctt tttattcaca      1740
taaccctctg aaaccctgtc ttgtcctcct gttacttgct tctgctgtac aagatgtagc      1800
accttttctc ctctttgaac atgggtctagt gacacggtag caccagttgc aggaaggagc      1860
cagacttggt ctcagagcac tgtgttcaca cttttcagca aaaatagcta tggttgtaac      1920
atatgtattc ccttctctct atttgaaggc aaaaatctac agtgtttctt cacttctttt      1980
ctgatctggg gcatgaaaaa agcaagattg aaatttgaac tatgagtctc ctgcatggca      2040

```

acaaaatgtg tgtcaccatc aggccaacag gccagccctt gaatggggat ttattactgt	2100
tgtatctatg ttgcatgata aacattcacc accttcctcc tgtagtcctg cctcgtactc	2160
cccttccctc atgattgaaa agtaaacaaa acccacattt cctatcctgg ttagaagaaa	2220
attaatgttc tgacagttgt gatcgcttg agtaacttta gacttttagc attcgttttt	2280
tacctgtttg tggatgtgtg tttgtatgtg catacgtatg agataggcac atgcatcttc	2340
tgtatggaca aagggtgggt acctacagga gagcaaagg taaattttgtg cttttagtaa	2400
aaacatttaa atacaaagt ctttattggg tggaattata tttgatgcaa atatttgatc	2460
acttaaaact tttaaaactt ctaggtaatt tgccacgctt tttgactgct caccaatacc	2520
ctgtaaaaat acgtaattct tcctgtttgt gtaataagat attcatattt gtagttgcat	2580
taataatagt tatttcttag tccatcagat gttcccggtg gcctctttta tgccaaattg	2640
attgtcatat ttcattgttg gaccaagtag tttgccatg gcaaacctaa atttatgacc	2700
tgtgagggcc tctcagaaaa ctgagcatac tagcaagaca gctcttcttg aaaaaaaaa	2760
tatgtataca caaatatata cgtatatcta tatatacgta tgtatataca cacatgtata	2820
ttcttctctg attgtgtagc tgtccaaaat aataacatat atagaggag ctgtattcct	2880
ttatacaaat ctgatggctc ctgcagcact ttttcttct gaaaatattt acattttgct	2940
aacctagttt gttactttta aatcagttt tgatgaaagg agggaaaagc agatggactt	3000
gaaaaagatc caagctccta ttagaaaagg tatgaaaatc tttatagtaa aattttttat	3060
aaactaaagt tgtacctttt aatatgtagt aaactctcat ttatttgggg ttcgctcttg	3120
gatctcatcc atccattgtg ttctctttta tgctgcctgc cttttgaggc attcactgcc	3180
ctagacaatg ccaccagaga tagtggggga aatgccagat gaaaccaact cttgctctca	3240
ctagttgtca gcttctctgg ataagtgacc acagaagcag gagtcctcct gcttgggcat	3300
cattggggcca gttccttctc tttaaatcag atttgtaatg gctcccaaat tccatcacat	3360
cacatttaaa ttgcagacag tgttttgac atcatgtatc tgttttgtcc cataatatgc	3420
tttttactcc ctgatccag tttctgctgt tgactcttcc attcagtttt atttattgtg	3480
tgttctcaca gtgacaccat ttgtcctttt ctgcaacaac ctttccagct acttttgcca	3540
aattctattt gtcttctcct tcaaaacatt ctcttttgca gttcctcttc atctgtgtag	3600
ctgctctttt gtctcttaac ttaccattcc tatagtactt tatgcatctc tgettagttc	3660
tattagtttt ttggccttgc tcttctcctt gattttaaaa ttccttctat agctagagct	3720
tttctttctt tcattctctc ttcttgcagt gttttgcata catcagaagc taggtacata	3780
agttaaatga ttgagagttg gctgtattta gatttatcac tttttaatag ggtgagcttg	3840
agagttttct ttcttctgt tttttttttt tgtttttttt tttttttttt tttttttttt	3900
ttttgactaa tttcacatgc tctaaaaacc ttcaaagggtg attatttttc tctggaaac	3960
tccagggtcca ttctgtttta atccctaaga atgtcagaat taaaataaca gggctatccc	4020
gtaattggaa atatttcttt tttcaggatg ctatagtcaa ttagtaagt gaccacaaa	4080
ttgttatttg cactaacaaa gctcaaaaca cgataagttt actcctccat ctacagtaata	4140
aaaattaagc tgtaatcaac cttctaggtt tctcttgtct taaaatgggt attcaaaaat	4200
ggggatctgt ggtgtatgta tggaacaca tactccttaa tttacctgtt gttggaaact	4260
ggagaaatga ttgtcgggca accgtttatt ttttattgta ttttatttgg ttgagggatt	4320
tttttataaa cagttttact tgtgtcatat tttaaaatta ctaactgcca tcacctgtg	4380
gggtcctttg ttaggtcatt ttcagtgact aatagggata atccaggtaa ctttgaagag	4440
atgagcagtg agtgaccag cagtttttct gccttttagct ttgacagttc ttaattaaga	4500
tcattgaaga ccagctttct cataaatttc tctttttgaa aaaaagaaag catttgtact	4560
aagctcctct gtaagacaac atcttaaatc ttaaaagtgt tgttatcatg actggtgaga	4620

```

gaagaaaaca ttttgttttt attaaatgga gcattattta caaaaagcca ttgttgagaa 4680
ttagatccca catcgataaa atatctatta accattctaa ataaagagaa ctccagtgtt 4740
gctatgtgca agatcctctc ttggagcttt ttgcatagc aattaaaggt gtgctatttg 4800
tcagtagcca tttttttgca gtgatttgaa gaccaaagtt gttttacagc tgtgttaccg 4860
ttaaaggttt ttttttttat atgtattaaa tcaatttatc actgtttaaa gctttgaata 4920
tctgcaatct ttgccaaggt acttttttat ttaaaaaaaaa acataacttt gtaaataatta 4980
ccctgtaata ttatatatac ttaataaaac attttaagct a 5021

```

<210> 10

<211> 293

<212> PRT

<213> Homo sapiens

<400> 10

```

Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly
1          5          10          15

Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe
20          25          30

Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala
35          40          45

Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp
50          55          60

Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp
65          70          75          80

Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala
85          90          95

Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr
100         105         110

Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu
115         120         125

Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu
130         135         140

Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe
145         150         155         160

Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr
165         170         175

Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val
180         185         190

Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr
195         200         205

Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His
210         215         220

Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala
225         230         235         240

Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu
245         250         255

```

Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile
 260 265 270

Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr
 275 280 285

Met Lys Phe Val Glu
 290

<210> 11

<211> 5288

<212> DNA

<213> Homo sapiens

<400> 11

```

gggggagcagg cggggggagcg ggcgggaagc agtgggagcg cgcgtgcgcg cggccgtgca      60
gcctgggcag tgggtcctgc ctgtgacgcg cggcggcggt cggtcctgcc tgtaacggcg      120
gcggcggtcg ctgctccaga cacctgcggc ggcggcgcg accccgcggc gggcgcgag      180
atgtggcccc tggtagcgcg gctgttgctg ggctcgcgct gctgcggatc agctcagcta      240
ctatttaata aaacaaaatc tgtagaattc acgttttgta atgacactgt cgtcattcca      300
tgctttgtta ctaatatgga ggcacaaaac actactgaag tatacgtaaa gtggaaattt      360
aaaggaagag atatttacac ctttgatgga gctctaaaca agtccactgt cccactgac      420
tttagtagtg caaaaattga agtctcaca ttactaaaag gagatgcctc ttggaagatg      480
gataagagtg atgctgtctc acacacagga aactacactt gtgaagtaac agaattaacc      540
agagaaggtg aaacgatcat cgagctaaaa ttcgtgttg tttcatggtt ttctccaaat      600
gaaaatatcc ttattgttat ttcccaatt tttgctatac tctgttctg gggacagttt      660
ggtattaaaa cacttaata tagatccggt ggtatggatg agaaaacaat tgctttactt      720
gttgctggac tagtgatcac tgtcattgtc attgttgag coattctttt cgtcccaggt      780
gaatattcat taaagaatgc tactggcctt ggtttaattg tgacttctac agggatatta      840
atattacttc actactatgt gtttagtaca gcgattggat taacctcctt cgtcattgcc      900
atattggtta ttcagggtgat agcctatata ctcgctgtgg ttggactgag tctctgtatt      960
gcggcgtgta taccaatgca tggccctctt ctgatttcag gtttgagtat cttagctcta      1020
gcacaattac ttggactagt ttatatgaaa tttgtggctt ccaatcagaa gactatacaa      1080
cctcctagga ataactgaag tgaagtgatg gactccgatt tggagagtag taagacgtga      1140
aaggaataca cttgtgttta agcaccatgg ccttgatgat tcaactgttg ggagaagaaa      1200

caagaaaagt aactggttgt cacctatgag acccttacgt gattgttagt taagttttta      1260
ttcaaagcag ctgtaattta gttataaaaa taattatgat ctatgttggt tgcccaattg      1320
agatccagtt tttgttggtt atttttaatc aattaggggc aatagtagaa tggacaattt      1380
ccaagaatga tgcctttcag gtcctagggc ctctggcctc taggtaacca gtttaaattg      1440
gttcagggtg ataactactt agcactgccc tggtgattac ccagagatat ctatgaaaac      1500
cagtggcttc catcaaacct ttgccaaact aggttcacag cagctttggg cagttatggc      1560
agtatggcat tagctgagag gtgtctgcc cttctgggtc aatggaataa taaattaagt      1620
acaggcagga atttggttgg gagcatcttg tatgatctcc gtatgatgtg atattgatgg      1680
agatagtggc cctcattctt gggggttgcc attcccacat tccccctca acaaacagtg      1740
taacaggctc ttcccagatt tagggtaact ttattgatgg atatgttttc cttttattca      1800
cataaccctc tgaaccctg tcttgctctc ctgttacttg cttctgctgt acaagatgta      1860
cgagctttta tcaatcttca ccatgctata ctgagaggtt cggagagatt cggagagagc      1920

```

gcaccccccc cccccctga acatggtcca gtyacacggt agcaccagtc gcaygaayga	1920
gccagacttg ttctcagagc actgtgttca cacttttcag caaaaatagc tatggttgta	1980
acatatgtat tcccttcttc tgatttgaag gcaaaaatct acagtgttcc ttcacttctt	2040
ttctgatctg gggcatgaaa aaagcaagat tgaaatttga actatgagtc tcctgcatgg	2100
caacaaaaatg tgtgtcacca tcaggccaac aggccagccc ttgaatgggg atttattact	2160
gttgatatcta tgttgcatga taaacattca tcaccttcct cctgtagtcc tgcctcgta	2220
tccccctccc ctatgattga aaagtaaaca aaaccacat ttcctatcct ggtagaaga	2280
aaattaatgt tctgacagtt gtgatcgctt ggagtacttt tagactttta gcattcgttt	2340
tttacctgtt tgtggatgtg tgtttgtatg tgcatacgta tgagataggc acatgcatct	2400
tctgtatgga caaaggtggg gtacctacag gagagcaaa gtttaattttg tgcttttagt	2460
aaaaacattt aaatacaaa ttctttattg ggtggaatta tatttgatgc aaatatttga	2520
tcacttaaaa cttttaaaac ttctaggtaa ttggccacgc tttttgactg ctcaccaata	2580
ccctgtaaaa atacgtaatt cttcctgttt gtgtaataag atattcatat ttgtagttgc	2640
attaataata gttattttctt agtccatcag atgttcccgt gtgcctcttt tatgccaaat	2700
tgattgtcat atttcatgtt gggaccaagt agtttgccca tggcaaacct aaatttatga	2760
cctgctgagg cctctcagaa aactgagcat actagcaaga cagctcttct tgaaaaaaa	2820
aatatgtata cacaaatata tacgtatata tatatatac tatgtatata cacacatgta	2880
tattcttctt tgatttgtga gctgtccaaa ataataacat atatagagg agctgtattc	2940
ctttatacaa atctgatggc tcctgcagca ctttttctt ctgaaaatat ttacattttg	3000
ctaacctagt ttgttacttt aaaaatcagt ttgatgaaa ggagggaaaa gcagatggac	3060
ttgaaaaaga tccaagctcc tattagaaaa ggtatgaaaa tctttatagt aaaatttttt	3120
ataaactaaa gttgtacctt ttaatatgta gtaaaactct atttatttgg gggtcgtct	3180
tggtatctcat ccatacattg tgttctcttt aatgctgctt gccttttgag gcattcactg	3240
ccctagacaa tggcaccaga gatagtgggg gaaatgccag atgaaaccaa ctcttgcct	3300
cactagtgtg cagcttctct ggataagtga ccacagaagc aggagtctct ctgcttgggc	3360
atcattgggc cagttccttc tctttaaatc agatttgtaa tggctcccaa attccatcac	3420
atcacattta aattgcagac agtgttttgc acatcatgta tctgttttgt ccataatat	3480
gctttttact cctgatccc agtttctgct gttgactctt ccattcagtt ttattttattg	3540
tgtgttctca cagtgcacc atttgcctt ttctgcaaca acccttccag ctacttttgc	3600
caaattctat ttgtctcttc cttcaaaaca ttctcctttg cagttcctct tcatctgtgt	3660
agctgctctt ttgtctctta acttaccatt cctatagtac tttatgcata tctgcttagt	3720
tctattagtt ttttggcctt gctctctctc ttgattttaa aattcctct atagctagag	3780
cttttcttcc ttctattctc tcttctgca gtgttttgca tacatcagaa gctaggta	3840
taagttaaat gattgagagt tggctgtatt tagattttat actttttaat agggtagact	3900
tgagagtttt ctttctctct gttttttttt ttgttttttt tttttttttt ttttttttt	3960
ttttttgact aatttcacat gctctaaaaa ccttcaaagg tgattatttt tctcctggaa	4020
actccaggtc cattctgttt aaatccctaa gaatgtcaga attaaaataa cagggtatc	4080
ccgtaattgg aaatatttct tttttcagga tgctatagtc aatttagtaa gtgaccacca	4140
aattgttatt tgcactaaca aagctcaaaa cagcataagt ttactcctcc atctcagtaa	4200
taaaaattaa gctgtaatca accctctagg tttctcttgt cttaaaatgg gtattcaaaa	4260
atggggatct gtggtgtatg tatggaaca catactcctt aatttacctg ttgttgaaa	4320
ctggagaaat gattgtcggg caaccgttta ttttttattg tattttattt gggtgagga	4380
tttttttata aacagtttta cttgtgtcat attttaaaat tactaactgc catcacctgc	4440
tggggtcctt tgttaggtca ttttcagtga ctaatagga taatccaggt aactttgaag	4500

```

agatgagcag tgagtgacca ggcagttttt ctgccttttag ctttgacagt tcttaattaa 4560
gatcattgaa gaccagcttt ctcataaatt tctctttttg aaaaaaagaa agcatttgta 4620
ctaagctcct ctgtaagaca acatcttaaa tcttaaaagt gttgttatca tgactggtga 4680
gagaagaaaa cattttgttt ttattaaatg gagcattatt tacaaaaagc cattgttgag 4740
aattagatcc cacatcgtat aaatatctat taaccattct aaataaagag aactccagtg 4800
ttgctatgtg caagatcctc tcttgagct tttttgcata gcaattaaag gtgtgctatt 4860
tgtcagtagc catttttttg cagtgatttg aagaccaaag ttgttttaca gctgtgttac 4920
cgttaaaggt tttttttttt atatgtatta aatcaattta tcactgttta aagctttgaa 4980

tatctgcaat ctttgccaag gtactttttt atttaaaaaa aaacataact ttgtaaatat 5040
tacctgtaa tattatatat acttaataaa acattttaag ctattttgtt gggctatttc 5100
tattgctgct acagcagacc acaagcacat ttctgaaaaa tttaatttat taatgtattt 5160
ttaagttgct tatattctag gtaacaatgt aaagaatgat ttaaaatatt aattatgaat 5220
tttttgagta taatacccaa taagctttta attagagcag agttttaatt aaaagtttta 5280
aatcagtc 5288

```

<210> 12

<211> 305

<212> PRT

<213> Homo sapiens

<400> 12

```

Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly
1          5          10          15

Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe
20          25          30

Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala
35          40          45

Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp
50          55          60

Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp
65          70          75          80

Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala
85          90          95

Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr
100         105         110

Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu
115         120         125

Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu
130         135         140

Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe
145         150         155         160

Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr
165         170         175

Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val
180         185         190

```

```

-- -- -- - - - - - -- -- - - - - - - - - - - - - - - - - - - - -

```

Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr
195 200 205

Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His
210 215 220

Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala
225 230 235 240

Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu
245 250 255

Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile
260 265 270

Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr
275 280 285

Met Lys Phe Val Ala Ser Asn Gln Lys Thr Ile Gln Pro Pro Arg Asn
290 295 300

Asn

305

<210> 13

<211> 5078

<212> DNA

<213> Homo sapiens

<400> 13

agtgggagcg cgcggtgcgcg cggccgtgca gcctgggcag tgggtcctgc ctgtgacgcg	60
cggcggcggt cggtcctgcc tgtaacggcg gcggcggctg ctgctccgga cacctgcggc	120
ggcggcgcg accccgcggc gggcgcggag atgtggcccc tggtagcggc gctgttgctg	180
ggctcggcgt gctgcggatc agctcagcta ctatttaata aaacaaaatc tgtagaattc	240
acgttttcta atgacactgt cgtcattcca tgctttgtta ctaatatgga ggcacaaaac	300
actactgaag tatacgtaaa gtggaaattt aaaggaagag atatttacac ctttgatgga	360
gctctaaaca agtccactgt cccactgac tttagttagt caaaaattga agtctcacia	420
ttactaaaag gagatgcctc ttgaaagatg gataagagtg atgctgtctc acacacagga	480
aactacactt gtgaagtaac agaattaacc agagaaggag aaacgatcat cgagctaaaa	540
tatcgtgttg tttcatggtt ttctccaaat gaaaatatc ttattgttat tttcccaatt	600
tttgctatac tcctgttctg gggacagttt ggtattaaaa cacttaaata tagatccggt	660
ggtatggatg agaaaacaat tgctttactt gttgctggac tagtgatcac tgtcattgtc	720
attgttgag ccattctttt cgtcccaggt gaattatcat taaagaatgc tactggcctt	780
ggtttaattg tgactcttac agggatatta atattacttc actactatgt gtttagtaca	840
gcgattggat taacctcctt cgtcattgcc atattggta ttcaggatg agcctatata	900
ctcgtgtgg ttggactgag tctctgtatt gcggcgtgta taccaatgca tggccctctt	960
ctgatttcag gtttgagtat cttagctcta gcacaattac ttggactagt ttatatgaaa	1020
tttgtggcct ccaatcagaa gactatacaa cctcctagga aagctgtaga ggaacccctt	1080
aatgaataac tgaagtgaag tgatggactc cgatttgag agtagtaaga cgtgaaagga	1140
atacacttgt gtttaagcac catggccttg atgattcact gttggggaga agaaacaaga	1200
aaagtaactg gttgtcacct atgagaccct tacgtgattg ttagttaagt ttttattcaa	1260
agcagctgta atttagttaa taaaataatt atgatctatg ttgtttgccc aattgagatc	1320
cagttttttg ttgttatatt taatcaatta ggggcaatag tagaatggac aatttccaag	1380

aatgatgcct ttcaggctcct agggcctctg gcctctaggt aaccagttta aattggttca	1440
gggtgataac tacttagcac tgccttggtg attaccacaga gatatctatg aaaaccagtg	1500
gcttccatca aacetttgcc aactcagggt caccagcagct ttgggcagtt atggcagtat	1560
ggcattagct gagagggtgc tgcaccttct gggccaatgg aataataaat taagtacagg	1620
caggaatttg gttgggagca tcttgatga tctccgtatg atgtgatatt gatggagata	1680
gtggtcctca ttcttggggg ttgccattcc cacattcccc cttcaacaaa cagtgtacaa	1740
ggtccttccc agatttaggg taacttttatt gatggatatg ttttcctttt attcacataa	1800
ccccttgaaa cctgtcttg tctcctgtt acttgcttct gctgtacaag atgtagcacc	1860
ttttctctc tttgaacatg gtctagtgc acggtagcac cagttgcagg aaggagccag	1920
acttgttctc agagcactgt gttcacactt ttcagcaaaa atagctatgg ttgtaacata	1980
tgtattccct tctctgatt tgaaggcaaa aatctacagt gtttcttcac ttcttttctg	2040
atctggggca tgaaaaaagc aagattgaaa ttgaaactat gagtctcctg catggcaaca	2100
aatgtgtgt caccatcagg ccaacaggcc agcccttgaa tggggattta ttactgttgt	2160
atctatgttg catgataaac attcatcacc ttcctcctgt agtcctgctt cgtactcccc	2220
ttccccctatg attgaaaagt aaacaaaacc cacatttcct atcctggtta gaagaaaatt	2280
aatgttctga cagttgtgat cgcttgaggt acttttagac ttttagcatt cgttttttac	2340
ctgtttgttg atgtgtgttt gtatgtgcat acgtatgaga taggcacatg catcttctgt	2400
atggacaaag gtgggggtacc tacaggagag caaagggtta ttttgtgctt ttagtaaaaa	2460
catttaaaata caaagtctct tattgggtgg aattatattt gatgcaataa ttgatcact	2520
taaaactttt aaaacttcta ggtaatttgc cacgcttttt gactgctcac caataccctg	2580
taaaaatcag taattcttcc tgtttgtgta ataagatatt catatttgta gttgcattaa	2640
taatagttat ttcttagtoc atcagatgtt cccgtgtgcc tcttttatgc caaattgatt	2700
gtcatatttc atgttgggac caagtagttt gcccatggca aacctaaatt tatgacctgc	2760
tgaggcctct cagaaaactg agcatactag caagacagct cttcttgaaa aaaaaatat	2820
gtatacacia atatatacgt atatctatat atacgtatgt atatacacac atgtatattc	2880
ttccttgatt gtgtagctgt ccaaataat aacatatata gaggagctg tattccttta	2940
tacaaactg atggctctg cagcactttt tcttctgaa aatatttaca ttttgctaac	3000
ctagtttggt actttaaaaa tcagtttga tgaaaggagg gaaaagcaga tggacttgaa	3060
aaagatccaa gctcctatta gaaaaggat gaaaactctt atagtaaaat tttttataaa	3120
ctaaagtgt accctttaat atgtagtaaa ctctcattta tttggggttc gctctggat	3180
ctcatccatc cattgtgttc tctttaatgc tgcctgcctt ttgaggcatt cactgcctca	3240
gacaatgcca ccagagatag tgggggaaat gccagatgaa accaactctt gctctcacta	3300
gttgtcagct tctctggata agtgaccaca gaagcaggag tctcctgctt tgggcatcat	3360
tgggccagtt ccttctcttt aaatcagatt tgtaatggct cccaaattcc atcacatcac	3420
atttaaattg cagacagtgt ttgcatcac atgtatctgt tttgtcccat aatatgcttt	3480
ttactccctg atcccagttt ctgctgttga ctcttcatt cagttttatt tattgtgtgt	3540
tctcacagtg acaccatttg tcttttctg caacaacctt tccagctact tttgccaaat	3600
tctatttgtc ttctccttca aaacattctc ctttgcagtt cctcttcac tgtgtagctg	3660
ctcttttgtc tcttaactta ccattcctat agtactttat gcatctctgc ttagttctat	3720
tagttttttg gccttgctct tctccttgat tttaaaattc cttctatagc tagagctttt	3780
ctttctttca ttctctcttc ctgcagtgtt ttgcatacat cagaagctag gtacataagt	3840
taaatgattg agagttggct gtatttagat ttatcacttt ttaatagggt gagcttgaga	3900
gttttcttcc tttctgtttt tttttttgt tttttttttt tttttttttt tttttttttt	3960
tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	4020

```

cgactaattt cacatgctct aaaaaccttc aaaggtgatt atttttcttc tggaaatttc 4020
agggtccattc tgtttaaatc cctaagaatg tcagaattaa aataacaggg ctatcccgtc 4080
attggaaata tttctttttt caggatgcta tagtcaattt agtaagtgc caccaaattg 4140
ttattttgcac taacaaagct caaaacacga taagtttact cctccatctc agtaataaaa 4200
attaagctgt aatcaacctt ctaggtttct cttgtcttaa aatgggtatt caaaaatggg 4260
gatctgtggt gtatgtatgg aaacacatac tccttaattt acctgttggt ggaaactgga 4320
gaaatgattg tcgggcaacc gtttattttt tattgtattt tatttggttg agggattttt 4380

ttataaacag ttttacttgt gtcataattt aaaattacta actgccatca cctgctgggg 4440
tcctttgtta ggtcattttc agtgactaat agggataatc caggttaactt tgaagagatg 4500
agcagtgagt gaccaggcag tttttctgcc tttagctttg acagttctta attaagatca 4560
ttgaagacca gctttctcat aaatttctct ttttgaaaaa aagaagcat ttgtactaag 4620
ctcctctgta agacaacatc ttaaattctta aaagtgttgt tatcatgact ggtgagagaa 4680
gaaaacattt tgtttttatt aaatggagca ttatttacia aaagccattg ttgagaatta 4740
gatcccacat cgtataaata tctattaacc attctaaata aagagaactc cagtgttgct 4800
atgtgcaaga tcctctcttg gagctttttt gcatagcaat taaaggtgtg ctatttgtca 4860
gtagccattt ttttgcatg atttgaagac caaagttgtt ttacagctgt gttaccgtta 4920
aaggtttttt tttttatag tattaatatc atttatcact gtttaaagct ttgaatatct 4980
gcaatctttg ccaaggtact tttttattta aaaaaaaca taactttgta aatattacc 5040
tgtaatatta tatatactta ataaaacatt ttaagcta 5078

```

<210> 14

<211> 312

<212> PRT

<213> Homo sapiens

<400> 14

```

Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly
1          5          10          15

Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe
20          25          30

Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala
35          40          45

Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp
50          55          60

Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp
65          70          75          80

Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala
85          90          95

Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr
100         105         110

Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu
115         120         125

Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu
130         135         140

Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe
145         150         155         160

```

[illegible]

<210> 15

<211> 5346

<212> DNA

<213> Homo sapiens

<400> 15

gggggagcag	cgggggagcg	ggcggggaagc	agtggggagcg	cgcggtgcgcg	cggccgtgca	60
gcctggggcag	tgggtcctgc	ctgtgacgcg	cggcgggcggt	cggtcctgcc	tgtaacggcg	120
gcggcgggctg	ctgctccaga	cacctgcggc	ggcgggggcg	accccgcggc	gggcgcggag	180
atgtgcccc	tggtagcggc	gctgttgctg	ggctcgcggt	gctgcggatc	agctcagcta	240
ctatttaata	aaacaaaatc	tgtagaattc	acgtttttgta	atgacactgt	cgctattcca	300
tgctttgtta	ctaatatgga	ggcacaaaac	actactgaag	tatacgtaaa	gtggaattt	360
aaaggaagag	atatttacac	ctttgatgga	gctctaaca	agtccactgt	ccccactgac	420
tttagtagtg	caaaaattga	agtctcacia	ttactaaaag	gagatgcctc	tttgaagatg	480
gataagagtg	atgctgtctc	acacacagga	aactacactt	gtgaagtaac	agaattaacc	540
agagaaggtg	aaacgatcat	cgagctaaaa	tatcggtgtg	tttcatgggt	ttctccaaat	600
gaaaatattc	ttattgttat	tttcccaatt	tttgctatac	tcctgtttctg	gggacagttt	660
ggtattaaaa	cacttaaata	tagatccggg	ggtatggatg	agaaaacaat	tgctttactt	720
gttgctggac	tagtgatcac	tgtcattgtc	attgttggag	ccattctttt	cgtcccaggt	780
gaatatccat	taaagaatgc	tactggcctt	ggtttaattg	tgactttctac	agggatatta	840
atattacttc	actactatgt	gtttagtaca	gcgattggat	taacctcctt	cgtcattgcc	900
atattggtta	ttcaggtgat	agcctatatc	ctogctgtgg	ttggactgag	tctctgtatt	960
qcgccgtgta	taccaatqca	tggccctctt	ctgatttcag	gtttgagtat	cttaqctcta	1020

gcacaattac ttggactagt ttatatgaaa tttgtggcctt ccaatcagaa gactatacaa	1080
cctcctagga aagctgtaga ggaacccctt aatgcattca aagaatcaaa agaatgatg	1140
aatgatgaat aactgaagtg aagtgatgga ctccgatttg gagagtagta agacgtgaaa	1200
ggaatacact tgtgtttaag caccatggcc ttgatgattc actgttgggg agaagaaaca	1260
agaaaagtaa ctggttgta cctatgagac ccttacgtga ttgttagtta agtttttatt	1320
caaagcagct gtaatttagt taataaaata attatgatct atgttgtttg cccaattgag	1380
atccagtttt ttgttgttat ttttaataca ttaggggcaa tagtagaatg gacaatttcc	1440
aagaatgatg cctttcaggt cctagggcct ctggcctcta ggtaaccagt ttaaattggt	1500
tcagggtgat aactacttag cactgccctg gtgattaccc agagatatct atgaaaacca	1560
gtggcttcca tcaaaccttt gccaaactcag gttcacagca gctttgggca gttatggcag	1620
tatggcatta gctgagaggt gtctgccact tctgggtcaa tggaataata aattaagtac	1680
aggcaggaat ttggttggga gcactctgta tgatctccgt atgatgtgat attgatggag	1740
atagtgtgcc tcattcttgg gggttgccat tcccacattc ccccttcaac aaacagtgt	1800
acaggctcctt cccagattta gggtaactttt attgatggat atgttttctt tttattcaca	1860
taaccctctg aaaccctgtc ttgtcctcct gttacttgct tctgctgtac aagatgtagc	1920
accttttctc ctctttgaac atggtctagt gacacgtag caccagtgc aggaaggagc	1980
cagacttggt ctcagagcac tgtgttcaca cttttcagca aaaatagcta tggttgtaac	2040
atatgtattc ccttctctg atttgaaggc aaaaatctac agtgtttctt cacttctttt	2100
ctgatctggg gcataaaaa agcaagattg aaatttgaac tatgagtctc ctgcatggca	2160
acaaaatgtg tgtcaccatc aggccaacag gccagccctt gaatgggat ttattactgt	2220
tgtatctatg ttgcatgata aacattcatc accttccctc tgtagtctg cctcgtactc	2280
cccttccctt atgattgaaa agtaaacaaa acccacattt cctatcctgg ttagaagaaa	2340
attaatgttc tgacagttgt gatcgcttg agtactttta gacttttagc attcgttttt	2400
tacctgtttg tggatgtgtg tttgtatgtg catacgtatg agataggcac atgcatcttc	2460
tgtatggaca aagggtgggt acctacagga gagcaaaggt taattttgtg cttttagtaa	2520
aaacatttaa atacaaagt ttttattggg tggattata tttgatgcaa atatttgatc	2580
acttaaaact tttaaaactt ctaggtaatt tgccacgctt tttgactgct caccaatacc	2640
ctgtaaaaat acgtaatctt tcctgtttgt gtaataagat attcatattt gtagtggcat	2700
taataatagt tatttcttag tccatcagat gttcccggtg gcctctttta tgccaaattg	2760
attgtcatat ttcattgttg gaccaagtag tttgccatg gcaaacctaa atttatgacc	2820
tgctgaggcc tctcagaaaa ctgagcatac tagcaagaca gctcttcttg aaaaaaaaa	2880
tatgtatata caaatatata cgtatatcta tatatacgta tgtatataca cacatgtata	2940
ttcttctctg attgtgtagc tgtccaaaat aataacatat atagaggag ctgtattcct	3000
ttatacaaat ctgatggctc ctgcagcact ttttcttctt gaaaatattt acattttgct	3060
aacctagttt gttactttaa aaatcagttt tgatgaaagg agggaaaagc agatggactt	3120
gaaaaagatc caagctccta ttagaaaagg tatgaaaatc tttatagtaa aattttttat	3180
aaactaaagt tgtacctttt aatatgtagt aaactctcat ttatttgggg ttcgctcttg	3240
gatctcatcc atccatttg tttcttttaa tgetgcctgc cttttgaggc attcaactgcc	3300
ctagacaatg ccaccagaga tagtggggga aatgccagat gaaaccaact cttgctctca	3360
ctagttgtca gcttctctg ataagtgacc acagaagcag gagtcctcct gcttgggcat	3420
cattgggcca gttccttctc tttaaatcag atttgtaatg gctcccaaat tccatcacat	3480
cacatttaaa ttgcagacag tgttttgac atcatgtatc tgttttgtcc cataaatgac	3540
tttttactcc ctgatccag tttctgctgt tgactcttcc attcagtttt atttattgtg	3600
tgttctcaca gtgacaccat ttgtcctttt ctgcaacaac ctttccagct acttttgcca	3660

```

aattctatctt gtctctctct tcaaaacatt ctcccttgca gttcctcttc atctgtgtag 3720
ctgctctctt gtctcttaac ttaccattcc tatagtactt tatgcatctc tgcttagttc 3780
tatttagttt ttggccttgc tcttctcctt gattttaaaa ttccctctat agctagagct 3840
ttctctctct tcattctctc ttccctgcagt gttttgcata catcagaagc taggtacata 3900
agttaaataa ttgagagttg gctgtattta gatttatcac tttttaatag ggtgagcttg 3960
agagttttct ttctttctgt tttttttttt tgtttttttt tttttttttt tttttttttt 4020
ttttgactaa ttccacatgc tctaaaaacc ttcaaaggtg attattttto tcttggaac 4080

tccaggtcca ttctgtttta atccctaaga atgtcagaat taaaataaca gggctatccc 4140
gtaattggaa atatttcttt ttccaggatg ctatagtcaa tttagtaagt gaccaccaa 4200
ttgttatttg cactaacaaa gctcaaaaca cgataagttt actcctccat ctccagtaata 4260
aaaattaagc tgtaatcaac ctctcaggtt tctcttgtct taaaatgggt attcaaaaat 4320
ggggatctgt ggtgtatgta tggaaacaca tactccttaa tttacctgtt gttggaaact 4380
ggagaaatga ttgtcgggca accgtttatt ttttattgta ttttatttgg ttgagggatt 4440
tttttataaa cagttttact tgtgtcatat tttaaaatta ctaactgcca tcacctgtg 4500
gggtcctttg ttaggtcatt ttcagtactt aatagggata atccaggtaa ctttgaagag 4560
atgagcagtg agtgaccagg cagtttttct gcctttagct ttgacagttc ttaattaaga 4620
tcattgaaga ccagctttct cataaatttc tctttttgaa aaaaagaaag catttgtact 4680
aagctcctct gtaagacaac atcttaaatc ttaaaagtgt tgttatcatg actggtgaga 4740
gaagaaaaaa ttttgttttt attaaatgga gcattattta caaaaagcca ttgttgagaa 4800
ttagatccca catcgtataa atatctatta accattctaa ataaagagaa ctccagtgtt 4860
gctatgtgca agatcctctc ttggagcttt ttgcatagc aattaaaggt gtgctatttg 4920
tcagtagcca ttttttttgc gtgatttgaa gaccaaaagt gttttacagc tgtgttaccg 4980
ttaaaggttt ttttttttat atgtattaaa tcaatttato actgtttaaa gctttgaata 5040
tctgcaatct ttgccaaggt acttttttat ttaaaaaaaa acataacttt gtaaatatta 5100
ccctgtataa ttatatatac ttaataaaac attttaagct attttgttgg gctatttcta 5160
ttgctgctac agcagaccac aagcacattt ctgaaaaatt taatttatta atgtattttt 5220
aagttgctta tattctaggt aacaatgtaa agaattgatt aaaatattaa ttatgaattt 5280
tttgagtata ataccaata agcttttaat tagagcagag ttttaattaa aagttttaaa 5340
tcagtc 5346

```

<210> 16

<211> 323

<212> PRT

<213> Homo sapiens

<400> 16

```

Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly
1           5           10           15

```

```

Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe
20           25           30

```

```

Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala
35           40           45

```

```

Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp
50           55           60

```

```

Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp
65           70           75           80

```

Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala
 85 90 95
 Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr
 100 105 110
 Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu
 115 120 125
 Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu
 130 135 140
 Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe
 145 150 155 160
 Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr
 165 170 175
 Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val
 180 185 190
 Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr
 195 200 205
 Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His
 210 215 220
 Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala
 225 230 235 240
 Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu
 245 250 255
 Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile
 260 265 270
 Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr
 275 280 285
 Met Lys Phe Val Ala Ser Asn Gln Lys Thr Ile Gln Pro Pro Arg Lys
 290 295 300
 Ala Val Glu Glu Pro Leu Asn Ala Phe Lys Glu Ser Lys Gly Met Met
 305 310 315 320
 Asn Asp Glu
 <210> 17
 <211> 293
 <212> PRT
 <213> Artificial Sequence
 <220>
 <221> source
 <223> /note="Description of Artificial Sequence: Synthetic polypeptide"
 <400> 17
 Met Trp Pro Leu Ala Ala Leu Leu Leu Gly Ser Cys Cys Gly
 1 5 10 15
 Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe
 20 25 30

Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala
35 40 45

Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp
50 55 60

Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp
65 70 75 80

Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala
85 90 95

Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr
100 105 110

Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu
115 120 125

Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu
130 135 140

Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe
145 150 155 160

Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr
165 170 175

Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val
180 185 190

Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr
195 200 205

Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His
210 215 220

Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala
225 230 235 240

Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu
245 250 255

Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile
260 265 270

Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr
275 280 285

Met Lys Phe Val Glu
290

<210> 18

<211> 305

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 18

Met Trp Pro Leu Ala Ala Ala Leu Leu Leu Gly Ser Cys Cys Cys Gly
1 5 10 15

Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe
 20 25 30
 Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala
 35 40 45
 Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp
 50 55 60
 Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp
 65 70 75 80
 Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala
 85 90 95
 Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr
 100 105 110
 Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu
 115 120 125
 Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu
 130 135 140
 Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe
 145 150 155 160
 Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr
 165 170 175
 Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val
 180 185 190
 Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr
 195 200 205
 Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His
 210 215 220
 Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala
 225 230 235 240
 Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu
 245 250 255
 Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile
 260 265 270
 Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr
 275 280 285
 Met Lys Phe Val Ala Ser Asn Gln Arg Thr Ile Gln Pro Pro Arg Asn
 290 295 300

Arg
305

<210> 19

<211> 312

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 19

```

Met Trp Pro Leu Ala Ala Ala Leu Leu Leu Gly Ser Cys Cys Cys Gly
1           5           10           15

Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe
          20           25           30

Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala
          35           40           45

Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp
          50           55           60

Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp
65           70           75           80

Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala
          85           90           95

Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr
          100          105          110

Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu
          115          120          125

Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu
          130          135          140

Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe
          145          150          155          160

Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr
          165          170          175

Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val
          180          185          190

Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr
          195          200          205

Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His
          210          215          220

Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala
225          230          235          240

Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu
          245          250          255

Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile
          260          265          270

Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr
          275          280          285

Met Lys Phe Val Ala Ser Asn Gln Arg Thr Ile Gln Pro Pro Arg Lys
          290          295          300

Ala Val Glu Glu Pro Leu Asn Glu
--

```

305

310

<210> 20

<211> 323

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic polypeptide"

<400> 20

Met Trp Pro Leu Ala Ala Ala Leu Leu Leu Gly Ser Cys Cys Cys Gly
 1 5 10 15

Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe
 20 25 30

Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala
 35 40 45

Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp
 50 55 60

Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp
 65 70 75 80

Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala
 85 90 95

Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr
 100 105 110

Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu
 115 120 125

Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Ile Leu
 130 135 140

Ile Val Ile Phe Pro Ile Phe Ala Ile Leu Leu Phe Trp Gly Gln Phe
 145 150 155 160

Gly Ile Lys Thr Leu Lys Tyr Arg Ser Gly Gly Met Asp Glu Lys Thr
 165 170 175

Ile Ala Leu Leu Val Ala Gly Leu Val Ile Thr Val Ile Val Ile Val
 180 185 190

Gly Ala Ile Leu Phe Val Pro Gly Glu Tyr Ser Leu Lys Asn Ala Thr
 195 200 205

Gly Leu Gly Leu Ile Val Thr Ser Thr Gly Ile Leu Ile Leu Leu His
 210 215 220

Tyr Tyr Val Phe Ser Thr Ala Ile Gly Leu Thr Ser Phe Val Ile Ala
 225 230 235 240

Ile Leu Val Ile Gln Val Ile Ala Tyr Ile Leu Ala Val Val Gly Leu
 245 250 255

Ser Leu Cys Ile Ala Ala Cys Ile Pro Met His Gly Pro Leu Leu Ile
 260 265 270

Ser Gly Leu Ser Ile Leu Ala Leu Ala Gln Leu Leu Gly Leu Val Tyr
 275 280 285

Met Lys Phe Val Ala Ser Asn Gln Arg Thr Ile Gln Pro Pro Arg Lys
 290 295 300

Ala Val Glu Glu Pro Leu Asn Ala Phe Lys Glu Ser Lys Gly Met Met
 305 310 315 320

Asn Asp Glu

<210> 21

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic primer"

<400> 21

tgcagaagtc actaggagga at 22

<210> 22

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic probe"

<400> 22

ttagtcaact tcttctgggt tgtttcc 27

<210> 23

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic primer"

<400> 23

gtgccagact cactttctat cca 23

<210> 24

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic primer"

<400> 24
tgctgccaat atacggcttc tg 22

<210> 25
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic probe"

<400> 25
cagctctcat agccaactat ggtgcc 26

<210> 26
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic primer"

<400> 26
tcaagcagag cctggtatc tg 22

<210> 27
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic primer"

<400> 27
gtcgtcattc catgctttgt tac 23

<210> 28
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic probe"

<400> 28
tggaggcaca aaacactact gaagtatacg 30

<210> 29
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic primer"

<400> 29

ggacagtgga ctgtttaga gc 22

<210> 30

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic primer"

<400> 30

ggcttggtgg ctgattgtc t 21

<210> 31

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic probe"

<400> 31

agcacccaaa ctgatatgcc tgtatttg 28

<210> 32

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic primer"

<400> 32

tgggaactgg tgttcaagt cta 23

<210> 33

<211> 158

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 33

gcagacatga ttacttcaga gctttcaaag ctatatactg taccttgcac attccaacac 60

gcgacatgcac tttaagattt tccatcctag tggaaagata tgatttgatt catcctattt 120

... .. --

actttgtata tttaaagtaca gtagaacctg ccactttt 158

<210> 34

<211> 160

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 34

ggatccattt taagtaatag aataggattt ttaattgttc cagtgtttct gtgatatagac 60

tgtcctgcac agacctgttt ctcgagataa cttcgtataa tgtatgctat acgaagttat 120

atgcatggcc tccgcgccgg gttttggcgc ctcccgcggg 160

<210> 35

<211> 160

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 35

catgtctgga ataacttcgt ataattgatg ctatacgaag ttatgctagt aactataacg 60

gtcctaaggc agcgactagc attagtagtg aagggtccgc cactgtccag gttcctcttg 120

cggagctctt tgtctctctg gactctgtat acactgcttg 160

<210> 36

<211> 239

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic polynucleotide"

<400> 36

ggatccattt taagtaatag aataggattt ttaattgttc cagtgtttct gtgatatagac 60

tgtcctgcac agacctgttt ctcgagataa cttcgtataa tgtatgctat acgaagttat 120

gctagtaact ataacggtcc taaggtagcg actagcatta gtatggaagg tccgtccact 180

gtccagggtc ctcttgccga gctctttgtc tctctggact ctgtatacac tgcttgcac 239

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US62087992A](#) [\[0001\]](#)
- [WO2007033221A](#) [\[0004\]](#)
- [WO2013063556A](#) [\[0004\]](#)
- [US5670356A](#) [\[0123\]](#)
- [US5874304A](#) [\[0123\]](#)
- [US8697851B](#) [\[0126\]](#) [\[0164\]](#)
- [US8518392B](#) [\[0126\]](#) [\[0164\]](#)
- [US8354389B](#) [\[0126\]](#) [\[0164\]](#)
- [US2010051339W](#) [\[0128\]](#)
- [US2013058448W](#) [\[0128\]](#)
- [US2013045788W](#) [\[0128\]](#)
- [US2014056910W](#) [\[0128\]](#) [\[0128\]](#)
- [US2014060568W](#) [\[0128\]](#)
- [US2012025040W](#) [\[0128\]](#)
- [US2012062379W](#) [\[0128\]](#)
- [US2014064806W](#) [\[0128\]](#)
- [US2014064810W](#) [\[0128\]](#)
- [US6586251B](#) [\[0163\]](#)
- [US7294754B](#) [\[0166\]](#)
- [US1456910W](#) [\[0178\]](#)
- [WO62087992A](#) [\[0187\]](#)

Non-patent literature cited in the description

- **GONNET et al.** Exhaustive Matching of the Entire Protein Sequence Database *Science*, 1992, vol. 256, 1443-45 [\[0070\]](#)
- **HOOGENBOOM H. R.** *TIB Tech.*, 1997, vol. 15, 62-70 [\[0085\]](#)
- **AZZAZY H. HIGHSMITH W. E.** *Clin. Biochem.*, 2002, vol. 35, 425-445 [\[0085\]](#)
- **GAVILONDO J. V. LARRICK J. W.** *BioTechniques*, 2002, vol. 29, 128-145 [\[0085\]](#)
- **HOOGENBOOM H. CHAMES P.** *Immunology Today*, 2000, vol. 21, 371-378 [\[0085\]](#)
- **TAYLOR, L. D. et al.** *Nucl. Acids Res.*, 1992, vol. 20, 6287-6295 [\[0085\]](#)
- **KELLERMANN S-A. GREEN L. L.** *Current Opinion in Biotechnology*, 2002, vol. 13, 593-597 [\[0085\]](#)
- **LITTLE M. et al.** *Immunology Today*, 2000, vol. 21, 364-370 [\[0085\]](#)
- **MURPHY, A.J.** *Proc. Natl. Acad. Sci. U. S. A.*, 2014, vol. 111, 145153-5158 [\[0085\]](#)
- **ALTSCHUL et al.** Basic local alignment search tool *J. Mol. Biol.*, 1990, vol. 215, 3403-410 [\[0092\]](#) [\[0093\]](#)
- **ALTSCHUL et al.** Methods in Enzymology, 1997, [\[0092\]](#)
- **ALTSCHUL et al.** Gapped BLAST and PSI-BLAST: a new generation of protein database search programs *Nucleic Acids Res.*, vol. 25, 3389-3402 [\[0092\]](#)
- A Practical Guide to the Analysis of Genes and Proteins **BAXEVANIS et al.** *Bioinformatics* Wiley 1998 0000 [\[0092\]](#)
- *Bioinformatics Methods and Protocols* *Methods in Molecular Biology* Humana Press 1999 0000 vol. 132, [\[0092\]](#) [\[0093\]](#)
- **ALTSCHUL et al.** *Methods in Enzymology*, [\[0093\]](#)

- **ALTSCHUL et al.** Nucleic Acids Res., 1997, vol. 25, 3389-3402 [0093]
- **BAXEVANIS et al.** Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins Wiley 1998 0000 [0093]
- **REINHOLD et al.** J. Cell Sci., 1995, vol. 108, 3419-3425 [0100]
- **CHAO et al.** Curr Opin Immunol., 2012, vol. 24, 2225-232 [0100]
- **FESTING et al.** Mammalian Genome, 1999, vol. 10, 836- [0132]
- **AUERBACH, W. et al.** Biotechniques, 2000, vol. 29, 5 [0132]
- **KOSHIMIZU H. et al.** PLoS One, 2014, vol. 9, 2e89584- [0134]
- **LAVENDER, K.J. et al.** J. Immunol. Methods, 2014, vol. 407, 127-134 [0134]
- **TENA, A. et al.** Am. J. Transplant, 2014, [0134]
- **LAVENDER K.J. et al.** Blood, 2013, vol. 122, 254013-4020 [0134]
- **TENA, A. et al.** Transplantation, 2012, vol. 94, 10S776- [0134]
- **WANG, C. et al.** Cell Transplant, 2011, vol. 20, 11-12 1915-1920 [0134]
- **JOHANSEN, M.L.BROWN, E.J.J.** Biol. Chem., 2007, vol. 282, 24219-24230 [0134]
- **WANG, H. et al.** Proc. Nat. Acad. Sci. U.S.A., 2007, vol. 104, 13744-13749 [0134]
- **TULASNE D. et al.** Blood, 2001, vol. 98, 123346-52 [0134]
- **OLDENBORG, P. et al.** Science, 2000, vol. 288, 2051-2054 [0134]
- **VERDRENGH, M. et al.** Microbes Infect., 1999, vol. 1, 10745-751 [0134]
- **CHANG, H.P. et al.** Learn Mem., 1999, vol. 6, 5448-457 [0134]
- **WANG, X.Q. et al.** J. Cell Biol., 1999, vol. 147, 2389-400 [0134]
- **LINDBERG, F.P. et al.** Science, 1996, vol. 274, 5288795-798 [0134]
- **TAKENAKA, K. et al.** Nat. Immunol., 2007, vol. 8, 1201313-1323 [0134]
- **BRUCE, L. et al.** Blood, 2003, vol. 101, 4180-4188 [0134]
- **MOURO-CHANTELOUP, L. et al.** VoxSanguinis, 2000, vol. 78, 030- [0134]
- **MOURO-CHANTELOUP, L. et al.** Blood, 2003, vol. 101, 338-344 [0134]
- **GIMENO, R. et al.** Blood, 2004, vol. 104, 3886-3893 [0134]
- **TRAGGIAI, E. et al.** Science, 2004, vol. 304, 104-107 [0134]
- **LEGRAND, N. et al.** Blood, 2006, vol. 108, 238-245 [0134]
- **VALENZUELA et al.** High-throughput engineering of the mouse genome coupled with high-resolution expression analysis Nature Biotech., 2003, vol. 21, 6652-659 [0163]
- **AUERBACH, W. et al.** Biotechniques, 2000, vol. 29, 51024-81030-1032- [0165]
- **POUEYMIROU et al.** F0 generation mice that are essentially fully derived from the donor gene-targeted ES cells allowing immediate phenotypic analyses Nature Biotech., 2007, vol. 25, 191-99 [0166]

Patentkrav

1. En gnaver, hvis genom består af et humaniseret CD47-gen, hvor det humaniserede CD47-gen omfatter ekson 1 af et endogent gnaver CD47-gen, ekson 2-7 af et humant CD47-gen og eksonerne downstream fra ekson 7 af det endogene gnaver CD47-gen, hvor det humaniserede CD47-gen er funktionsdygtigt forbundet med en endogen gnaver CD47-promoter.
2. Gnaveren i patentkrav 1, hvor gnaveren yderligere omfatter et SIRPa-gen, som koder for en SIRPa-polypeptid omfattende det ekstracellulære domæne af en human SIRPa-polypeptid og det intracellulære domæne af en endogen gnaver SIRPa-polypeptid, hvor SIRPa-polypeptiden interagerer med CD47, og SIRPa-genet valgfrit omfatter ekson 1, 5, 6, 7 og 8 af et endogent gnaver SIRPa-gen og ekson 2-4 af et humant SIRPa-gen.
3. Gnaveren i patentkrav 1 eller 2, hvor gnaveren er en rotte eller mus.
4. En isoleret gnavercelle eller -væv hvis genom omfatter et humaniseret CD47-gen, hvor det humaniserede CD47-gen omfatter ekson 1 af et endogent gnaver CD47-gen, ekson 2-7 af et humant CD47-gen, og eksonerne downstream fra ekson 7 af det endogene gnaver CD47-gen, hvor det humaniserede CD47-gen er funktionsdygtigt forbundet med en endogen gnaver CD47-promoter, og gnavercellen eller -vævet valgfrit er musecelle eller musevæv, eller en rottecelle eller rottevæv.
5. Gnaveren i patentkrav 4, hvor tidligere omtalte celle er en gnaver-embryonisk stamcelle, og den gnaver-embryonisk stamcelle valgfrit er en muse- eller rotte-embryonisk stamcelle.
6. Et gnaver-embryo genereret fra den embryoniske stamcelle i patentkrav 5.
7. En metode til at frembringe en gnaver, hvis genom omfatter et CD47-gen, som koder for en ekstracellulær del af en human CD47-polypeptid forbundet med en intracellulær del af en endogen CD47-polypeptid, hvor metoden omfatter modificering af genomet hos en gnaver, således at den omfatter et humaniseret

CD47-gen, hvor det humaniserede CD47-gen omfatter ekson 1 af et endogent gnaver CD47-gen, ekson 2-7 af et humant CD47-gen, og eksonerne downstream fra ekson 7 af det endogene gnaver CD47-gen, hvor det humaniserede CD47-gen er funktionsdygtigt forbundet med en endogen gnaver CD47-promoter, hvorved

5 hvor tidligere omtalte gnaver frembringes.

8. En metode til at frembringe en gnaver, som udtrykker en CD47-polypeptid fra en endogen CD47-locus, hvor CD47-polypeptiden omfatter en human sekvens, hvor metoden omfatter:

10 (a) indsættelse af et genomisk fragment i en endogen gnaver CD47-locus i en gnaver embryonisk stamcelle, hvor tidligere omtalte genomiske fragment omfatter ekson 2-7 af et humant CD47-gen, hvorved det humaniserede CD47-gen dannes på den endogene CD47-locus;

(b) frembringelse af en gnaver-embryonisk stamcelle omfattende det

15 humaniserede CD47-gen fra (a); og

(c) dannelse af en gnaver ved at bruge den gnaver-embryoniske stamcelle fra (b).

9. Metoden i patentkrav 7 eller patentkrav 8, hvor gnaveren er en mus eller rotte.

20 10. En metode til at vurdere transplantation af humane celler, hvor tidligere omtalte metode omfatter vurdering af transplantation af humane celler i en gnaver ifølge ethvert af patentkrav 1-3, hvor de humane celler valgfrit er hæmatopoietiske stamceller.

25 11. En metode til at vurdere den terapeutiske virkning af et lægemiddel rettet mod humane celler, hvor metoden omfatter:

indgivelse af en lægemiddelkandidat i en gnaver ifølge ethvert af patentkrav 1-3

hvor i en eller flere humane celler er blevet transplanteret; og

30 overvågning af de humane celler i gnaveren for at afgøre den terapeutiske effekt af lægemiddelkandidaten.


12. En metode til at vurdere hvorvidt en kandidat-modulator af et humant CD47-protein provokerer agglutination af røde blodceller, hvor tidligere omtalte metode omfatter

35 inkubation af røde blodceller isoleret fra en gnaver ifølge ethvert af patentkrav 1-3 i

tilstedeværelsen af kandidat-modulatoren; og
vurdering af hvorvidt kandidat-modulatoren provokerer agglutination af røde
blodceller.

DRAWINGS

Mouse CD47



Human CD47





Figure 1

Endogenous CD47 gene with human CD47 exons 2-7 inserted, neomycin cassette intact (~4995 bp)



Endogenous CD47 gene with human CD47 exons 2-7 inserted, neomycin cassette deleted (76 bp remain)




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9